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To date, nanotechnology is used to modify drug delivery and confer desirable 
pharmacokinetics to drugs and improve pharmacodynamics. Polymeric nanoparticles of Poly 
(lactide-co-glycolide) (PLGA) are proposed as suitable vehicles that desirably modify 
pharmacokinetics. The variability in PLGA and nanoparticle fabrication techniques results in 
nanoparticles with variable characteristics. It is important to identify factors that significantly 
influence particle characteristics during nanoparticle preparation to fabricate nanoparticles 
with the desired properties. Factors like size, zeta potential, and drug loading ability influence 
fate of nanoparticle and loaded drug in the body. 
An experimental factorial design based on the Taguchi robust model was used to 
evaluate the influence of preparation variables on nanoparticle characteristics. Docetaxel, an 
anticancer agent, was used in the design. Factors affecting nanoparticle properties with 
statistical significance were identified and models were built to predict particle 
characteristics. An optimized fabrication method was identified and used to prepare 
docetaxel-loaded PLGA nanoparticles and docetaxel-loaded PEGylated PLGA nanoparticles. 
Surface-modification with Poly (ethylene glycol) (PEG) conferred long-circulating properties 
to PLGA nanoparticles. A mass spectrometric analysis method was developed and partially 
validated for detection and quantification of docetaxel in biologic/non-biologic samples. 
Size, zeta potential, Poly-dispersity index, drug release, and cytotoxicity of un-
modified and surface-modified nanoparticles were determined. Pharmacokinetics and bio-
distribution of docetaxel loaded in nanoparticles and in free solution were evaluated in mice 
and compared. PLGA and PLGA-PEG nanoparticles had average diameters of around 120 
and 180 nm, respectively, with negative zeta potential. They demonstrated a biphasic release 
profile and were cytotoxic to Hela cells. Nanoparticles modified docetaxel’s bio-distribution 
by increasing docetaxel’s area under the curve, half-life, and mean residence time in blood 
iii 
 
while decreasing systemic clearance and apparent volume of distribution. Particle size and 
surface characteristics likely caused the modifications in docetaxel’s pharmacokinetics.    
In summary, nanoparticles modified docetaxel’s pharmacokinetics and bio-
distribution. The relationship between nanoparticle properties and pharmacokinetic 
modifications can be established and used to design nanoparticles with intended 
characteristics that could intentionally change docetaxel’s pharmacokinetics. Models built 
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1.1.Background 
Cancer in one of the leading causes of morbidity and mortality in Canada and around 
the world. Conventionally, chemotherapy has been the chief therapeutic technique to treat 
cancer. However, chemotherapy suffers disadvantages such as anticancer agents’ lack of 
water solubility, their non-selectivity, and their unfavorable pharmacokinetics. For example, 
docetaxel, a chemotherapeutic agent used to treat a variety of cancer types, is poorly water 
soluble. Therefore, co-solvents (ethanol and polysorbate 80) have been used in drug’s 
commercial formulation to make it soluble. Docetaxel has a high volume of distribution and 
binds to a wide range of tissues. The drug does not discriminate between normal and cancer 
cells and therefore acts non-selective. This results in a wide range of side effects. 
    The idea of applying nanotechnology and nanoparticles as drug delivery platforms 
to address disadvantages of conventional chemotherapy has led to the development of cancer 
nanomedicine. Accordingly, cancer nanomedicine represents as one of the most promising 
approaches to cancer treatment. Over the past decades, extensive research into cancer 
nanomedicine has significantly advanced scientists’ understanding of the contribution that 
nanomedicine could have to cancer treatment. Several nanoparticulate drug delivery 
platforms have been introduced to the field, offering various benefits and drawbacks. One of 
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these platforms, polymeric nanoparticles prepared from poly (lactide-co-glycolide) (PLGA), 
has been extensively used to deliver a wide-spectrum of drugs, including chemotherapeutic 
agents. 
 PLGA polymer has a variable physicochemical nature. In addition, various 
techniques have been used to fabricate PLGA nanoparticles. The variability of PLGA 
polymer and the variabilities in nanoparticle preparation methods result in nanoparticles with 
distinctly different properties. In other words, PLGA polymer properties and the nanoparticle 
preparation technique used determine nanoparticle characteristics. After administration, 
nanoparticle characteristics influence the fate of the nanoparticle and the loaded drug in the 
body (bio-fate). Thus, the relationship between PLGA polymer properties, nanoparticle 
preparation technique, and PLGA nanoparticle characteristics must be established because 
the nanoparticle’s characteristics affect the bio-fate of both the loaded drug and nanoparticle.  
PLGA nanoparticles are believed to modify the pharmacokinetics and biodistribution 
of various drugs, including chemotherapeutic agents. These modifications can potentially 
change the drug’s systemic concentration and the drug’s effectiveness in various organs. 
However, mode of changes made to the loaded drug’s pharmacokinetics and biodistribution 
mainly depends on the nanoparticles’ properties such as size, surface characteristics, and 
shape. PLGA nanoparticles are believed to help elevate blood concentration and residence 
time of drugs in systemic circulation, which secondarily increases tumor exposure. By 
establishing a relationship between PLGA nanoparticle characteristics and the mode of 
changes made to drugs’ pharmacokinetics and biodistribution profile, it would be possible to 
design nanoparticles with intended pharmacokinetic consequence.  
PLGA nanoparticles offer the possibility of surface-modification as well. The 
attachment of poly (ethylene glycol) (PEG) to the surface of PLGA nanoparticles has been 





Medically known as malignant neoplasm, cancer includes a wide spectrum of diseases 
that generally involve a circumstance of unregulated cell growth [1]. Cancer cells proliferate 
uncontrollably and potentially affect nearby organs, resulting in disorders. Although new 
diagnostic and therapeutic approaches have improved therapy’s success and patients’ quality 
of life, cancer is still a leading cause of death in Canada [2]. 
Currently applied and well-established treatments for cancer (e.g., chemotherapy, 
radiotherapy, surgery) are variably effective depending on the type of cancer [3]. For 
example, primary solid tumours localized in the body can usually be removed by surgical 
interventions or subjected to radiation therapy to shrink the cancer tissue. However, cases 
with spreading features and tumour metastasis require extensive chemotherapy [4]. 
Chemotherapy uses highly cytotoxic agents that interfere with normal cell activities, like cell 
division and growth, upon entering the body and might also activate cell death pathways, 
promoting tumour shrinkage. 
After administration, most anticancer agents demonstrate wide-spread distribution 
throughout the body and can easily reach non-tumour tissues. Furthermore, most 
chemotherapeutic agents possess a fairly rapid elimination rate after administration to the 
body. The wide-spread distribution of chemotherapeutic agents along with their fast 
elimination from the body results in pronounced drop in systemic concentration of anticancer 
agents. Therefore, to reach the required systemic therapeutic levels in the body, anticancer 
agents are required to be administered at high and frequent doses.  
Most types of anticancer agents do not discriminate between normal cells and cancer 
cells. Anticancer agents’ non-specific activity and their wide-spread distribution in the body 
lead to systemic toxicity and adverse effects [5]. A delicate balance must be maintained 
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between the therapeutic effectiveness and toxicity of anticancer agents: reducing the dose 
diminishes therapeutic outcomes and increasing the dose can give immoderate toxicity. 
Toxicity can cause extreme patient discomfort, contributing to delays, the reduction of doses, 
and the cessation of chemotherapy [6].  
Anticancer agents often have variable physicochemical characteristics such as 
variable water solubility. Incorporating such active agents into formulations suitable for 
administration to the body requires the use of non-active ingredients (i.e., excipients) such as 
co-solvents or vehicles in the formulation. These excipients can cause serious side effects on 
their own (e.g., hypersensitivity reaction, nephrotoxicity, neurotoxicity) to a level that would 
also contribute to the cessation of chemotherapy [7-10]. Therefore, the development of 
strategies that can modify cancer chemotherapy by intervening in the mechanisms that lead to 
toxicity would help patients tolerate the adverse effects, comply with their cancer treatment 
regimens, and ultimately have better qualities of life. 
To date, one of the strategies that show great promise to overcome the drawbacks of 
cancer chemotherapy is the application of ‘novel drug delivery systems’ (NDDS) [11-13]. 
The general idea behind NDDS is to modify the fate of drugs in the body after administration 
in a way that enhances therapeutic outcomes and at the same time undermines adverse 
effects, ultimately to increase patients’ compliance of drug-therapy. Because of the many 
adverse effects associated with chemotherapy, chemotherapeutic agents make suitable 
candidates to be involved with NDDS.      
Docetaxel has long been considered to be one of the most important and efficient 
anticancer agents being widely used in the chemotherapy of various cancer types. However, 
the clinical application of the drug is not without limitations due to docetaxel’s poor water 
solubility, non-selective bio-distribution, fast elimination, and hypersensitivity reactions. The 
chemotherapeutic agent can result in toxicity and a variety of side effects. Due to its dose-
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limiting toxicities, docetaxel’s application in cancer-patients has long been accompanied with 
matters of concern [6, 14, 15]. The application of new drug delivery systems to help 
overcome such limitations could ultimately result in more successful clinical outcomes.    
 
1.3.Docetaxel 
Docetaxel (figure 1-1) is a member of taxan family of antineoplastic agents that exert 
their cytotoxic effects on microtubules [16]. Docetaxel is derived semi-synthetically from 10-
deacetyl-baccatin III that is isolated from trees of Taxus family (e.g., Taxus baccata, Taxus 
brevifolia) [17]. Docetaxel inhibits the proliferation of cells by inducing a sustained block at 
the metaphase–anaphase boundary by disrupting the microtubular network necessary for 
mitotic cellular function [17, 18]. It inhibits the disassembly of tubulin leading to inhibited 
cell division and to cell death [19]. 
 
Figure 1-1. Docetaxel molecular structure 
 
Docetaxel has demonstrated antitumor activity in patients with recurrent ovarian 
cancer, non-small cell lung cancer, metastatic and adjuvant breast cancer, squamous cell head 
and neck cancer, and gastric cancer [18]. In addition, docetaxel has demonstrated activity in 
previously treated patients with carcinomas of endometrial cancer, esophageal cancer, 
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bladder cancer, prostate cancer, small cell lung cancer, lymphomas, and other neoplasms 
[19]. Commonly, docetaxel is administered every three weeks at a doses-range of 60-100 
mg/m2 being infused in one hour. Dose of 75 mg/m2 is the recommended dose when the drug 
is given either as a single agent or in combination with another antineoplastic [18]. At higher 
doses, docetaxel may be less well-tolerated, especially by patients who have received 
extensive previous bone marrow suppressive therapies. A weekly schedule of docetaxel 
administration at lower doses (25-40 mg/m2) has been recommended and has had response 
rates similar to that of triweekly schedules with reduced myelosuppression [20]. Low-dose 
weekly infusion of docetaxel was investigated in patient groups such as elderly people, 
people with poor performance status, and those with a refractory disease [21].  
Upon intravenous administration, docetaxel is rapidly distributed to body tissues [17, 
22] and binds to plasma proteins (>90%) [23]. It has a relatively large volume of distribution 
accompanied with its binding to a wide range of tissues [18]. Its peak plasma concentrations 
generally exceeds levels required to induce relevant biologic effects [19]. However, the data 
about the bio-distribution of docetaxel in humans is limited. Immediately after treatment, the 
concentration is highest in the liver, bile, and intestines. Traces can also be found in the 
stomach, spleen, bone marrow, myocardium, and pancreas [19]. With the majority of 
excretion occurring in the first 48 hours, docetaxel gets eliminated predominantly through 
hepatic and biliary route and to a lesser extent by urinary excretion [18, 19, 21]. Plasma 
concentration profiles of docetaxel are determined by its elimination kinetics with an 
elimination half-life ranging from 11-19 hours [18]. 
Neutropenia, anaemia, and skin reactions are most common dose-limiting side effects 
of docetaxel [14]. Taking the extent of any existing myelosuppression (from previous 
therapy) into consideration as an important determinant, the blood counts are believed to 
reach lowest after 8-9 days of docetaxel treatment and recover by days 15-21 [18, 19]. 
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Between 50% and 75% of patients receiving docetaxel develop skin toxicity. Skin reactions 
can include a pruritic maculopapular rash appearing on the forearms, hands, or feet, and less 
commonly, desquamation of the palms or the soles of the feet (palmar-plantar 
erythrodysesthesia) [18, 21]. Alopecia is also extremely common. Other cutaneous effects 
include onychodystrophy, onycholysis, soreness, and brittleness of the fingernails. Other 
possible toxicity is fluid retention, characterized by edema, weight gain, pleural effusion and 
ascites, which may be attributed to increased capillary permeability caused by docetaxel [18, 
19, 21]. 
Because of docetaxel’s poor water solubility (3 µg/ml), in the commercial 
formulation, the drug is dissolved in 50 % polysorbate 80 (Tween™ 80) (a non-ionic 
surfactant) and 50 % ethanol [24]. Administration of docetaxel has been associated with 
hypersensitivity reactions such as pruritus and systemic anaphylaxis [25-27]. Evidence 
suggests that these allergic reactions are in part due to polysorbate 80 [10]. Polysorbate 80 is 
considered responsible for fluid retention/edema by increasing membrane permeability [28] 
and decreasing plasma colloid osmotic pressure [29, 30]. It has also been shown to influence 
protein binding of docetaxel at clinically relevant concentrations [31]. However, the 
mechanistic basis for this is not clear. Docetaxel is subjected to metabolic conversion and 
inactivation in the liver by the cytochrome P450 (CYP450) isoenzymes [22]. Elimination of 
docetaxel is also dependent on transporters, particularly P-glycoproteins (P-gp), that exist at 
the bile canalicular membrane. It is believed that polysorbate 80 or its metabolites can inhibit 
CYP450 [32, 33] and/or P-gp mediated elimination of docetaxel and consequently affect 
docetaxel clearance from the body. 
Other allergic reactions, such as dyspnea, bronchospasm, and hypotention, can happen 
within minutes after starting the infusion during the initial courses of docetaxel therapy; these 
reactions are attributed to the vehicle, solvent, or to the drug itself [18, 19, 21]. Docetaxel 
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also exerts adverse effects on other organs of the body such as the eyes (epiphoria), 
gastrointestinal tract (ischaemic colitis), heart (heart failure), and musculoskeletal system 
(arthralgia) [21]. 
 
1.4.Nanoparticle Drug Carrier Systems 
To date, different types of nanoparticles and strategies based on nanotechnology have 
been developed to deliver various drugs (including anti-cancer agents) to the body [34-38]. 
Using nanoparticles as means of drug delivery is usually done to improve the 
pharmacokinetic characteristics of an active agent [39] by changing the drug formulation to 
create a more desirable absorption, distribution, metabolism, and excretion (ADME) profile. 
For example nanoparticles as drug delivery vehicles can i) protect drugs from degradation, ii) 
enhance drug absorption, iii) modify the drug’s distribution profile, and iv) modify the drug’s 
elimination rate/profile. [36]. Regardless of the mode of intervention made by nanoparticulate 
drug carrier systems, the consequence, which is the improvement in pharmacokinetic 
characteristics, secondarily improves the drug’s pharmacodynamic characteristics.  
Successful nanoparticle drug carriers must be able to contribute desirable 
modifications in their cargo’s pharmacokinetic profile. In addition, ideal nano-carriers are 
expected to i) be biocompatible/biodegradable (i.e., be non-toxic to the human body), ii) have 
suitable drug loading capacities, iii) have physicochemical characteristics suitable for 
delivery purposes (e.g., targeted, non-targeted, systemic, and local drug delivery), and iv) 
have predictable and even controlled release profiles [35]. Nanoparticle drug carriers are 
categorized into various classes based on the component(s) used in their fabrication. The 
major categories of nanoparticulate drug carriers include lipid-based and polymer-based 





Figure 1-2. Various types of nanoparticles used in drug delivery. 
 
1.4.1. Lipid-Based Nanoparticle Drug Carriers 
1.4.1.1.Liposomes 
Liposomes are spherical vesicles comprising one or more bilayers of phospholipids 
that are arranged concentrically around one or more aqueous compartments and one central 
aqueous core (figure 1-2) [40, 41]. According to particle size and the number of phospholipid 
bilayers, liposomes are classified as large uni-lamellar vesicles (LUV), multi-lamellar 
vesicles (MLV), or small uni-lamellar vesicles (SUV) [40]. Liposomes can accommodate 
both hydrophilic and hydrophobic drugs [42]. Lipid bilayer of liposome acts as a membrane 
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to separate the aqueous core from the surrounding outside media [43]. Hydrophilic drugs are 
mainly entrapped in the core of liposomes or aqueous compartments [44], while hydrophobic 
drugs are mainly adsorbed or inserted in the lipid bilayers [45]. Drugs with poor water 
solubility are initially solubilized in the hydrophobic material (phospholipid) that forms the 
liposome bilayer. These drugs have poor water solubility and therefore low affinity towards 
the aqueous core or surrounding media [46]. Once placed in the liposome bilayer, they tend 
to remain entrapped in the region. 
Liposomes’ capability to contain both hydrophilic and hydrophobic drugs confers 
better solubility and distribution to the encapsulated drug than free drugs [47]. In addition, 
like other nanoparticle drug carriers, liposomes can be modified on the surface to enhance 
their bio-distribution and therapeutic efficiency [48]. Although liposomes’ physicochemical 
and biological stability have been a matter of concern, the formulation of anticancer agents in 
liposomes has been extensively investigated for drug delivery purposes [35, 37].   
Several liposomal formulations of anticancer agents are in clinical trial phases or have 
been approved for clinical application. Vinorelbine (Alocrest), docetaxel (ATI-1123), 
topotecan (Brakiva), doxorubicin (MCC-465), and an analogue of cisplatin (Aroplatin) are a 
few examples of chemotherapeutic agents in liposomal drug delivery systems in phase I 
clinical trials [49]. Liposomal formulations of paclitaxel (EndoTAG-1/LEP-ETU), oxaliplatin 
(MBP-426), and lurtotecan (OSI-211) are in phase II clinical trials [49]. Examples of 
liposomal formulation of anticancer agents in phase III trials include cisplatin (Lipoplatin), 
irinotecan (MM-398), and doxorubicin (Thermodox) [49]. Liposomal formulations of 
doxorubicin (Doxil/Myocet), daunorubicin (DaunoXome), vincristine (Marqibo), and 
cytarabine (DepoCyt) have been approved for treatment of various cancer types.  
Liposomes as nanoparticle drug delivery systems have several advantages [50, 51]: 
i) Liposomes increase efficacy and therapeutic index of loaded drugs, 
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ii) Liposomes protect the encapsulated drug from degradation (increased stability), 
iii) Liposomes reduce encapsulated agents’ toxicity,  
iv) Liposomes are suitable for systemic administration, 
v) Liposomes are biocompatible and biodegradable drug delivery systems, and 
vi) Liposomes can be surface-engineered for active targeting purposes. 
However, liposomes are not without drawbacks, which include [50, 51]: 
i) A short half-life, 
ii) The possibility of oxidation and hydrolysis of some phospholipids in nanoparticle 
formulation,  
iii) Low stability,  
iv) The possibility of leakage of encapsulated drug from liposomes, 
v) Low solubility, and 
vi) A high cost of production. 
 
1.4.1.2.Solid Lipid Nanoparticles and Nanostructured Lipid Carriers 
Solid lipid nanoparticles (SLNs) are spherical particles in the nanometer size range 
(figure 1-2) that are prepared from lipids that are in solid state both at room and body 
temperature [52, 53]. SLNs are usually prepared from triglycerides, a mixture of 
triglycerides, or even wax [54]. The incorporation of both lipophilic and hydrophilic drugs in 
SLNs is potentially feasible [55]. In SLNs, the drug is usually dispersed throughout the bulk 
of the lipid matrix forming the nanoparticle structure. A few advantages are offered by SLNs 
over other lipid-based nanoparticle formulations like liposomes such as flexibility in 
modulating the drug release profile, pronounced physical stability, and protection of loaded 
drug from chemical degradation [56]. However, SLNs’ disadvantages include low drug 
loading and the possibility of drug expulsion during shelf-life (as a result of polymorphic 
12 
 
transition of lipid to thermodynamically more stable form) [57]. To solve such disadvantages, 
another generation of lipid nanoparticles called nanostructured lipid carriers (NLCs) were 
introduced [58] based on an application of a mixture of a solid and a liquid lipid [59, 60]. 
NLCs are prepared from lipid mixtures in a way to create a spherical nanoparticle in which 
the liquid lipid is encapsulated (i.e., particle core) by the solid lipid (i.e., particle shell). The 
simultaneous encapsulation of the dissolution of a drug (in a liquid lipid core) by a solid lipid 
shell gives NLCs a higher loading capacity and more controlled release [61, 62].    
The important advantages attributed to solid lipid based nanoparticles include [63-66]: 
i) Protection and improved of stability loaded drug,  
ii) Increased non-toxicity (most lipids used in fabrication of solid lipid based 
nanoparticles are biocompatible),  
iii) Possibility of large-scale fabrication, 
iv) Avoidance of using organic solvents during preparation, 
v) Possibility of incorporating hydrophobic and hydrophilic drugs, and    
iv) Possibility of targeting.    
Also, important drawbacks of solid lipid based nanoparticles include [65, 66]: 
 i) Poor capacity for drug loading, 
 ii) Drug leakage and expulsion during storage (SLN), and  
iii) Particle growth. 
 
1.4.2. Polymer-Based Nanoparticle Drug Carriers 
1.4.2.1.Polymer-Drug Conjugate 
Polymer-drug conjugates are a type of nanoparticulate delivery system in which the 
drug and polymer are covalently attached to each other (Figure 1-2). This attachment creates 
a new molecule that predominantly demonstrates the polymer’s physicochemical 
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characteristics [67]. Usually, a water-soluble polymer is used to improve the solubility of 
conjugated drug. The covalent link between the drug and polymer is maintained by a spacer 
moiety (e.g., peptidyl or ester), which needs to be degradable in the physiologic/pathologic 
condition of the body (e.g., pH of the tumour tissue) to release the drug after administration 
to the body [68]. Other than being water-soluble, ideally, the polymer must be non-
immunogenic, non-toxic, and have an easy elimination pathway from the body. Wide 
spectrums of drugs have been formulated as polymer-drug conjugates, including anticancer 
agents [69, 70]. Several successful nanoparticle therapeutics in clinical cancer care are drug-
conjugates [36]. Many polymer-drug conjugate products are in the market or in the clinical 
phase, and others are being researched [71]. Asparaginase attached to PEG (Oncaspar®) is a 
well-known marketed product used for acute lymphoblastic leukaemia [72]. Other examples 
include Interferon α-2b attached to PEG (Sylatron™) as adjuvant therapy for resected stage 
III melanoma, PEGylated Interferon α-2a to treat melanoma (Phase I clinical study) and 
chronic myelogenous leukemia (phase II clinical study) [73], and Poly glutamic acid –
conjugated paclitaxel (Opaxio®) (phase III clinical study) to treat ovarian cancer [74]. 
Conjugation of polymer resulted in increased half-life and efficacy, and decreased 
administration frequency of the mentioned agents.  
Several advantages have been attributed to polymer-drug conjugates as nanoparticle 
drug delivery systems [72, 75]:  
i) Increased stability and protection of conjugated drug, 
ii) Prolongation of drug release and action, 
iii) Possibility of targeting of conjugated drug,   
v) Ability to delivery hydrophobic and hydrophilic drugs, and  
vi) Increased blood residence and circulation time.  
However, polymer-drug conjugates have some drawbacks which include [72, 74, 76]: 
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i) Potential toxicity of polymers (due to frequency of administration),  
ii) High cost of production, and 
 iii) Poor drug loading capacity. 
 
1.4.2.2.Dendrimers 
Dendrimers are spherical nanoparticles prepared from highly-branched polymers that 
form a macromolecular structure (figure 1-2) [77]. Dendrimers possess a unique three-
dimensional feature in which the polymer is repeatedly/regularly branched giving rise to a 
structure with a core at the centre, branching units surrounding the core, and terminal 
functional groups available for possible interaction forming the exterior [78]. The exterior 
section is responsible for chemical behaviour of the dendrimer and can be subjected 
functionalization/modification to further determine the solubility, miscibility, and reactivity 
of the nanoparticle [79, 80]. The core and the internal section offer a suitable environment 
(nano-cavity) in which drug molecules can either be physically entrapped or chemically 
conjugated to the branched polymer structure [81]. Containing the drugs in the core helps 
protect drugs from degradation and contributes to their solubility. The functionality of 
dendrimers’ exterior section allows for the complexation or conjugation of drugs to the 
surface of dendrimers as well [82-84]. Consequently, due to dendrimers’ favourable 
characteristics, such as tuneable functionality, mono-dispersity, encapsulation ability, and 
water solubility, they have been extensively investigated for the delivery of a wide spectrum 
of drugs [85, 86], including chemotherapeutic agents [87-90]. For example, association with 
dendrimers improved the bioavailability of methotrexate [91] and increased the water 
solubility of 5-fluorouracil, doxorubicin, and paclitaxel [91, 92].  
Advantages attributed to dendrimers in drug delivery include [93]: 
i) Possibility of targeting due to the presence of multiple functional groups, 
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ii) Possibility of controlling nanoparticle characteristics through preparation methods, 
iii) Possibility of delivering hydrophobic as well as hydrophilic drugs, and  
iv) Possibility of large-scale production 
Disadvantages attributed to dendrimers include [94-96]:  
i) Easy renal excretion due to relatively small particle size range, 
ii) Labour-intensive, multi-step fabrication process, and   
iii) Possibility of toxicity due to polymer accumulation (for non-biocompatible 
polymers).  
     
1.4.2.3.Polymeric Micelles  
Polymeric micelles are nanoparticles made from polymers with one hydrophilic end 
and one hydrophobic end (i.e., amphiphile molecules in water). Because of their dual 
physicochemical characteristics, amphiphilic polymers can interact with other polymers and 
water molecules. When the concentration of polymer in an aqueous environment is increased 
above a certain level known as critical micelle concentration (CMC), amphiphilic polymers 
self-assemble and form a micelle structure [97]. Structurally, hydrophobic segments of the 
polymer interact (by hydrophobic interactions) inside the micelle to form an internal zone 
(core) and hydrophilic segment of the polymers arrange at the surface to form a shell (figure 
1-2) [98]. Hydrophobic drugs can be entrapped in the hydrophobic environment of the 
internal zone by chemical conjugation or by physical means, which enhance the drug’s 
solubility [99, 100]. Entrapping the drug in the internal zone protects the associated drug 
from degradation or biological triggers and can modify the drug’s bio-distribution as well 
[101]. Due to their delivery performances, micelles have been used for the delivery of various 
drugs [102, 103], including anticancer agents [104] such as paclitaxel (in phase III clinical 
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study), doxorubicin (in phase II clinical study), cisplatin (in phase III clinical study), 
oxaliplatin (in phase I clinical study), and epirubicin (in phase I clinical study) [105]. 
To summarize, several important advantages are attributed to polymeric micelles 
[100, 106, 107]: 
i) Polymeric micelles are prepared relatively easy because they self-assemble,   
ii) They allow for the possibility of surface-modification and targeting,  
iii) They can solubilize drugs with poor water solubility, and 
iv) They protect incorporated drug.  
Disadvantages attributed to polymeric micelles include [100, 106, 108]: 
i) A high level of polymer chemistry and synthesis is usually required,  
ii) Scaling up preparation procedures is difficult, 
iii) The number of polymers for preparation of micelles is limited. 
 
1.4.2.4.Polymeric Nanoparticles 
Polymeric nanoparticles are solid colloidal drug carriers prepared from polymers (or 
macromolecules), and have a size range between 10 and 1000 nm [109]. Structurally, two 
types of nanoparticles are defined for polymeric nanoparticles—nanocapsule and nanosphere 
(figure 1-2)—which are obtained based on different methods of preparation [110]. Depending 
on its physicochemical characteristics, the drug or biologically active agent is usually 
associated to polymeric nanoparticles in one of three different forms: encapsulated (or 
entrapped), dissolved (or dispersed), or adsorbed (or attached) [111]. In nanospheres, the drug 
is uniformly (homogeneously) distributed throughout the matrix of polymer that forms the 
nanoparticle.  In nanocapsules, the drug is encapsulated inside the core of nanoparticle and is 
confined by a shell of polymer (around the central cavity) [112].  
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The polymers typically used to fabricate polymeric nanoparticles can be categorized 
as either biodegradable or non-biodegradable. The accumulation of non-biodegradable 
polymers in the body may cause toxicity. Additionally, non-biodegradable polymeric 
nanoparticles’ drug-release mechanism is dependent on drug characteristics, permeability, 
and diffusion [113]. Polymeric nanoparticles fabricated from biocompatible, biodegradable 
polymers are non-toxic and release the drug mainly as the polymer degrades in the body 
[114].   
Another way to categorize polymers used in preparation of polymeric nanoparticles is 
whether their source is natural or synthetic [115]. As mentioned, synthetic polymers 
contribute to a controlled release profile of the drug or active agent over a long period, while 
polymeric nanoparticles prepared from natural polymers tend to release the drug in relatively 
shorter time-periods. During nanoparticle fabrication, natural polymers lack the need for 
organic solvents, while synthetic polymers usually require organic solvents and harsh 
preparation [116, 117]. However, both types of polymers are being widely used in 
preparation of polymeric nanoparticles. Poly(esters), poly(cyanoacrilates), and 
poly(anhydrides) are examples of synthetic polymers; chitosan, albumin, dextrans, and 
alginate are examples of natural polymers [112]. 
Because of the diversity in the type and characteristics of polymers and approaches 
used in fabrication of polymeric nanoparticles, nanoparticles have versatile features and 
characteristics [36]. This makes polymeric nanoparticles a unique and promising tool to 
deliver a wide-spectrum of drugs and active agents with different purposes. Polymeric 
nanoparticles offer many advantages as drug-delivery systems [34-37]. Generally, they have 
high stability and confer stability and protection from degradation to the loaded drug. They 
can incorporate both hydrophobic and hydrophilic drugs and active agents to increase 
solubility compared to a free drug. They can also sustain or control the drug’s release from 
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the nanoparticle by masking the drug molecules and active agents from recognition in the 
body and therefore protecting the drug from rapid or premature elimination. In addition, they 
offer further structural modifications, particularly on the surface of nanoparticles, to enhance 
their therapeutic performance. These abilities help improve the drug’s 
absorption/bioavailability, distribution, metabolism, and elimination in the body and thus 
provide a favourable impact on pharmacodynamic features [118].  
To summarize, polymeric nanoparticles as drug delivery systems have the following 
advantages [117]: 
i) They have high stability,  
ii) They offer protection and increase the stability of loaded drugs, 
iii) They can incorporate hydrophobic and hydrophilic drugs,  
iv) They offer controlled and/or sustained release of loaded drug, and 
v) They allow for surface-modification and targeting.  
However, polymeric nanoparticles have some drawbacks [119, 120]: 
i) Non-biodegradable/biocompatible polymers may accumulate and cause toxicity, and 
ii) They may be cleared by the reticuloendothelial system (RES) (according to size). 
Among the long list of synthetic, natural, biodegradable, and non-biodegradable 
polymers, Poly (lactide-co-glycolide) (PLGA) has attracted substantial interest from 
researchers for the fabrication of polymeric nanoparticles for drug delivery because of 
PLGA’s unique features and characteristics.    
 
1.4.3. PLGA Nanoparticles 
1.4.3.1. PLGA polymer 
PLGA polymer has attracted considerable attention in the field of pharmaceutical and 
biomedical sciences [121, 122]. Owing to its variable nature, PLGA polymer demonstrates 
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variable physicochemical properties, such as tuneable mechanical characteristics and a wide 
range of degradation times. Furthermore, it has been approved by the United States Food and 
Drug Administration (FDA) for use in humans [123] because of its biocompatibility, 
biodegradability, and non-toxicity profiles [124, 125].  
 
1.4.3.1.1.  Physicochemical characteristics 
A thorough knowledge of PLGA’s physicochemical properties is essential in 
designing drug-delivery systems. PLGA is a linear co-polymer composed of monomer units 
of lactic acid (LA) and glycolic acid (GA) (figure 1-3). LA possesses a chiral centre (α 
carbon) to where the side methyl group is attached, which contributes to LA having two 
forms of D, L, or a racemic mixture of DL-isomers. Accordingly, poly(lactic acid) (PLA) can 
be prepared from either the isomers (i.e, D or L) or the optically inactive racemic mixture 
[126]. In D, L-PLA two stereo-isomeric forms of LA irregularly distribute in polymer chain 
and contribute to non-crystallinity in the material. GA lacks the pendant methyl group, which 
makes poly (glycolic acid) (PGA) highly crystalline. Non-crystallinity is considered 
important in the application of polymer for drug-delivery purposes because it contributes to a 
more homogenous distribution of the drug in the polymer matrix and to higher rates of 
polymer hydration and hydrolysis [121]. Therefore, the crystallinity of PGA is reduced when 
co-polymerized with PLA. In addition, using D,L-LA racemic mixture for PLGA preparation 





Figure 1-3. Monomers used in fabrication of PLGA. 
 
 
Figure 1-4. Molecular structure of PLGA. 
 
PLGA (figure 1-4) is usually categorized based on different characteristics including 
the ratio between two monomers (i.e., LA:GA), the polymer molecular weight, and the type 
of terminal functional group. GA is more hydrophilic compared to LA because of the 
presence of methyl on α carbon atom of LA. Consequently, PLGA polymers with more LA 
monomers in the polymer structure exhibit fewer hydrophilic characteristics. PLGA polymers 
with more hydrophilic characteristics absorb more water and degrade faster [128, 129]. 
Ultimately, higher degradation rates accelerate drug release. An exception is the polymer 
with 50:50 monomer ratio, which also demonstrates a higher degradation rate. Therefore, the 
degradation rate tends to increase when the portion of GA monomers increases from 50 to 
100 percent. Polymer molecular weight also influences the physicochemical characteristics of 
PLGA [129]. Polymers with lower molecular weight tend to degrade faster, which 
secondarily influences the rate of drug release from the polymeric delivery system. The 
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polymer degradation rate and drug release are also influenced by the type of polymer 
functional terminal group. Compared to ester-terminated PLGA polymers, free carboxyl end-
group has the potential to attract water and catalyse the hydrolysis reaction between LA and 
GA and thus increase degradation and release rates [130].      
 
1.4.3.1.2. Polymer Degradation and Drug Release from PLGA           
Upon contact with an aqueous environment, PLGA polymer undergoes hydrolytic 
degradation at the ester bond site where hydrolysis happens randomly [131]. Hydrolysis of 
the ester bonds throughout the polymer chain results in structures having COOH (carboxylic 
acid) and OH (hydroxyl) end-groups. Hydrolysis results in reduction of polymer molecular 
weight and creates fragments with higher water solubility. Further hydrolysis of these 
fragments creates LA and GA, which enter normal biochemical pathways of the body. It is 
believed that the produced acid environment catalyses the hydrolysis procedure (i.e., 
autocatalysis) and further contributes to degradation of PLGA polymer [123]. 
Various factors affect the degradation procedure of polymeric systems including 
PLGA (table 1-1). The important factors include polymer composition, polymer molecular 
weight, and the associated drug. Having a thorough understanding of these factors and the 
magnitude at which they affect the degradation procedure can help researchers design 
polymeric drug-delivery systems with desired characteristics: since release of the drug is a 
result of polymer degradation, when the degradation process is understood, release rates can 







Table 1-1. Factors affecting PLGA degradation and drug release from delivery systems. 
Factor Effect 




PLGA polymers with higher molecular weight degrade 
slower 
Associated Drug The drug’s chemistry determines interactions between the 
drug and polymer and affects polymer degradation rate 




Ester-terminated PLGA degrades slower than acid-
terminated polymers 
Delivery System Size Delivery systems with a smaller size (larger surface-area) 
have higher degradation rates  
 
The degradation process of PLGA is profoundly affected by the composition (i.e., the 
ratio between LA and GA) of the polymer. GA monomers in PLGA structure make the 
polymer more hydrophilic and thus accelerate the rate of degradation. This has been 
demonstrated by several research groups [132, 133]. For example, Wu and colleagues [130] 
used a set of PLGA polymers having similar molecular weight but different compositions 
(L:G ratio of 50:50, 65:35, 75:25, 85:15, 100:0) in a degradation experiment. They 
demonstrated that PLGA polymers with higher content of GA degrade faster. They attributed 
this relationship to the presence of the methyl group in LA, which hindered the approach of 
water molecules and the further hydrolysis of the ester bond. In another study, Lu et al. 
prepared foams from 85:15 and 50:50 L:G-ratio PLGA and conducted degradation tests 
[134]. The 85:15 polymer demonstrated little or no variation in water absorption, weight and 
other characteristics, while 50:50 polymer exhibited a marked increase and decrease 
respectively in water absorption and weight during the test period.               
Molecular weight has been demonstrated to influence degradation rate of PLGA 
polymers. The degradation rate of polymers is directly related to the polymer chain size. 
Molecular weight of polymers increases parallel to chain size. Thus, polymers with lower 
molecular weight possess a higher degradation rate (i.e., require less time to break down) 
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compared to polymers with higher molecular weight [135-137]. For example, Xie et al.[138] 
studied the effect of molecular weight on degradation of polymer membranes prepared from 
PLGA 85:15 at two different molecular weights (i.e., 2.3 and 3.1 dl/g inherent viscosity). The 
PLGA with lower molecular weight demonstrated faster weight loss compared to the polymer 
with higher molecular weight. Also, Tracy and colleagues [139] used 50:50 PLGA with 
various molecular weights (i.e., 0.17, 0.19, 0.23, and 0.4 dl/g inherent viscosity) to evaluate 
factors affecting degradation rate of microspheres including polymer molecular weight. They 
observed a faster degradation with lower molecular weight polymer microspheres.   
The chemical properties of the drug associated to the PLGA polymer can also affect 
the degradation rate [140]. Depending on the drug’s hydrophilicity/hydrophobicity and the 
potential bonds that can form between PLGA structure and loaded drug, the degradation 
mechanism can shift from bulk erosion to surface erosion [141]. If interactions between the 
drug and polymer are strong, surface erosion is the predominant mechanism of the release. In 
the case of weak drug-polymer interactions, water molecules can more easily access the bulk 
of the matrix of the particles and contribute to bulk erosion. Therefore, the potential 
interactions that can happen between drug and PLGA polymer and their influence on polymer 
degradation and drug release should be considered before designing a polymeric drug 
delivery system [131].    
Other factors can affect the degradation pace of PLGA polymer.  There are conflicting 
reports on the effect of crystallinity on PLGA degradation rate [123, 131, 142, 143]. Various 
studies have suggested that polymer non-crystallinity contributes to faster PLGA polymer 
degradation [144].  However, a few have proposed otherwise [131].  
The size and shape of the drug-delivery system are two of the factors affecting the rate 
of PLGA degradation due to the ratio of surface area to volume. Polymeric systems with 
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larger surface areas have larger amounts of the polymer matrix exposed to the surrounding 
media, which contributes to higher degradation rates [144, 145]. 
The type of terminal functional group on the PLGA polymer chain has been reported 
to influence polymer degradation time [146]. Ester-terminated PLGA polymer was reported 
to have delayed degradation time in comparison with acid-terminated (i.e., COOH) polymer 
of similar composition and molecular weight.      
 
1.4.3.1.3. Drug Release from PLGA Matrices 
As noted, upon contact with an aqueous environment, PLGA undergoes hydrolysis. 
The degradation of polymer is commenced with the cleavage of the ester bond between 
monomers, which leads to formation of oligomers and ultimately monomers [143]. This 
process releases the associated drug into the surrounding media. Generally, the release of 
drugs from polymeric drug-delivery systems happens as a function of polymer degradation. 
Three mechanisms are considered responsible for drug-release [123, 147]: i) erosion of 
polymer at surface of drug-delivery systems that contributes to the release of the physically-
entrapped drug (i.e., surface erosion (figure 1-5)), ii) erosion of polymer within the matrix of 
the drug-delivery system, which releases the drug by diffusion (i.e., bulk erosion (figure 1-
5)), and iii) cleavage of bonding between the polymer and drug molecules (i.e., for example 





   Figure 1-5. Polymeric nanoparticles erosion mechanisms that leads to eventual drug release. 
  
Although surface erosion in part contributes to drug-release, bulk erosion is 
considered to be the main degradation mechanism of PLGA matrices and therefore is mainly 
responsible for the release of loaded drug [143]. In bulk erosion, the rate of hydrolysis of the 
PLGA polymer is less than the rate of water uptake into the matrix of the polymer [145]. As 
degradation propagates within the polymer matrix, degradation products become more water 
soluble. This attracts more water, which allows the degradation products and the loaded drug 
to diffuse out of the eroding matrix.   
Degradation of PLGA polymer is a collective process of different mechanisms that 
can be affected by many factors, such as polymer composition, polymer molecular weight, 
the associated drug, and polymer crystallinity. Therefore, the rate and pattern of the release of 
the drug associated to the PLGA matrix is largely unpredictable. Although zero-order release 
from PLGA matrices is more desired, mono-phasic release pattern is rare [143]. Bi-phasic or 
even tri-phasic drug release profile is most commonly seen in PLGA polymer matrices. Small 
particles usually exhibit biphasic release pattern [148].  
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Phase one is usually described as a burst release [149]. During phase one, drug 
molecules on the surface of polymer matrix or close to the surface are in more contact with 
the surrounding medium and as a result prone to hydration [150]. Disintegration of particles 
and the formation of cracks are considered to be other reasons for burst release [151]. The 
initial burst is also affected by the loaded drug’s physicochemical characteristics, 
concentration, and even polymer hydrophilicity. During this phase random cleavage of the 
ester bond contributes to the formation of oligomers and reduction in polymer molecular 
weight but soluble monomer products are not formed [152]. 
During phase two, the drug and water diffuse slowly through depleted layers and 
existing pores while hydration/hydrolysis and polymer degradation is in process [143]. The 
hydrolysis of PLGA within the matrix of polymer forms more soluble oligomers and 
monomers and creates pathways for water and drug to diffuse in and out, respectively, until 
erosion and drug release is complete [153]. Attraction of aqueous phase to the PLGA matrix 
plays an important role in determining the rate of polymer degradation and drug release 
[142].  Overall, the second phase is slow and usually the drug is released in a progressive 
manner.        
 
1.4.3.2.PLGA Nanoparticle Preparation Methods 
Several techniques have been developed by researchers to produce polymeric 
nanoparticles from preformed polymers. In these techniques, two main steps are usually 
followed: an emulsified system is prepared and nanoparticles are formed from the emulsified 
system. The first step is usually similar in all nanoparticle fabrication methods, while the 
second step varies and gives the name to the method. Common nanoparticle fabrication 




1.4.3.2.1. Emulsification Solvent Evaporation  
Emulsification solvent evaporation method is one of the most common and the oldest 
technique used for fabrication of PLGA nanoparticles [122]. In this method, the polymer and 
drug are first dissolved in an organic solvent. The organic solvent is usually volatile and 
water-immiscible, like chloroform, methylene chloride, and ethyl acetate. The organic phase 
is then emulsified in an aqueous phase containing a stabilizer such as poly(vinyl alcohol) or 
vitamin E-TPGS  to stabilize the emulsion. The obtained emulsion is then subjected to a 
source of high-energy shear stress (like a high-pressure homogenizer or an ultrasonic device) 
to break large emulsion droplets into smaller droplets. The reduction in the size of emulsion 
droplets in this step is crucial since it directly relates to the final size of obtained 
nanoparticles [122]. The emulsified system is then exposed to a reduced pressure or vacuum 
condition that results in the evaporation of the organic solution and ultimately disperses 
nanoparticles in the aqueous phase [154]. During this evaporation step, the organic solvent 
first diffuses out of emulsion droplets into the aqueous surrounding medium and then is 
removed by evaporation [155]. 
Based on the type of emulsion prepared during the first step (i.e., oil in water (O/W), 
water in oil in water (W/O/W)), the emulsification solvent evaporation technique can be used 
to accommodate drugs with different properties in PLGA nanoparticles [122]. W/O/W type 
obtained from double-emulsion procedure is used to entrap hydrophilic material while O/W 
emulsion is suitable for hydrophobic drugs [156].  
 
1.4.3.2.2. Emulsification Solvent Diffusion            
In the emulsification solvent diffusion method, PLGA polymer and drug are dissolved 
in an organic solvent that must be partially miscible with water [157]. Suitable organic 
solvents with partial miscibility with water include benzyl alcohol, propylene carbonate, and 
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isopropyl acetate. The obtained organic phase is then emulsified in an aqueous phase under 
vigorous stirring [158]. The aqueous phase should contain a stabilizing agent such as poly 
(vinyl alcohol) (PVA), sodium dodecyl sulfate (SDS), or didodecyl dimethyl ammonium 
bromide (DMAB) to stabilize the emulsion. The obtained emulsion is then diluted with large 
quantities of water. This dilution diffuses the organic solvent (present in emulsion droplets) 
into the water and ultimately leads to the solidification and precipitation of the nanoparticles 
[122].  
 
1.4.3.2.3. Emulsification Salting Out           
Emulsification salting out is another method widely used to prepare polymeric 
nanoparticles [159].  In this method, the polymer and drug are dissolved in an organic solvent 
that must be miscible with water (e.g., acetone, tetrahydrofuran). While exposed to a high-
energy shear stress, the organic phase and aqueous phase (containing a stabilizing agent) are 
mixed together to prepare an emulsion. Compared to the emulsification steps of other 
fabrication methods, the aqueous phase here contains a high concentration of salts (which are 
not soluble in the organic solvent) such as calcium chloride, magnesium chloride, and 
magnesium acetate. The high concentration of salt prevents the organic solvent in the 
emulsion droplets from diffusing into the surrounding aqueous medium. A sufficient quantity 
of water is then added to the emulsion under mild stirring condition. This dilutes the salts and 
promotes the rapid diffusion of organic solvent into the surrounding medium, which solidifies 
and precipitates PLGA nanoparticles [160]. Compared to emulsification solvent diffusion 
method (that has similar steps), the salting out technique’s use of salts requires final 






1.4.3.2.4. Nanoprecipitation       
Unlike other nanoparticle fabrication techniques, the nanoprecipitation procedure has 
only one step. The method is usually suitable for hydrophobic materials, but it has been 
modified to accommodate water-soluble drugs as well [161, 162]. In this method, the 
polymer, drug, and a lipophilic stabilizing agent are dissolved in a polar organic solvent that 
is water miscible, such as acetone, acetonitrile, ethanol, or methanol. The organic solution is 
then added in a controlled way (e.g., pour drop-wise or injected) to an aqueous phase 
containing a surfactant under continuous stirring [163]. As a result of fast diffusion of the 
organic solvent into the aqueous phase, nanoparticles are formed and precipitated. The 
dispersion is then subjected to a reduced-pressure or vacuum condition to evaporate the 
organic solvent [121].         
 
1.4.3.2.5. Other Preparation Methods 
Other PLGA nanoparticle fabrication techniques follow quite different steps. 
Spray-drying: The spray-drying approach has also been used for fabrication of PLGA 
nanoparticles [164]. In this method, an emulsion (e.g., W/O) is prepared and sprayed into a 
stream of air, which leads to instantaneous formation of nanoparticles [165]. This method has 
few processing steps and therefore is a rapid method of nanoparticle preparation [166].   
Shirasu porous glass-emulsification: The method is a modified form of emulsion solvent 
evaporation technique. In this method, an emulsion is made and then subjected to high 
pressure in the presence of a glass membrane. The emulsion passes through a porous 
membrane and as a result, emulsion droplets break into smaller homogenous nano-droplets. 




Particle Replication in Non-wetting Templates (PRINT®): The method is based on soft-
lithography technology [168] and creates a population of PLGA nanoparticles with 
monodispersed distribution. It provides control over important characteristics such as 
nanoparticle size, shape, and drug loading. In this method, the drug and PLGA polymer are 
dissolved in an organic solvent, which is then deposited on a sheet made from poly(ethylene 
terephthalate) (PET) and spread using a rod. The solvent is then evaporated with heat to 
obtain a very thin film. The film and PET sheet is placed in contact with a patterned side of a 
mold and passed through heated nips. Nanoparticles form in the mold. The patterned side of 
the mold containing the formed nanoparticles is then placed in contact with another PET 
sheet that has been coated with a stabilizer (e.g., PVA). It is then passed through a hot 
laminator to transfer particles from the mold to the PET sheet and the mold is then separated. 
The nanoparticles are released from PET sheets using motorized rollers.    
     
1.4.3.3.Nanoparticle surface Modification 
PLGA nanoparticles offer advantages in the delivery of a wide spectrum of drugs 
owing to their unique characteristics, such as nano-meter size range, biocompatibility, 
biodegradability, and non-toxicity. To be able to meet their therapeutic potential as a 
controlled or targeted drug delivery system, PLGA nanoparticles must be able to remain in 
the systemic circulation for a long period of time after injection into the blood stream [169]. 
Long circulation times increase the chance that the nanoparticles will either reach their target 
tissue or release the loaded drug in a controlled manner in the blood stream. Despite several 
favourable attributes, PLGA nanoparticles encounter clearance from circulation by various 
natural clearing mechanisms in the body [170]. The fate of nanoparticles in the body is 
determined by nanoparticle’s characteristics. Accordingly, several nanoparticle parameters, 
such as size, shape, and surface chemistry, have been manipulated to increase the residence 
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time of nanoparticles in the systemic circulation and reduce non-specific distribution [171]. 
Modification of nanoparticles’ surface properties is one of the most widely used approaches 
to increase nanoparticles’ retention time and their drug-payload in blood [172]. For example, 
Park and colleagues [173] used PLGA nanoparticles for doxorubicin delivery and found out 
that surface-modification of nanoparticles was effective in increasing the drug’s retention 
time in the blood compared to un-modified nanoparticles. Approximately 40% of the initial 
dose of doxorubicin administered as surface-modified nanoparticles was still present in the 
blood after 24 hours, while the free drug and the drug loaded in un-modified nanoparticles 
were not detectable after 24 hours.  
Long circulating PLGA nanoparticles are usually obtained by coating of nanoparticles 
with other types of polymers that confer stealth properties to the nanoparticles so they can 
escape the natural clearing mechanisms of the body [169]. A stealth property is a 
characteristic that makes nanoparticles invisible to the biological mechanisms involved in the 
clearance of nanoparticles [169]. The polymers used to endow stealth properties to PLGA 
nanoparticles are typically highly hydrophilic, flexible, and electrostatically neutral. A few 
examples include PEG, poloxamers, polysaccharides (e.g., dextran), chitosan, and human 
serum albumin. PEG has increased blood circulation residence time of different type of 
nanoparticles, including PLGA nanoparticles [174]. For example, Duan et al. prepared 
surface-modified PLGA nanoparticles with PEG for mitoxantrone delivery [175] . PEGylated 
PLGA nanoparticles contributed to up to a 10-fold increase in drug concentration in the blood 
compared to un-modified PLGA nanoparticles. Murugesan and colleagues [176] found a two-
fold increase in blood residence time using PEGylated PLGA nanoparticles delivering 





1.4.3.4. PEGylation of PLGA nanoparticles 
PEG is a polymer prepared from repeating units of ethylene oxide (figure 1-6) with 
various molecular weights and configurations (e.g., linear or branched). The polymer 
possesses two reactive hydroxyl end groups (-OH) that can be used to covalently attach PEG 
to other molecules (i.e, PEG derivatization). To prevent unwanted crosslinking of PEG with 
other molecules, one of the terminal hydroxyl groups is substituted with a chemically inert 
group (e.g., OCH3) [177]. Therefore, covalent attachment of PEG to another molecule (such 
as PLGA polymer) is limited to the remaining hydroxyl group, which consequently controls 
the stoichiometry of PEG derivatization [178].  PEG is a biocompatible, biodegradable, and 
non-toxic polymer [179]. 
 
 
Figure 1-6. Molecular structure of PEG. (n = number of monomers repeated in the chain)   
 
1.4.3.4.1. Particle PEGylation 
Surface-decoration of nanoparticles with PEG chains is simply referred to as 
PEGylation. PEG is a flexible, neutral (non-ionic), hydrophilic polymer [180]. Therefore, 
when stationed on the surface of PLGA nanoparticles, the polymer forms a barrier-like layer 
that sterically hinders the surface of the original nanoparticle [181]. In addition, it confers a 
hydrophilic neutral attribute to the surface of nanoparticles. Surface-modification of 




i) Fabrication of nanoparticles with block-copolymer of PLGA and PEG. During 
preparation, due to PEG’s hydrophilicity and PLGA’s hydrophobicity, PLGA forms the 
nanoparticle body while PEG chains interact with the aqueous surrounding media and 
form the hydrophilic corona on the surface of nanoparticles. 
ii) Fabrication of PLGA nanoparticles and then chemical coupling (i.e., covalent 
bonding) of PEG moieties to the surface of the preformed nanoparticles.   
iii) Fabrication of PLGA nanoparticles and then physically adsorbing PEG copolymers 
onto the surface of the fabricated nanoparticles. 
Various strategies have been considered to determine the optimal PEGylation 
approach suitable for PLGA nanoparticles [184]. The fabrication of nanoparticles from block-
copolymers (first method) and the conjugation of PEG to preformed PLGA nanoparticles 
(second method) demonstrated higher PEGylation efficiencies [172]. PEGylated PLGA 
nanoparticles are expected to have a core-shell structure with PLGA as the core and PEG as 
the shell [174]. However, PEG chains can also be entrapped within the core of nanoparticles 







Figure 1-7. Various techniques for preparing PEGylated PLGA nanoparticles. 
 
As mentioned, the PEG coating on the surface of nanoparticles works as a barrier 
layer opposing the interaction of the nanoparticle surface and other material (e.g., opsonins, 
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proteins) in the surrounding medium. To provide an efficient protection to nanoparticle 
surface against such interactions, PEG coating must exceed a minimum level of thickness, 
which is usually difficult to control in various conditions. The level of PEG layer thickness 
surrounding the nanoparticle surface is believed to be determined by PEG polymer chain 
conformation, molecular weight, and surface density (coverage) [183, 186, 187].  
 
1.4.3.4.2. Effect of PEGylation on Fate of PLGA Nanoparticles in the Body  
PEGylation of PLGA nanoparticles through adsorption or grafting is the preferred 
method of surface modification to increase blood residence time of both the loaded drug and 
nanoparticle itself [188]. PEG polymer creates a protective, hydrophilic, neutral layer that 
blocks the adsorption of plasma proteins (opsonins) onto the surface of nanoparticles and 
therefore delays the opsonisation process required for the clearance of nanoparticles from the 
systemic circulation [189]. Opsonisation is the first step of the mononuclear phagocytic 
system (MPS) cells’ recognition mechanism, which ultimately results in phagocytosis and the 
removal of nanoparticles from blood. Surface-modification of drug-loaded PLGA 
nanoparticles can potentially allow nanoparticles to evade the MPS system, elevate plasma 
half-life, and ultimately result in prolonged exposure of the body to the nanoparticle and 
loaded drug [190].   
 
1.5. PLGA Nanoparticles for Delivery of Docetaxel 
As mentioned, docetaxel is considered to be one of the most important and efficient 
anticancer agents being widely used in the chemotherapy of various cancer types. However, 
the clinical application of the drug has limitations due to docetaxel’s poor water solubility, 
low selective bio-distribution, fast elimination, and hypersensitivity reactions. With the 
purpose to overcome such limitations, much attention has been drawn to alternative drug 
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delivery means [191-193]. The application of polymeric nanoparticles, especially the ones 
made from PLGA, as docetaxel-delivery systems has demonstrated great promise.  
 
1.5.1. Docetaxel-loaded PLGA Nanoparticles 
Many researchers have investigated the contribution of PLGA nanoparticles to 
delivery of docetaxel; their research is briefly discussed below. 
Musumeci et al. [194] used low molecular weight PLGA polymer (0.16-0.24 dl/g) 
with acid end-groups (50:50, L:G molar ratio) to develop docetaxel-loaded nanoparticles 
using the emulsification solvent diffusion method. Sphere-shape PLGA nanoparticles 
demonstrated 157 to 172 nm of size, -5 to -10 mV zeta potential, and 16 to 23% drug 
entrapment efficiency. A biphasic docetaxel release profile was evident from PLGA 
nanoparticles liberating over 80% of the loaded drug in isotonic Phosphate Buffer Saline 
(PBS, pH = 7.4) during 14 days.      
Murugesan and colleagues [195] prepared docetaxel-loaded PLGA nanoparticles and 
evaluated the influence of preparation conditions on different characteristics of nanoparticle 
formulations. They used 50:50 (L:G molar ratio), carboxylic-acid terminated PLGA polymer 
with molecular weight of 45,500 Da ( ̴ 0.45-0.6 dl/g) to fabricate docetaxel-loaded 
nanoparticles using the emulsification solvent evaporation technique. Nanoparticles were 
prepared in various conditions of polymer concentrations, aqueous to organic phase volume 
ratios, stabilizing agent concentrations, docetaxel concentrations, and sonication times. 
Nanoparticles obtained through various preparation conditions were spherical in shape and 
demonstrated entrapment efficiencies between 25 to 84% while particle size ranged between 
69 to 141 nm. They found out that variation in the abovementioned factors directly affected 
particle characteristics such as drug entrapment efficiency and average particle size. 
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Nanoparticles had a negative zeta potential equal to -36 mV and released around 40% of the 
loaded drug (in PBS pH = 7.4) during release test incubation period (30 days). 
Later studies evaluated the cytotoxicity of docetaxel-loaded nanoparticles and the cell-
uptake. Esmaeili and colleagues [196] prepared, characterized, and evaluated cell cytotoxicity 
and cell-uptake of docetaxel-loaded PLGA nanoparticles. Acid-terminated PLGA polymer 
with a 50:50 monomer ratio and 48,000 Da molecular weight ( ̴ 0.45-0.6 dl/g) was used to 
prepare docetaxel-loaded nanoparticles using a modified emulsification solvent diffusion 
technique. The nanoparticles’ size, zeta potential, and drug-loading efficiency was 175±13 
nm, -12.2±0.6 mV, and 68±2% respectively. Nanoparticles were spherical in shape. The 
nanoparticles’ biphasic release profile (in isotonic PBS pH = 7.4) was characterized by an 
initial 28% release over the first 24 hours followed by sustained release up to around 80% of 
the loaded drug. Cytotoxicity of docetaxel loaded in nanoparticles was evaluated using four 
types of cancer cells (human breast cancer cells MCF7, breast cancer cells T47D, ovary 
cancer cells SKOV3, and lung cancer cells A549). In all cancer cell lines, docetaxel 
formulated in PLGA nanoparticles inhibited proliferation more than that obtained from the 
free solution of the drug (i.e., the PLGA nanoparticles had a higher cytotoxicity at the 
equivalent dose of docetaxel). The authors attributed this increased cytotoxicity to uptake and 
retention of nanoparticles by the cells.  
In a study by Yu et al. [167], Shirasu porous glass-emulsification technique was used 
to prepare docetaxel-loaded nanoparticles. The method resulted in around 64% entrapment 
efficiency and yielded docetaxel-loaded PLGA nanoparticles with a size and zeta potential of 
334.1±2.7 nm and -16.4±1.0 mV, respectively. These nanoparticles demonstrated a sustained 
drug release behavior (in isotonic PBS pH = 7.4). In addition, their effectiveness in inhibiting 
tumor growth in mice inoculated by murine hepatic carcinoma cell lines (H22) indicated that 
the nanoparticle formulation decreased tumor size and increased the mean survival rate.     
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Applying PRINT® technology, Chu and colleagues [197] used PLGA polymer with 
85:15 monomer ratio and 0.65 dl/g inherent viscosity to prepare docetaxel-loaded 
nanoparticles with two different cylinder shapes. One formulation with 200 nm diameter × 
200 nm height and another one with 80 nm diameter × 320 nm height. Characterization of 
these cylinder-shaped nanoparticles indicated these drug loadings for both types of 
nanoparticles: 33.5% and 45.2% (w/w %) for 80×320 and 200×200 formulations, 
respectively. The 80×320 and 200×200 nanoparticles had average sizes of 227±10 nm and 
263±1.8 nm, respectively, while both formulations had negative zeta potential around -3 mV. 
Both formulations showed a biphasic sustained release profile. Interestingly, the 200×200 
nanoparticle formulation exhibited a lower initial release (38% after 3 hours) and lower 
overall drug release (i.e., around 72%) after 24 hour of incubation in PBS (37 °C). The 
80×320 nanoparticle formulation released around 60% of docetaxel after 3 hours and near 
100% of the loaded drug after 24 hours.      
In another study, Manoochehri and colleagues [198] used carboxylic-acid terminated 
PLGA polymer with 48,000 Da molecular weight ( ̴ 0.45-0.6 dl/g) and 50:50 monomer ratio 
to prepare docetaxel-loaded nanoparticles. They applied the emulsification solvent 
evaporation technique and used different ratios of acetone:dichloromethane (i.e., 2.5:97.5, 
5:95, 10:90, 20:80, 30:70, and 40:60) and organic:aqueous phase (i.e., 10 % and 20 %) to 
prepare nanoparticles. The obtained nanoparticles were spherical and had an average size 
range between 180 nm and 221 nm. The fabrication process had entrapment efficiencies 
between 3 % and 48 % and yielded nanoparticles with zeta potential around -11 mV. A 
biphasic pattern was obtained from a study of the drug release (in PBS, pH = 7.4, 37 °C) in 
which 40% of the loaded drug was initially liberated within 10 hours followed by sustained 
release of the remainder of the drug over 13 days. Cytotoxicity of docetaxel loaded in PLGA 
nanoparticle was evaluated on human hepatocellular carcinoma cells (HepG2). At equivalent 
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concentrations of docetaxel between 0.3 and 20 µg/ml, docetaxel-loaded PLGA nanoparticle 
demonstrated a higher cytotoxicity. However, at higher concentrations (i.e., 40, 80 and 160 
µg/ml), cytotoxicity obtained from free docetaxel and nanoparticle-loaded docetaxel was not 
different (IC50 of docetaxel loaded nanoparticles was three folds lower than free docetaxel). 
Recently, Mody and colleagues [199] compared docetaxel delivery potential of four 
types of nanoparticles including PLGA nanoparticles. In their study, docetaxel-loaded PLGA 
nanoparticles, dendrimers, liposomes, and carbon nanotubes were prepared and characterized 
in vitro and compared with each other. The prepared PLGA nanoparticles had 178±1.4 nm 
average size, -11.8±0.8 mV zeta potential, and 62% drug entrapment efficiency. To monitor 
potential interactions between nanoparticles and red blood cells, a hemolytic toxicity study 
was also done. The test determined that free docetaxel had the most hemolytic toxicity. In 
contrast, PLGA nanoparticles were second least toxic nanoparticles to red blood cells after 
liposomes. They also conducted docetaxel release tests on nanoparticle formulations in PBS 
(pH = 7.4, 37 °C). The dendrimer formulation released the drug during the first 12 hours. The 
others demonstrated a biphasic release profile during the 72-hour study period. The PLGA 
nanoparticles released 23% of the loaded drug during the initial phase and up to around 60% 
until the end of incubation time (three days), which was lower than that observed from 
liposome or carbon nanotube formulations. A cytotoxicity test using the human cervical 
cancer cell line SiHa was also conducted, which exhibited the following trend for IC50: free 
docetaxel < carbon nanotubes < dendrimer < liposome < PLGA nanoparticles. 
In another recent study, docetaxel was loaded in PLGA nanoparticles and extensively 
evaluated. Gupta and colleagues [200] used low molecular weight PLGA (0.22 dl/g) with 
50:50 monomer ratio and applied an emulsion solvent evaporation technique to prepare the 
nanoparticles. Docetaxel-loaded nanoparticles had an average size of 167.4±5.1 nm and zeta 
potential of -23.9±1.6 mV. The nanoparticle fabrication method demonstrated a drug 
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entrapment efficiency of 74.9±3.9 %. The in vitro release study (in PBS, pH = 7.4) 
demonstrated a biphasic profile: an initial rapid release of docetaxel (within the first 24 
hours), followed by a slower rate that ultimately led to liberation of 74.4% of the loaded drug 
over 10 days of incubation time. They also evaluated the plasma protein adsorption by 
nanoparticles, since nanoparticles’ adsorption of plasma proteins after administration can 
potentially facilitate phagocytosis and clear the nanoparticles from systemic circulation. 
Docetaxel-loaded PLGA nanoparticles demonstrated aggregates, increased average size and 
poly-dispersity index after 24 hour of incubation with bovine serum albumin. Hemolytic 
toxicity of nanoparticles demonstrated the free solution of docetaxel had a higher hemolysis 
compared to nanoparticles. Furthermore, the toxicity of docetaxel-loaded nanoparticles was 
evaluated on two types of cell lines: human umbilical vein endothelial cells (HUVEC) and 
fibrosarcoma cells (HT-1080). In case of HUVEC cells, the anti-proliferative activity of 
PLGA nanoparticles (after 48 and 72 hours) was higher than that observed from the free 
solution of docetaxel. IC50 of the nanoparticle formulation was 1.8- and 1.5-fold lower than 
free docetaxel after 48 and 72 hours respectively. Likewise, the results for the HT-1080 cell 
line demonstrated pronounced cytotoxicity profiles related to docetaxel loaded in 
nanoparticles compared to free solution of the drug, particularly after the long incubation 
times (i.e., 48 and 72 hours). Anti-tumor activity of the docetaxel-loaded nanoparticles was 
also evaluated in vivo on mice bearing HT-1080 tumors (based on tumor volume and weight 
change). The animal group treated with free docetaxel demonstrated a progressive reduction 
of body weight and lost 8.8% of their initial body weight. In contrast, the body weight of the 
animal group treated with docetaxel-loaded PLGA nanoparticles increased by 8.2%. Also, the 
docetaxel-loaded PLGA nanoparticles’ tumor inhibition performance was better than the free 
solution of the drug. The percentage of tumor volume growth inhibition was 43.5% and 
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31.1% and the percentage of tumor weight growth inhibition was 27.4% and 18.5% for 
docetaxel-loaded nanoparticles and free docetaxel, respectively. 
Jain and colleagues also used PLGA nanoparticles for docetaxel drug delivery [201]. 
They used 48,000 Da molecular weight ( ̴ 0.45-0.6 dl/g), 50:50 (L:G) PLGA polymer and a 
modified emulsion solvent diffusion/evaporation technique to prepare nanoparticles. 
Nanoparticles had 207.8±9.5 nm size and -9.7±0.3 mV zeta potential, with a 95.5±2.8 % drug 
entrapment efficiency. Biphasic release of the drug from the nanoparticles lead to rapid 
liberation of docetaxel after 24 hours followed by release of 50% (in total) after 5 days (in 
PBS pH = 7.4). Docetaxel-loaded nanoparticles had a higher cytotoxicity effect after 24 and 
48 hours of incubation with MCF7 cells than the free solution of drug (i.e., nanoparticle 
formulation had lower IC50 values). The IV injection of docetaxel-loaded PLGA 
nanoparticles to tumor-inoculated animals resulted in higher tumor regression compared to 
that from free docetaxel solution (i.e., up to around 52% for nanoparticles compared to 
around 36% for the free docetaxel solution).   
In another study, docetaxel was loaded in nanoparticles prepared from PLGA polymer 
with 25,000-35,000 Da ( ̴ 0.32-0.44 dl/g) molecular weight by Park et al. [202]. A modified 
emulsification solvent evaporation technique was used to obtain PLGA nanoparticles with 
254.5±8.9 nm size, -10.5±0.6 mV zeta potential, and 67.11% entrapment efficiency. 
Evaluation of the docetaxel release profile from nanoparticles (in isotonic PBS pH = 7.4) 
demonstrated a rapid release during the first 48 hour of incubation, which was followed by 
slow release leading to an overall cumulative release around 25 % (up to 10 days).  
 
As exhibited above, PLGA polymer has been widely used in the preparation of 
docetaxel-loaded nanoparticles. Docetaxel-loaded nanoparticles demonstrated average sizes 
as small as 69 nm and as large as 334 nm, while zeta potential varied between -36 and -3 mV. 
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Between studies, entrapment efficiencies of the nanoparticle preparation methods were also 
different, ranging from 3% to 95%. The various types of docetaxel-loaded PLGA 
nanoparticles demonstrated different biphasic release profiles in terms of amount and time. 
However, docetaxel kept its biological activity after loading into PLGA nanoparticles.  
In each study, a type of PLGA polymer was used to prepare docetaxel-loaded 
nanoparticles and nanoparticles were characterized accordingly. However, the approaches 
and materials used for nanoparticle preparation were different between different studies, 
which provided nanoparticles with different properties. In other words, the docetaxel-loaded 
PLGA nanoparticles demonstrate different characteristics because they have been prepared 
differently during independent studies. Accordingly, it does not seem to be scientifically right 
to compare these nanoparticles. 
 In this regards, a systematic study that provides valuable insight into how important 
properties of PLGA (such as polymer molecular weight, monomer ratio (L:G), and terminal 
functional group type) influence particle characteristics is simply lacking. In parallel, studies 
need to be conducted to evaluate how preparation conditions (in a typical nanoparticle 
fabrication method) determine particle-important characteristics. Establishing the relationship 
between PLGA polymer properties, nanoparticle fabrication method, and nanoparticle 
characteristics would allow researchers to prepare docetaxel-loaded PLGA nanoparticles with 
intended characteristics.       
 
1.6.Pharmacokinetics and Bio-distribution of Nanoparticles after IV administration 
1.6.1. Factors Controlling Nanoparticle Pharmacokinetics 
Aside from the fact that nanoparticles offer suitable means for delivery of a wide 
spectrum of agents, the association between drugs and nanoparticle vehicles can favourably 
impact the pharmacokinetics of the parent drug, leading to favourable biological responses 
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[182, 203]. In this regard, a complex set of determinants are considered to be influential on 
the bio-distribution and fate of nanoparticles after in vivo administration [171, 183, 204]. 
These include the physicochemical properties of nanoparticle, the interaction between the 
drug and nanoparticle, and the set of events imposed to the nanoparticles by the host body. 
The nanoparticles’ physicochemical factors control the particles’ residence time in the blood 
circulation, tissue distribution pattern, mode of cell internalization and intracellular 
trafficking, release profile, and toxicity [182, 205]. The most important nanoparticle 
physicochemical properties are particle size, shape, chemical composition, mechanical 
properties (e.g., rigidity, deformability, and strength), and surface characteristics [172, 206]. 
 
1.6.1.1.Particle Size 
 Particle size helps determine the bio-fate of nanoparticles upon administration to the 
body [203, 207]. It is believed that a size range less than 10 nm results in the removal of 
nanoparticles by renal filtration [208, 209]. On the other hand, nanoparticles with 
hydrodynamic radii of over 200 nm demonstrate a higher rate of clearance compared to 
smaller particles [183]. In other words, very small particles can be rapidly cleared from the 
systemic circulation via renal filtration while very big particles can potentially become 
trapped inside the RES organs such as the liver, spleen, and bone marrow [203]. However, 
the latter phenomenon offers advantages for targeting of particles to RES organs when the 
RES is the treatment target. Nanoparticles with suitable size ranges can evade both renal and 
RES clearance systems of the body and circulate in the systemic circulation longer [210, 
211]. This was demonstrated by Yadav and colleagues [212] who prepared etoposide-loaded 
PLGA nanoparticles at two sizes (105 and 160 nm) and subjected them to blood clearance 
and biodistribution studies after IV administration. The 105 nm nanoparticles remained in the 
blood circulation longer and had lower RES uptake compared to the 160 nm nanoparticles. 
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This information is essential in designing delivery systems with systemically sustained drug 
release objectives. In such systems, a circulating drug reservoir is present in the body, which 
maintains the systemic drug concentration within acceptable therapeutic indices, ultimately 
leading to less adverse drug reactions and patient discomfort [213].  
 
1.6.1.2. Particle Surface Properties 
Particles’ surface characteristics can also affect the fate of nanoparticles in the 
systemic circulation. These properties include hydrophilicity/hydrophobicity, presence and 
conformation of any kind of adsorbed or grafted polymer/ligand, and electric charge [172, 
214]. Positively-charged nanoparticles have a higher rate of cell-uptake and clearance when 
compared to neutral and negatively-charged formulations [215]. To test this, Yuan et al. [216] 
designed zwitterionic nanoparticles. They had a neutral surface charge in the blood to 
maximize systemic circulation time and further tumor accumulation. The surface charge 
switched to positive in tumor tissue to maximize cellular uptake. Ymamoto and colleagues 
[217] prepared polymeric micelles with negative (-10.6 mV) and neutral (1.3 mV) surface 
charges and exhibited their advantage in long circulation. They demonstrated that 
nanoparticles with negative zeta potential resulted in lower spleen and liver accumulation. 
This could be attributed to the presence of glycocalix with a negative charge stationed on the 
cells’ surface that contributed to lower electrostatic interactions between nanoparticles and 
the cell membrane [218]. The presence of negatively-charged serum proteins can cause 
aggregates to form after IV administration of positively-charged nanoparticles and vice versa 
[219]. These aggregates can secondarily become trapped inside RES organs or cause an 
embolism in blood capillaries. In addition, nanoparticles can bind to serum opsonins, be 
opsonized and become recognized by the scavenging processes of the RES and immune 
system [220]. In fact, the initial opsonization of nanoparticles is important in determining the 
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phagocytic events and clearance from systemic circulation. Currently, research is mainly 
focusing on methods that can help effectively undermine this event [183]. As such, some 
trends have been proposed. Generally, particles with hydrophilic surface properties tend to 
opsonize more slowly than hydrophobic particles, which is attributed to the weaker 
absorbability of blood serum proteins on the hydrophilic particles’ surface [183, 221, 222]. 
Nanoparticles opsonization has been correlated to the surface charge as well. Thus, efforts 
have been made to station surface-adsorbed or grafted shielding moieties on the surface of 
nanoparticles to block the particles’ hydrophobic/hydrophilic and electrostatic features [183]. 
Surface engineering of nanoparticles with polymer coatings such as PEG can effectively 
hinder the surface charge of nanoparticles and reduce particle opsonization, which 
subsequently decreases nanoparticles’ non-specific clearance from the body.  
 
1.6.1.3. Particle Shape  
Shape is another important property that determines the bio-fate of nanoparticulate 
drug-delivery systems in the body [223-227]. Most nanoparticulate systems under extensive 
in vitro and in vivo studies are spherical in shape. However, researchers have applied various 
methods to fabricate nanoparticles with non-spherical shapes [228], such as ellipsoids [229], 
cubes [230], rods [231], cones [232], cylinders [233], and discs [206, 234]. The diversity in 
shape has a profound effect on factors like the residence time of nanoparticles in the systemic 
circulation [235], endocytosis [236-238] and phagocytosis [239], transport through the 
vasculature [236, 240], and even intracellular transport of nanoparticles [234]. For example, 
phagocytosis of nanoparticles as a mechanism of nanoparticle clearance from the systemic 
circulation has been proposed to strongly depend on nanoparticle shape [239, 241, 242]. 
Spherical nanoparticles are internalized faster than nanoparticles with higher aspect ratios 
[236]. In fact, phagocytosis is a two-step procedure (i.e., macrophage attachment and then 
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internalization) and particle shape can influence each step independently [243]. In other 
words, the local geometry of nanoparticles at contact point (between macrophage and 
particle) simply determines whether the phagocytic cell internalizes the particle or just 
spreads around the particle [239]. The event is proposed to be basically dependent on the 
contact angle (θ) [239, 244] at the site of attachment between particle and phagocytic cell 
(figure 1-8). In the case of rod-shaped nanoparticles with major axis being perpendicular to 
the membrane of phagocytic cell, internalization happens fairly quickly. In contrast, when 
contact between cell membrane and rod-shaped nanoparticle happens on the sides (i.e., more 
tangential), the rate of uptake decreases [227]. Spherical nanoparticles are internalized more 
successfully at a rate that is independent of the contact angle [227]. Therefore, non-spherical 
particles with high aspect ratios are believed to be able to evade the up-take mechanisms of 
the RES and persist in the systemic circulation longer than their spherical counterparts [206, 
235]. Changing particles away from spherical shape could affect circulation time and particle 
bio-distribution [206, 235].  
 
      Figure 1-8. Influence of nanoparticle contact angle on rate of uptake by phagocytic cells. 
 
Nanoparticles’ shapes also affect their movement in the blood and through the 
vasculature. Nanoparticles are believed to be exposed to several forces in the systemic 
circulation (e.g., buoyancy, gravity, van der Waals, and electrostatic interactions) [227] 
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including the blood flow. Based on the shape, nanoparticles behave differently when 
subjected to blood flow (figure 1-9). Spherical nanoparticles tend to stay in the streamline of 
the blood flow they are moving in [240, 245], which makes escaping the blood flow towards 
vessel wall challenging. Therefore, the movement of spherical nanoparticles to marginal zone 
of the blood vessel greatly depends on convection and nanoparticle size [207, 246]. In 
contrast, particles with a high aspect ratio, such as rod-shaped nanoparticles, are subjected to 
transverse drifts because of the torques and forces exerted to the nanoparticles based on the 
angle of nanoparticle orientation [247]. Therefore, rod-shaped nanoparticles are believed to 




Figure 1-9. Influence of shape on migration behaviour of nanoparticles to the margins of 
blood vessels.   
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In general, one or more particle features affect the fate of the drug and result in a 
different drug-concentration versus time curve and pharmacokinetic profile. Depending on 
the properties of the drug and nanoparticles, the pattern of drug release from the nanoparticles 
plays a key role in determining the new kinetics of the drug in the body. In other words, if the 
drug is rapidly released from the particulate carrier system, the original drug pharmacokinetic 
governs the final behaviour. However, if the drug is released in a more sustained manner, the 
outcome pharmacokinetic is more determined by nanoparticle’s fate in the body (e.g., 
erosion, disintegration, clearance) [182].         
 
1.6.2. Bio-distribution of Nanoparticles 
Upon entrance into the systemic circulation, nanoparticles are carried by the blood 
flow and are distributed to the tissues and organs of the body [249]. Once the nanoparticles 
enter the systemic circulation, interaction between nanoparticles and blood constituents can 
potentially be initiated. These include plasma proteins, coagulation factors, platelets, and red 
and white blood cells [250-253]. Then, nanoparticles are carried throughout the systemic 
circulation and distributed to different organs of the body. The accumulation of nanoparticles 
in different tissues depends on the nanoparticles’ properties and the potential interactions 
with the living system. 
Almost immediately after particle entrance to the blood circulation, opsonization 
occurs [183, 254] and often creates nanoparticle-protein complexes with different 
characteristics than the original nanoparticles [255, 256]. The protein coating varies 
considerably in terms of amount and pattern and is dependent on exposure time, 
physicochemical characteristics, and dose of nanoparticles [257]. Nanoparticle-protein 
interaction is a major step in the recognition and clearance of nanoparticles from the body 
[258, 259]. Blood vessels and their varying endothelia can also influence nanoparticle 
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distribution in the body [260] and contribute to their departure from or retention in the blood 
circulation. In addition, in cases of changes in the integrity of endothelial structure like what 
is seen in inflamed tissues, nanoparticles with even higher size ranges can evade the systemic 
circulation [261]. The distribution of nanoparticles can also potentially be affected by the 
amount of blood supply to a tissue [262]. In addition, physiological barriers (e.g., blood brain 
barrier) can lower nanoparticle accumulation in tissues with barriers compared to other parts 
of the body.  
The RES is responsible for rapidly capturing and retaining nanoparticles [262]. In the 
liver, as the main organ of accumulation (particularly after IV administration), nanoparticles 
are retained by hepatocytes, kupffer cells, and endothelial cells [263-265]. In addition, open 
fenestrations of the liver’s sinusal endothelia possessing diameters as large as 150 nm can 
contribute to particle retention in the liver [261]. On the other hand, in the spleen, where 
blood flows mainly through a pathway with minimal endothelial continuity, nanoparticles 
come into contact with the reticular meshwork of the marginal zone and red pulp [266]. They 
can easily get filtered there, particularly when nanoparticles are non-deformable entities with 
size ranges higher than the width of the cell slits (200-250 nm) [182].  
As another RES organ, nanoparticles in the systemic circulation could reach the bone 
marrow compartment as well. However, they would have to go through transport mechanisms 
at blood-bone marrow barrier [267], so, although reported, the accumulation of nanoparticles 
in bone marrow has not been routinely studied [262]. The fate of nanoparticles in the body 
can also be affected by lymphatic system. Nanoparticles in the systemic circulation can leave 
the blood vessels through the permeable vascular endothelium present in lymph nodes and 
enter the lymphatic circulation [262, 268-270]. From the nanoparticle population that have 
gained access the lymphatic system, a portion accumulates and becomes trapped in lymph 




1.7. Pharmacokinetic Consequences of Docetaxel Loading in PLGA nanoparticles   
As mentioned earlier, PLGA nanoparticles have the ability to drastically modify the 
pharmacokinetics of the loaded drug in the body. Upon administration to the systemic 
circulation, nanoparticles carry the entrapped drug with them as they circulate in the body 
and therefore impart a different pharmacokinetic behaviour to the loaded drug. Modification 
of docetaxel pharmacokinetics using PLGA nanoparticles has been the objective of several 
studies [272-275], but only a few studies have advanced to in vivo experiments on animals to 
determine pharmacokinetic outcomes. 
 Esmaeili and colleagues have demonstrated changes in docetaxel’s pharmacokinetic 
characteristics after loading into PLGA nanoparticles [196]. In the experiment, docetaxel-
loaded PLGA nanoparticles were prepared and fully characterized in vitro before 
administration to animals. The area under the curve (AUC) calculated for the nanoparticle 
formulation was markedly higher than that obtained from the free docetaxel solution 
(approximately 4.5-fold). Nanoparticle formulation also increased docetaxel’s mean 
residence time (MRT) in the systemic circulation by 1.67-fold. In addition, the drug in the 
PLGA nanoparticle formulation had a longer plasma half-life (T1/2) than the free drug alone.  
In another study, Yu et al. compared the pharmacokinetic behaviour of docetaxel-
loaded nanoparticles to that of the drug’s commercial product (Taxoter®) and demonstrated 
that the formulation of docetaxel in polymeric nanoparticles resulted in superior 
pharmacokinetic characteristics [167]. The obtained nanoparticle formulation increased 
docetaxel’s AUC by approximately 1.5-fold. Compared to Taxoter, PLGA nanoparticles 
increased the drug’s half-life and MRT by 2.1 and 4.7 times, respectively. Furthermore, the 
drug’s clearance from the body decreased. In general, PLGA nanoparticles exhibited a longer 
retention time in systemic circulation than the free drug formulation.  
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In another study, docetaxel-loaded PLGA nanoparticles were prepared using PRINT® 
technology and the corresponding pharmacokinetic behaviour was evaluated in vivo [197]. In 
the study, two types of PLGA nanoparticles were prepared. One formulation had dimensions 
equal to d=200 nm × h=200 nm and another to d=80 nm × h=320 nm. The PRINT® 
nanoparticles demonstrated approximately 20-fold higher plasma drug exposure as calculated 
by the AUC compared to that of the Taxoter drug formulation. In addition, the volume of 
distribution (Vd) of docetaxel from Taxoter was significantly higher (p<0.05) from that 
obtained from docetaxel in PLGA nanoparticle formulations. Compared to Taxoter, the Vd 
was respectively 33- and 18-fold lower in the case of both the 200 nm × 200 nm and 80 nm × 
320 nm formulations. The difference observed between the Vd of the PLGA nanoparticle 
formulations was reported to be due to the smaller diameter of the 80 nm × 320 nm 
formulation and its higher chance to evade clearance mechanisms of the body (e.g., 
phagocytic cells). Furthermore, docetaxel entrapment in fabricated PLGA nanoparticles 
reduced the plasma clearance of the drug to approximately 24 times less than that observed 
from the commercial drug formulation. 
In a recent study by Jain and colleagues [201], docetaxel-loaded PLGA nanoparticles 
were prepared, fully characterized and evaluated in an animal model. Pharmacokinetic 
characteristics of docetaxel due to PLGA nanoparticles were calculated and compared to 
those obtained from a free solution of docetaxel (Taxoter). Prepared nanoparticles had 
207.8±9.5 nm size and -9.7±0.3 mV zeta potential. Taxoter had a higher plasma 
concentration after 30 minutes of IV injections, which was declined significantly afterwards, 
compared to PLGA nanoparticles. The calculation of AUC for both docetaxel formulations 
demonstrated that PLGA nanoparticles had increased docetaxel exposure by 3.2-fold. 
Interestingly, the PLGA nanoparticles increased docetaxel’s half-life to 18.1 hours from the 
Taxoter formulation’s 2.2 hours (i.e., 8.2-fold increase).     
52 
 
As mentioned, surface-modification of nanoparticles with PEG confers effective 
characteristics to the nanoparticles to evade clearance mechanisms of the body (e.g., 
opsonization events) and prolong blood circulation of injected nanoparticles. This in turn can 
potentially affect the pharmacokinetics of the loaded drug. 
 Senthilkumar and colleagues [176] evaluated the performance of PLGA and 
PEGylated PLGA nanoparticles in modifying the pharmacokinetics of docetaxel in vivo. 
They fabricated three formulations: PLGA nanoparticles, surface-modified PLGA 
nanoparticles with 2kDa PEG, and surface-modified PLGA nanoparticles with 5kDa PEG.  In 
vitro characterization steps were also performed on all formulations. PLGA nanoparticles had 
102±0.24 nm size and -37±0.6 mV zeta potential while PLGA-PEG (2kDa) and PLGA-PEG 
(5kDa) nanoparticles had similar size range (103±0.16 and 107±0.25 nm, respectively) and 
zeta potential (-5.3±0.5 and -5.3±0.7 mV, respectively). The pharmacokinetic profile of 
docetaxel in Balb/C mice was then evaluated after IV injections with either the free docetaxel 
solution or nanoparticle formulations. The obtained data exhibited delayed blood clearance of 
docetaxel by the nanoparticle formulations compared to that from the free drug solution. 
Although not statistically significant, blood clearance of free docetaxel was approximately 
1.5, 2.4, and 2.7 times higher than the PLGA, PLGA-PEG (2kDa), and PLGA-PEG (5kDa) 
nanoparticle formulations, respectively. The AUC of docetaxel was increased for all 
nanoparticle formulations compared to the free drug solution, though the PLGA-PEG (5kDa) 
formulation’s increase was statistically significant (p<0.05). MRT of the drug increased from 
2.3 h (free drug) to 3.6 h (1.5-fold) for the PLGA nanoparticle and to 4.5h (1.9-fold) and 4.9h 
(2.1-fold) for the PLGA-PEG (2kDa) and PLGA-PEG (5kDa) formulations respectively.  
Ultimately, docetaxel’s half-life increased 1.7, 3.5, 3.7 times when PLGA, PLGA-PEG 
(2kDa), PLGA-PEG (5kDa) nanoparticle formulations were used (respectively) compared to 
the free drug solution. 
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The effect of the PEGylation of PLGA nanoparticle in modifying docetaxel 
pharmacokinetics was also evaluated by Jain and colleagues [201]. Docetaxel-loaded 
PEGylated PLGA nanoparticles demonstrated an average size of 224.9±10.8 nm and zeta 
potential of -5.6±0.3 mV. PEGylation of nanoparticles increased docetaxel half-life by nearly 
13-fold and 1.5-fold compared to free solution of docetaxel (Taxoter) and PLGA 
nanoparticles, respectively (i.e., Taxoter: 2.2 hour; PLGA nanoparticles:18.1 hour; and PEG-
PLGA: 28.5 hour). Overall exposure of docetaxel (AUC) was also increased seven times 
compared to free solution of drug and two times compared to unmodified PLGA 
nanoparticles.  
Docetaxel-loaded nanoparticles act as drug reservoirs that circulate in the blood and 
provide the systemic circulation with the drug in a sustained manner. In addition, PLGA 
nanoparticles as docetaxel reservoirs potentially retain the drug in the blood and prevent it 
from wide distribution to various organs of the body, which includes organs that are involved 
in clearing docetaxel from the body. Accordingly, PLGA nanoparticles keep docetaxel in the 
blood longer than when naked docetaxel is used. In other words, docetaxel spends more time 
in the systemic circulation, and of course, in the body. Consequently, PLGA nanoparticles are 
expected to prevent wide-distribution of docetaxel, which would decrease docetaxel’s 
apparent volume of distribution as well as its systemic clearance. Similarly, PLGA 
nanoparticles are expected to increase the total docetaxel exposure (AUC), half-life, and 
mean residence time of docetaxel in the body.          
 As noted in the examples above, the pharmacokinetics of docetaxel could be 
modified using PLGA nanoparticles as drug delivery means. Throughout various studies, 
AUC (total body exposure) of docetaxel was increased between 1.5- and 20-fold.  PLGA 
nanoparticles also increased docetaxel’s mean residence time by as high as 4.7-fold. Due to 
the application of PLGA nanoparticles, docetaxel’s apparent volume of distribution was also 
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decreased by as low as 30-fold. Generally, the studies provided above also demonstrated an 
increase in docetaxel’s half-life and decrease in its systemic clearance when PLGA 
nanoparticles were used.  
It is worth mentioning that each study used nanoparticles that were uniquely distinct 
from that nanoparticles used in other studies.  In other words, docetaxel-loaded PLGA 
nanoparticles of various studies had different characteristics, so their contribution to the 
pharmacokinetic profile of docetaxel has been evaluated independently. Accordingly, 
comparing the mode and extent of pharmacokinetic consequences of different PLGA 
nanoparticle formulations does not seem to be scientifically correct. 
 
1.8.Bio-distribution Consequences of Docetaxel Loading in PLGA nanoparticles   
The fate of nanoparticles in the biologic system after administration determines the 
extent of various organs’ and tissues’ exposure to the drug. Highly distributed nanoparticles 
can carry the drug to a wide range of tissues and make the drug available more universally. 
Due to physicochemical properties or to targeting features, bio-distribution of some 
nanoparticle formulations can be limited. Accordingly, the bio-distribution of docetaxel 
loaded in PLGA nanoparticles to various organs/tissues, including tumour tissues, has been 
studied extensively.  
 
1.8.1.  Biodistribution in Healthy Animals 
Esmaeili and colleagues [196] demonstrated that the most important difference 
between docetaxel-loaded PLGA nanoparticles’ and Taxoter’s in vivo bio-distribution 
behaviour was that the nanoparticles maintained docetaxel’s plasma levels, while the free 
drug solution’s plasma levels dropped significantly. In addition, the researchers exhibited that 
the nanoparticles increased levels of docetaxel in RES organs such as liver, lungs, and spleen 
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more than Taxoter did and concluded that docetaxel’s incorporation in PLGA nanoparticles 
can be manipulated in the treatment of RES organ carcinomas.  
 
1.8.2.  Biodistribution in Tumour-Bearing Animals 
Senthilkumar and colleagues evaluated the bio-distribution of docetaxel in 
nanoparticles of PLGA and PEGylated PLGA with two molecular weight PEG moieties 
(2kDa and 5kDa) [176] in tumour-bearing mice. Different nanoparticle formulations and a 
free docetaxel solution were subsequently injected to animals and at certain time-points 
organs/tissues were then collected and analysed. The time-course of docetaxel level in tissues 
demonstrated that drug distribution to non-tumour organs was more pronounced with the free 
drug solution. PLGA nanoparticle formulation had no targeting characteristics and therefore 
was eliminated from the blood circulation quicker than their PEGylated counterparts. The 
PLGA nanoparticle formulation did decrease docetaxel distribution to non-tumour tissues and 
increase drug transport to tumour tissue. However, PEGylated PLGA nanoparticles delivered 
significantly higher concentrations of the drug into the tumour tissue. Interestingly, the 
docetaxel levels in the blood were markedly higher with the PEGylated PLGA than those of 
PLGA nanoparticle formulation (at similar time-points), while drug transport to non-tumour 
tissues was limited. In addition, PEGylation of PLGA nanoparticles with a PEG chain of 
5kDa demonstrated a longer blood circulation and therefore resulted in higher levels of drug 
accumulation in tumour tissue compared to the formulation with the 2kDa PEG chain. The 
5kDa chain provided more chances for the particles to extravasate through the leaky 
vasculature of tumour tissue, which increased the exposure times and drug concentration 
levels. 
The bio-distribution of docetaxel-loaded PRINT nanoparticles at two different 
sizes/shapes was evaluated by Chu at al. [197]. Compared to the commercial formulation of 
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the drug (Taxoter), PRINT nanoparticles increased the total tumour exposure of docetaxel by 
53% and 76% for of 80 nm × 320 nm and 200 nm × 200 nm formulations, respectively. The 
200 nm × 200 nm nanoparticle formulation had a higher docetaxel tumour exposure, although 
plasma drug exposure for both formulations was similar. Both nanoparticle formulations had 
higher drug exposure in spleen and liver in contrast to Taxoter, as expected for a nanoparticle 
formulation. Compared to the 80 nm × 320 nm nanoparticle formulation, the 200 nm × 200 
nm formulation demonstrated 4.8 times more docetaxel exposure in spleen and 1.5 times 
more in the liver and lungs. The observed behaviour from PRINT nanoparticles was 
attributed to the existing difference in the nanoparticles’ aspect ratios, which can affect the 
nanoparticles’ interactions with biological mechanisms.  
 
1.9. Conclusion and Summary 
Polymeric nanoparticles of PLGA are suitable means of drug delivery since they offer 
advantages as drug delivery vehicles. Accordingly, PLGA polymer has been extensively used 
to prepare nanoparticles to deliver a wide range of pharmaceutically active agents including 
chemotherapeutics. The polymer can assume different physicochemical characteristics based 
on the type and number of monomers present in the PLGA structure. Therefore, nanoparticles 
prepared from PLGA polymer can assume variable features and characteristics based on the 
type of polymer, type of loaded drug, and nanoparticle fabrication method. As mentioned 
above, several studies have prepared and characterized PLGA nanoparticles for the delivery 
of docetaxel as a chemotherapeutic agent with wide application in a variety of cancer types. 
These studies have been conducted independently to prepare PLGA nanoparticles as a new 
means for docetaxel drug delivery with pharmacokinetic- and biodistribution-modification 
benefits. In these studies, a variety of PLGA polymers and fabrication methods have been 
used to prepare docetaxel-loaded PLGA nanoparticles. Consequently, obtained nanoparticles 
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of these studies demonstrated a variety of characteristics. Therefore, the pharmacokinetic and 
biodistribution consequences of corresponding nanoparticle formulations cannot be compared 
between different studies.           
Several studies used PLGA polymer to prepare nanoparticles for the delivery of 
docetaxel following extensive in vitro steps to characterize the prepared formulations. 
However, not all of the studies proceeded to in vivo steps. Based on the data from these 
studies, it is apparent that PLGA nanoparticles could potentially modify the pharmacokinetic 
and biodistribution of docetaxel. Accordingly, a few general conclusions could be made in 
this regard: 
1) Changes made to docetaxel’s pharmacokinetic and biodistribution profile were 
attributed to the form of the drug delivery system itself, the nanoparticle.  
2) The mode of these changes have been attributed to main particle characteristics 
including average size, surface properties (zeta potential), and shape. 
3)  Almost all the relevant data from these studies only provide general insight of how 
“typical” PLGA nanoparticle formulations modified docetaxel’s pharmacokinetic and 
biodistribution profile in animal models. 
4)  The studies provided above have only reported their data. No comparison was made 
between in vitro characteristics of nanoparticles and also between in vivo 
performances of docetaxel nanoparticle formulations. 
5) There has not been enough progress towards clinical application of docetaxel-loaded 
PLGA nanoparticles in humans (based on United States National Institutes of Health, 
ClinicalTrials.gov) yet.  
6) PLGA nanoparticles’ performance in modifying docetaxel’s pharmacokinetic and 
biodistribution profile depends on the nanoparticles’ features and characteristics, 
while the nanoparticles’ features and characteristics depend on the type of PLGA 
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polymer and the nanoparticle preparation conditions. In other words, PLGA polymer 
properties, nanoparticle fabrication method, and PLGA nanoparticles’ contribution to 
docetaxel’s pharmacokinetic and biodistribution profile are linked like the links of a 
chain. However, so far no systematic study has been conducted in a way to explain 





Purpose of the Project 
 
2.1.Study Rationale  
2.1.1. The need for New Drug Delivery Systems  
Today, novel drug delivery systems (NDDS) have demonstrated great promise in 
improving the delivery of many drugs and active pharmacological agents. NDDS are either 
used to deliver newly discovered active pharmacological agents (i.e., develop drug 
formulations) or used to deliver already formulated drugs trying to improve upon the drugs’ 
limitations. Generally, modifications in a drug’s delivery are performed ultimately to improve 
the drug’s pharmacodynamic characteristics. However, the drug’s pharmacodynamic 
characteristics and therapeutic outcomes also depend on its own pharmacokinetic 
characteristics. When components of pharmacokinetics (i.e., absorption, distribution, 
metabolism, and excretion (ADME)) are desirably modified, therapeutic outcomes are 
favorably modified as well. NDDS are usually used to modify as many components as 
possible.  
 
2.1.2. Polymeric Nanoparticles 
Among NDDS, nanoparticulate drug carrier systems have great potential to desirably 
modify the delivery of conventional or newly-discovered drugs. Compared with other types 
of developed nanoparticle drug carriers, polymeric nanoparticles are one of the most 
promising drug delivery systems. Polymeric nanoparticles are classified into different 
categories based on their structure (e.g., nanosphere and nanocapsule) and type of polymer 
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used for fabrication of the nanoparticle (e.g., synthetic, semi-synthetic, and natural). Various 
types of polymers are used in the preparation of polymeric nanoparticles. 
 
2.1.3. PLGA Nanoparticles 
Owing to several favourable characteristics, PLGA is a suitable polymer to prepare 
polymeric nanoparticles as drug delivery vehicles for various types of drugs. PLGA polymer 
provides nanoparticles with unique properties that do not have most of the concerns 
accompanied with other types of polymeric nanoparticles (e.g., polymer toxicity).  
PLGA has a variable nature that gives the polymer different physicochemical 
characteristics. The polymer has different molecular weights based on the number of 
monomers that participate in the polymer chain. The ratio of monomers in the polymer chain 
(i.e., lactic acid: glycolic acid) can also vary. The polymer can have different terminal 
functional groups as well. Other than the polymer itself, several nanoparticle fabrication 
methods can be used. Therefore, the variability in the type of drugs and pharmacologically 
active agents to be delivered, the availability of different techniques for nanoparticle 
preparation, and most importantly, the remarkable variability in PLGA polymer itself results 
in extreme variability in PLGA nanoparticle features and characteristics. So, any PLGA 
nanoparticle formulation is uniquely distinct from another formulation prepared differently. 
This variability brings more attraction to PLGA nanoparticle drug delivery, creates more 
room for research and development, and provides more areas to explore. Because the 
fabrication methods create nanoparticles with unique properties, the formulation conditions 
that lead to nanoparticles with most intended characteristics need to be identified. This is 





2.1.4. PLGA Nanoparticles’ Contribution to Pharmacotherapy  
PLGA nanoparticles have been used for systemic and targeted drug delivery. PLGA 
nanoparticles with systemic delivery purposes are used as drug reservoirs that can remain in 
the blood for prolonged time and release the drug in a sustained manner. Sustainable 
availability of drug to the systemic circulation potentially reduces the drug concentration 
fluctuations in the blood and keeps the concentration within the therapeutic window of the 
medication. Modifications to the nanoparticles’ surface can prolong their residence time in 
the systemic circulation, which further enables PLGA nanoparticles to be used as sustained-
releasing, long-circulating drug-delivery systems. Maintaining drug concentration in the 
blood within the therapeutic window reduces the chances of developing drug toxicity and 
side effects while presenting the therapeutic outcomes. It also prolongs dosing intervals and 
reduces the need for frequent dose administrations. Both outcomes benefit pharmacotherapy 
and patient compliance to the treatment.  
 
2.1.5. Anticancer Agent         
Docetaxel is a highly potent anticancer agent being used to treat a wide spectrum of 
cancer types. The drug is insoluble in water, so a combination of co-solvents is used in the 
commercial formulation to enhance the solubility. Issues such as hypersensitivity reactions, 
lower level of uptake by tumour tissue, and extensive toxicity/side effects have been 
associated with the formulation, which may partly be attributed to formulation’s ingredients. 
An alternate drug-delivery system, such as PLGA nanoparticles, may help circumvent these 
problems with conventional docetaxel pharmacotherapy and improve patient comfort and 





2.2. Study Hypothesis 
- Taguchi factorial design determines optimum condition for fabrication of PLGA 
nanoparticles loaded with docetaxel. 
- PLGA nanoparticles loaded with docetaxel possess the characteristics of a sustained-
release drug-delivery vehicle. 
- PLGA nanoparticles increase the blood circulation time for docetaxel by increasing 
the exposure, elimination half-life, and mean residence time of docetaxel in body. 
 
2.3.Study Objectives 
2.3.1. Objective 1 
Specific aim: To design an optimized preparation method for PLGA nanoparticles loaded 
with the anticancer agent docetaxel. 
 
2.3.1.1.Experiments Corresponding with Objective 1  
Design and Optimization of Nanoparticle Preparation: PLGA polymer was used to 
prepare nanoparticles as delivery vehicles of the anticancer drug docetaxel. A modified 
emulsification solvent evaporation technique was used to fabricate nanoparticles. To obtain a 
suitable PLGA nanoparticle formulation, a factorial experimental design was used to 
optimize nanoparticle fabrication method. Instead of following the conventional approach 
towards optimization of a process, in which the effect of one variable is evaluated while other 
variables are kept constant, a fractional factorial design was used. In fractional factorial 
designs, a reduced number of experiments (i.e., a fraction of the full factorial combinations) 
is used to draw out valuable conclusions and establish a relationship between process 
variables and the outcome of interest. Six factors were of interest, from which two were 
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evaluated at four levels and four factors were evaluated at two levels. Such combinations of 
factors and levels require the use of mathematical algorithms with asymmetrical matrices. 
The Taguchi method is a robust method that allows for fractional design of factorial 
experiments and asymmetrical mathematical matrices. Therefore, the Taguchi L16 (4**2 
2**4) array with 16 different combinations of factors/levels has been used to prepare drug-
loaded PLGA nanoparticles. The data obtained was applied to identify preparation factors 
with the highest magnitude of effectiveness on important nanoparticle characteristics, 
including size, zeta potential, PDI, and drug-loading efficiency. Models were built to predict 
important characteristics based on evaluated factors. The statistical significance of each factor 
in determining the important characteristics was checked as well. Based on the factorial 
experimental design, an optimized nanoparticle fabrication method was selected.  
 
2.3.2. Objective 2 
Specific aim 1: To prepare docetaxel-loaded PLGA nanoparticle formulations based on the 
optimized method of fabrication. 
Specific aim 2: To prepare surface-modified (i.e., PEGylated) docetaxel-loaded PLGA 
nanoparticle formulations based on the optimized method of fabrication. 
 Specific aim 3: To characterize docetaxel-loaded PLGA nanoparticles in terms of important 
particle properties. 
Specific aim 4: To characterize docetaxel-loaded surface-modified (i.e., PEGylated) PLGA 




2.3.2.1.Experiments Corresponding with Objective 2 
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The selected optimized fabrication method was used to prepare docetaxel-loaded 
nanoparticles. PLGA nanoparticles were prepared at four different docetaxel concentrations 
(i.e., low to high concentration) to have four nanoparticle formulations (i.e., low to high drug-
loading formulations) to choose from.  
PEGylated PLGA nanoparticles were also prepared following the same fabrication 
method as PLGA nanoparticles. The polymer used was the di-block co-polymer of PLGA 
(with the same characteristics as parent PLGA) and PEG (with 5000 Da molecular weight). 
Both nanoparticle formulations were subjected to extensive in vitro characterization 
including measurement of average size, zeta potential, poly-dispersity index, drug loading, 
drug-release profile, and cytotoxicity.        
 
2.3.3. Objective 3 
Specific aim: To set up and partially validate analysis methods for the detection and 
quantification of docetaxel in polymeric and biologic matrices (based on guidelines of the 
FDA).  
 
2.3.3.1.Experiments Corresponding with Objective 3 
To detect and quantify docetaxel in biologic (i.e., mouse tissues) and non-biologic 
(i.e., PLGA and PLGA-PEG nanoparticles) matrices, an analysis method based on mass 
spectrometry was developed, partially validated and used throughout the project.  
 
 
2.3.4. Objective 4 
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Specific aim 1: To determine the pharmacokinetic characteristics and bio-distribution (i.e. in 
the serum, liver, kidney, heart, and lung) of docetaxel (in mice) when used in PLGA 
nanoparticles, in surface-modified (i.e., PEGylated) PLGA nanoparticles, and in a free 
solution.  
Specific aim 2: To establish a relationship between PLGA nanoparticle characteristics and 
the mode of changes made to docetaxel’s pharmacokinetics and bio-distribution profile.    
 
2.3.4.1.Experiments Corresponding with Objective 4 
To determine how the loading of docetaxel in nanoparticles contributes to 
modifications of the drug’s pharmacokinetic characteristics and bio-distribution profile, the 
optimized formulation of docetaxel in PLGA and PLGA-PEG nanoparticles were 
intravenously injected to mice. An equivalent dose of a free docetaxel solution was also 
administered to mice. Then, docetaxel concentration versus time profile in serum and tissues 
under study was established for each formulation. Pharmacokinetic parameters and tissue 






Experimental Section on Taguchi Design for Formulation and Optimization of 
Docetaxel-loaded PLGA Nanoparticles 
  
3.1. Materials and Chemicals 
PLGA polymers of different terminal groups (i.e., acid or ester), lactide:glycolide 
monomer ratios (i.e., 50:50 and 75:25), and polymer molecular weight (i.e., PLGA inherent 
viscosity of 0.15-0.25 and 0.55-0.75 dl/g in hexafluoroisopropanol) were purchased from 
Absorbable Polymers International (Pelham, AL, USA). Docetaxel was purchased from LC 
laboratories (Woburn, MA, USA). All reagents were analytical grade or above and used as 
received, unless otherwise stated. 
 
3.2. Experimental Factorial Design for Preparation of Docetaxel-loaded PLGA 
Nanoparticles 
3.2.1. Taguchi Experimental Factorial Design 
A L16 Taguchi robust design was used to prepare, optimize, and evaluate the effect of 
different factors on important characteristics of docetaxel-loaded PLGA nanoparticles. Table 
3-1 exhibits six factors and their corresponding levels. Two factors—initial drug 
concentration and organic/aqueous phase ratio—were evaluated at four levels, while polymer 
molecular weight, polymer terminus, L:G monomer ratio, and PVA concentration were 
evaluated at two levels. To examine the factors under investigation, 16 combinations of factor 
and levels were used based on the Taguchi array (table 3-2). To reach the precision required 





Table 3-1: Variables (Factors) with their corresponding values and trial levels in the Taguchi 
experimental design used in the fabrication of docetaxel-loaded PLGA nanoparticles through 
an emulsification solvent evaporation technique. 
 Level 
Code Factor 1 2 3 4 
A Drug Concentration (mg/ml) 0.25 0.5 1 1.5 
B Organic/Aqueous phase ratio 1:2 1:3 1:4 1:5 
C Polymer Molecular weight (dl/g) 0.15 - 0.25 0.55-0.75   
D Polymer Terminus Acid Ester 
E Lactide:Glycolide Ratio  50:50 75:25 


















Table 3-2. Combination of different factors/levels of Taguchi design studied to prepare the 















1 0.25 1:2 0.15 - 0.25 Acid 50:50 2.2% 
2 0.25 1:3 0.15 - 0.25 Acid 50:50 9% 
3 0.25 1:4 0.55-0.75 Ester 75:25 2.2% 
4 0.25 1:5 0.55-0.75 Ester 75:25 9% 
5 0.5 1:2 0.15 - 0.25 Ester 75:25 2.2% 
6 0.5 1:3 0.15 - 0.25 Ester 75:25 9% 
7 0.5 1:4 0.55-0.75 Acid 50:50 2.2% 
8 0.5 1:5 0.55-0.75 Acid 50:50 9% 
9 1 1:2 0.55-0.75 Acid 75:25 9% 
10 1 1:3 0.55-0.75 Acid 75:25 2.2% 
11 1 1:4 0.15 - 0.25 Ester 50:50 9% 
12 1 1:5 0.15 - 0.25 Ester 50:50 2.2% 
13 1.5 1:2 0.55-0.75 Ester 50:50 9% 
14 1.5 1:3 0.55-0.75 Ester 50:50 2.2% 
15 1.5 1:4 0.15 - 0.25 Acid 75:25 9% 
16 1.5 1:5 0.15 - 0.25 Acid 75:25 2.2% 
 
 
3.2.2. PLGA Nanoparticle Preparation For Experimental Design 
Drug-loaded nanoparticles were prepared using a modified emulsification solvent 
evaporation technique as established in our lab. Briefly, PLGA polymer and docetaxel were 
dissolved in ethyl acetate to give a solution of 10% (w/v) PLGA and either 0.25, 0.5, 1, or 1.5 
mg/ml docetaxel, which was then added to a PVA solution of 2.2 or 9 % (w/v) concentration 
at 1:2, 1:3, 1:4, or 1:5 organic:aqueous phase ratios. The mixture was then subjected to 
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sonication followed by evaporation. Nanoparticles were ultimately obtained after consecutive 
washing steps. The freeze-dried nanoparticles were then kept at -20 °C for further use.  
 
3.2.3. PLGA Nanoparticle Characterization  
3.2.3.1. Determination of Average Size and Zeta Potential  
Nanoparticles’ mean diameter/size distribution profiles, polydispersity index (PDI) 
and zeta potential characteristics were measured using a Malvern Zetasizer (Nano-series, 
Nano ZS, model ZEN3600, Malvern Instruments, Worcestershire, UK). The nanoparticles (at 
least three replicates) were suspended in water prior to the measurements at 25°C. 
 
3.2.3.2. Determination of Nanoparticle Drug Loading and Encapsulation Efficiency 
Embedded docetaxel in PLGA nanoparticles was extracted twice with acetone as 
follows. Acetone was added to drug-loaded PLGA (0.5 % w/v) nanoparticles to dissolve both 
the polymer and the drug. The mixture was centrifuged. These steps were repeated twice. 
Obtained supernatants were mixed and evaporated. Methanol was added to the residue to 
precipitate the polymer. Docetaxel was then quantified in supernatant using the tandem mass 
spectrometry method. 
Drug loading of nanoparticles and encapsulation efficiency of the preparation method 
were calculated as follows: 
Equation 3-1: Drug loading (%) = (weight of drug in particles/weight of particles) ×100 
Equation 3-2: Encapsulation efficiency (%) = (weight of drug in particles/initial weight of 






3.2.4. Experimental Design Data Analysis  
The experimental design was used to develop models as means to define the factor(s) 
in the preparation procedure that significantly affect different characteristics of the obtained 
nanoparticle formulation. The statistical analysis of the results was performed with 
MINITAB® statistical software, version 16 (Minitab, State College, PA, USA). The qualities 
of the fitted models were examined by the coefficient of determination (R2). The data were 
analysed by analysis of variance (ANOVA) combined with the F test to evaluate whether a 
given term had a significant effect on the particle characteristic of interest. A p-value of 
<0.05 was considered statistically significant, unless otherwise stated. Particle characteristics 
included in the analysis comprised of particle size, zeta potential, poly dispersity index, and 
drug-loading efficiency of the method. A model was fitted for each particle characteristic, 
and based on ANOVA and F test, factors with statistically significant contributions (p-value 
of <0.05) to the characteristic of interest were determined. Then, based on final models, 
surface-response graphs were plotted between the particle characteristic of interest (size, zeta 
potential, poly dispersity index, and drug-loading efficiency), the significant factor, and other 
factors. 
 
3.3. Optimized PLGA Nanoparticle Formulation 
Response optimization was applied to identify the combination of nanoparticle 
preparation factors/levels that jointly optimize nanoparticle characteristics of interest. 
Response optimization was done for nanoparticle size, zeta potential, PDI, and drug-loading 
efficiency. Based on the data obtained from the experimental design and response 
optimization analysis, the below preparation conditions were the optimized fabrication 




Docetaxel Concentration: Level 4 (1.5 mg/ml) 
Organic/Aqueous phase ratio: Level 2 (1:3) 
PLGA Molecular weight: Level 1 (0.15 - 0.25 dl/g) 
PLGA polymer Terminus: Level 1 (Acid terminated) 
Polymer lactide/glycolide ratio: Level 1 (50:50) 
PVA Concentration: Level 1 (2.2%) 






Experimental Section on Preparation and Characterization of Optimized PLGA and 
PLGA-PEG Nanoparticle Formulation  
 
4.1. Materials and Chemicals 
PLGA polymer with an acid terminal group (COOH), a lactide:glycolide monomer 
ratio of 50:50, and a low molecular weight (inherent viscosity 0.15-0.25 dl/g in 
hexafluoroisopropanol) was purchased from Absorbable Polymers International (Pelham, AL, 
USA). Docetaxel was purchased from LC laboratories (Woburn, MA, USA). PLGA-PEG di-
block co-polymer (50:50 PLGA attached to mPEG 5000, 15% wt) was purchased from 
Evonik Degussa Corp. (Birmingham, AL, USA). All reagents were analytical grade or above 
and used as received, unless otherwise stated. 
 
4.2. Formulation Development of Nanoparticles   
The optimized formulation of docetaxel-loaded PLGA nanoparticles was prepared 
using an emulsification solvent evaporation technique. Briefly, PLGA polymer (10 % w/v) 
and docetaxel (1.5 mg) were dissolved in ethyl acetate, and added to a 2.2% (w/v) PVA 
solution (1:3 organic: aqueous phase ratio) to obtain the optimized nanoparticle formulation. 
The mixture was subjected to high-energy ultrasonication and evaporation. Then the 
nanoparticles were washed repeatedly to remove the free drug and other materials. The 
nanoparticles were finally re-suspended in a 1% (w/v) sucrose aqueous solution and freeze-
dried. The freeze-dried nanoparticles were then kept at -20°C. To create PLGA nanoparticle 
formulations with different drug loadings, the optimized preparation method was applied to 
prepare PLGA nanoparticles with three different docetaxel amounts: 0.25, 0.5, and 1 mg. 
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Plain PLGA nanoparticles were also fabricated following the same procedure without adding 
the drug to the organic phase.    
Surface-modified docetaxel-loaded PLGA nanoparticles were prepared using PLGA-
PEG to obtain PEGylated PLGA nanoparticles (below). 
Plain PLGA-PEG nanoparticles and docetaxel-loaded PLGA-PEG nanoparticles were 
prepared using the same emulsification solvent evaporation technique used to fabricate un-
modified PLGA nanoparticles. Briefly, PLGA-PEG di-block co-polymer (10 % w/v) alone or 
along with docetaxel (1.5 mg) was dissolved in ethyl acetate, and added to a 2.2% (w/v) PVA 
solution (1:3 organic: aqueous phase ratio) to obtain drug-loaded PEGylated PLGA 
nanoparticle or drug-free PEGylated PLGA nanoparticle formulations. The mixture was 
subjected to high-energy ultrasonication and evaporation. Then nanoparticles were repeatedly 
washed to remove the free drug and other materials. Obtained nanoparticles were finally re-
suspended in a 1% (w/v) sucrose aqueous solution and freeze-dried. The freeze-dried 
nanoparticles were then kept at -20°C. Again, to have PEGylated nanoparticle formulations 
with different drug loadings, the optimized preparation method was applied to prepare 
PLGA-PEG nanoparticles with three different docetaxel amounts: 0.25, 0.5, and 1 mg. 
 
4.3. Freeze-Drying of Nanoparticles and Cryoprotection 
The effectiveness of three cryoprotective agents during the freeze-drying process was 
determined. After the nanoparticles were prepared, aliquots of nanoparticle suspension (20 
mg/ml) were dispensed into glass vials and enough cryoprotectant was added to obtain 
trehalose and sucrose concentrations of 1, 3, 5 and 10% (w/v) and PVA concentrations of 
0.25, 0.5, 1, or 2% (w/v). Samples were then kept at -80°C for 30 minutes and subjected to a 
freeze-drying procedure at temperature of -84°C and a pressure of 0.12 mBar for 2 days 
(FreeZone Plus 6 Liter Cascade Freeze Dry System, Labconco Co., Kansas City, MO, USA) 
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using independent samples from each concentration (n=3). Similar aliquots of nanoparticles 
were also freeze-dried without using any cryoprotectant to be considered as reference 
samples. Samples were reconstituted with water, left for five minutes to ensure enough 
wetting, and then vortexed and subjected to sonication. The reconstituted nanoparticles were 
evaluated in terms of their average size, polydispersity index (PDI), and zeta potential. The 
equation below was used to determine the cryoprotective agent’s effectiveness in preserving 
average nanoparticle size: 
Equation 4-1: R = (Sf) / (Si) 
Where Sf and Si are the average size of nanoparticles after and before freeze-drying, 
respectively. 
 
4.4. Characterization of Nanoparticle Formulations 
4.4.1. Determination of Average Size and Zeta Potential  
Nanoparticles’ mean diameter/size distribution profiles, polydispersity index (PDI) 
and zeta potential were measured using a Malvern Zetasizer (Nano-series, Nano ZS, model 
ZEN3600, Malvern Instruments, Worcestershire, UK). At least three replicates of 
nanoparticles were suspended in water prior to the measurements at 25°C. 
 
4.4.2. Determination of Drug Loading and Encapsulation Efficiency 
Loaded docetaxel in PEGylated PLGA nanoparticle formulations and un-modified 
PLGA nanoparticle formulations was determined using a double extraction method with 
acetone as follows. Acetone was added to drug-loaded nanoparticles (0.5 % w/v) to dissolve 
both the polymer and the drug. The mixture was centrifuged. These steps were repeated 
twice. The obtained supernatants were mixed and evaporated. Methanol was added to the 
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residue to precipitate the polymer. Docetaxel was then quantified in supernatant using the 
tandem mass spectrometry method. 
The yield of the preparation method, drug loading, and encapsulation efficiency of 
nanoparticles were calculated as follows: 
Equation 4-2: Yield (%) = (weight of obtained particles/initial weight of polymer and drug 
added) ×100 
Equation 4-3: Drug loading (%) = (weight of drug in particles/weight of particles) ×100 
Equation 4-4: Encapsulation efficiency (%) = (weight of drug in particles/initial weight of 
drug added) ×100 
 
4.4.3. Docetaxel Release profile from Nanoparticle Formulations 
To evaluate the rate and pattern of release of docetaxel from PLGA and PEGylated 
PLGA nanoparticles, in vitro drug release tests were performed as described below. Drug-
loaded nanoparticles from either PLGA or PEGylated PLGA nanoparticle formulation at the 
different concentrations (0.25, 0.5, 1, and 1.5 mg/ml) were re-suspended in phosphate-
buffered saline (PBS) (0.5 % w/v) and placed at 37 °C in a shaker-incubator (n=3). At 
designated time-points (1h, 6h, 12h, followed by 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 days for the PLGA 
nanoparticle formulation, and 1h, 6h, 12h, followed by 1, 2, 3, 4, 5 days for the PEGylated 
PLGA nanoparticle formulation), samples were collected and fresh PBS was added in the 
original tube for further incubation. The supernatant was then freeze-dried and the drug was 
extracted twice from the lyophilized powder using acetone. The acetone extract was then 
evaporated. Methanol was added to the residue to dissolve the drug. Samples were then 






4.5. Determination of Cytotoxicity of Docetaxel Loaded in Nanoparticles 
4.5.1. Cell Culture 
Hela cell (American Type Culture Collection, Manassas, VA, USA) lines were 
cultivated in high glucose Dulbecco's modified Eagle's medium (DMEM) culture media 
supplemented with 10% fetal bovine serum (FBS) and 1% antibiotic (100 unit/ml penicillin, 
100 µg/ml streptomycin, and 0.25 µg/ml amphotericin B) at 37°C in a humidified incubator 
with 5% CO2. The cells were maintained in an exponential growth phase by periodic sub-
cultivation.  
 
4.5.2. MTT Assay 
Hela cells were seeded into 96-well plates at a density of 5000 per well and incubated 
for 24 hours (humidified 37°C, and 5% CO2). Then, the growth medium was removed from 
the wells and replaced with 90 µl of fresh medium. Cells were then treated with 10 µl of the 
following:  
1. Free drug solution in culture media at 4, 2, 1, 0.5, and 0.25 µg/ml docetaxel 
concentrations. 
2. PLGA or PEGylated PLGA nanoparticle suspension in phosphate buffer (pH= 7.4) 
with equivalent docetaxel concentrations of 4, 2, 1, 0.5, and 0.25 µg/ml.  
3. Plain PLGA or PEGylated PLGA  nanoparticle suspension (control) 
Blank wells were also included in the assay to exclude the potential absorbance of 
culture media and PLGA or PEGylated PLGA nanoparticles. Blank samples were as follows: 
1. Wells with culture media without cells. 
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2. Wells with culture media without cells treated with plain PLGA or PEGylated PLGA 
nanoparticle suspension.    
After cell treatment, plates were incubated for 6, 12, 24, and 48 hours. The percentage 
of cell viability was assayed by the number of surviving cells after incubation. At each time-
point, medium in each well was replaced with 100 µl fresh medium containing 10 µl 
CellTiter 96® AQueous One Solution Cell Proliferation Assay Reagent (Promega, WI, 
USA). The compound in the reagent was bio-converted by cells into a coloured product. 
After incubating the plate for one to four hours, absorbance at each well was measured at 490 
nm using a 96-well plate reader. Cell viability was calculated using the following equation:    









Experimental Section on Mass spectrometry Method for Quantification of Docetaxel 
 
 
5.1. Materials and Chemicals 
PLGA polymer with acid terminal group (COOH), lactide:glycolide monomer ratio of 
50:50, and low molecular weight (inherent viscosity 0.15-0.25 dl/g in hexafluoroisopropanol) 
was purchased from Absorbable Polymers International (Pelham, AL, USA). Docetaxel was 
purchased from LC laboratories (Woburn, MA, USA). PLGA-PEG di-block co-polymer 
(50:50 PLGA attached to mPEG 5000, 15% wt) was purchased from Evonik Degussa Corp. 
(Birmingham, AL, USA).  All reagents were analytical grade or above and used as received, 
unless otherwise stated. 
Mouse serum was purchased from Biocell Laboratories (Rancho Dominguez, CA, 
USA). Mouse organs, including livers, hearts, lungs, and kidneys were collected from cull 
mice provided by the Lab Animal Services Unit (LASU) of Health Sciences Building, at the 
University of Saskatchewan. Mouse serum and organs were used to develop and validate the 
analytical method. All animals were treated humanely and euthanized according to the 
protocols approved by the University of Saskatchewan’s Animal Research Ethics Board and 
adhering to the Canadian Council on Animal Care guidelines for humane animal use. 
 
5.2. Mass Spectrometry Method for the Quantitation of Docetaxel  
Mass spectrometry was used to quantitatively determine the docetaxel present in 
samples throughout the study. Paclitaxel was used as the internal standard in all the 








































Figure 5-1: Molecular structure of docetaxel (A) and paclitaxel (B). 





5.2.1. Determination of Docetaxel and Paclitaxel Fragmentation Patterns 
Solution of docetaxel and paclitaxel (10 μg/mL in methanol containing 0.1% (v/v) 
formic acid) were prepared and directly infused into the ionization source using a model 11 
Plus syringe pump (Harvard Apparatus, MA, USA) at a flow rate of 10 μL/min into a Hybrid 
Triple Quadrupole/Linear Ion trap mass spectrometer (AB Sciex 4000 QTRAP MS/MS 
system, Framingham, MA, US). The Turbo Ion-spray Source was set to 5500 volts. Curtain 
gas, nebulizer, and heater gas pressure were 30, 40, and 40 psi respectively. The de-clustering 
potential (DP) of docetaxel and paclitaxel was 46 and 55 volts respectively. The collision 
energy of docetaxel and paclitaxel was 21 and 93 respectively. Collision cell exit potential 
was 18 for both materials. Other instrument parameters were as follows: interface heater = 
ON (150°C), collisionally activated dissociation (CAD) = 5, and exit potential = 10. Product-
ion scans (MS/MS) were performed using positive electrospray ionization (+ESI) with 
appropriate set mass (parent m/z). 
According to the obtained pattern of docetaxel and paclitaxel fragmentation, two 
fragments of docetaxel (m/z = 226 and 528) were chosen to be used in Multiple Reaction 
Monitoring (MRM) transitions and docetaxel quantitation. Injection of the samples into the 
mass spectrometer was done using an Agilent Quaternary pump (1200 series) and Agilent 
G1329A (1200 series) auto sampler (Santa Clara, CA, USA) through a pre-column guard 
(Eclipse XDB-Rapid resolution, C18, 2.1×30mm, 3.5µ, Agilent, Santa Clara, CA, USA) with 
a mobile phase flow rate of 200 µl/min (Methanol, 0.1 % formic acid, isocractic elution). The 
quantitation procedure was performed on corresponding docetaxel and paclitaxel MRM 






5.2.2. Partial Analysis Validation Tests for Docetaxel in Non-biological Matrices 
To determine the reliability and suitability of the method of analysis for docetaxel in 
PLGA and PLGA-PEG nanoparticles, partial analysis validation tests were carried out as 
follows. 
 
5.2.2.1. Sample Preparation 
A stock solution of 100 µg/ml docetaxel was prepared by dissolving the drug in 
methanol and stored at -20°C for further use. Working solution concentrations of 3.9, 7.8, 
15.6, 31.2, 62.5, 125, 250, 500, 1000, 2000, 4000, 8000, and 16000 ng/ml were prepared by 
further diluting the stock solution with methanol. A stock solution of paclitaxel in methanol 
as the internal standard was also prepared at 100µg/ml.   
 
5.2.2.2. Preparation of Standard and Control Samples 
To prepare polymer-free standards (docetaxel in methanol), the internal standard and 
the working solution (3.9-1000 ng/ml) were transferred into tubes. Polymer-free controls 
were prepared as such to obtain 100, 200, 400, and 800 ng/ml docetaxel concentrations. To 
prepare standard samples of nanoparticle formulations, the internal standard and the working 
solution (125-8000 ng/ml and 125-16000 ng/ml for PLGA-PEG and PLGA nanoparticles, 
respectively) were transferred into tubes. The solvent was then evaporated and drug-free 
nanoparticles (0.5 % w/v) were added to the tube. A concentration set of 1250, 2500, 5000, 
and 10000 ng/ml was used to prepare quality-control samples of PLGA nanoparticles and a 
concentration set of 625, 1250, 2500, and 5000 ng/ml was used to prepare quality-control 
samples of PLGA-PEG nanoparticles. Paclitaxel was added to the control samples of PLGA 
and PLGA-PEG nanoparticles. The solvent was evaporated and drug-free nanoparticles (0.5 
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% w/v) were added to the tube. Standard and control samples of PLGA and PLGA-PEG 
nanoparticles were extracted twice with acetone.   
 
5.2.2.3. Docetaxel Extraction Method from Nanoparticles  
Docetaxel was extracted from PLGA and PLGA-PEG nanoparticles as follows. 
Acetone was added to drug-loaded nanoparticles (0.5 % w/v) to dissolve both the polymer 
and the drug. The mixture was centrifuged and the procedure was repeated. Obtained 
supernatants were mixed and evaporated. Methanol was added to the residue and centrifuged. 
Docetaxel was then quantified in supernatant using mass spectrometry. 
 
5.2.2.4. Determination of Limits of Detection and Quantitation 
The limit of detection (LOD) of docetaxel in methanol, PLGA nanoparticles, and 
PLGA-PEG nanoparticles were measured based on a signal-to-noise ratio of 3:1. The limit of 
quantitation (LOQ) of the method for the mentioned nanoparticle matrices were measured 
based on a signal-to-noise ratio of 10:1 with acceptable precision and accuracy (within ±20% 
of the nominal value).  
 
5.2.2.5. Linearity 
Standard samples of docetaxel in methanol (3.9-1000 ng/ml), PLGA nanoparticles 
(125-16000 ng/ml), and PLGA-PEG nanoparticles (125-8000 ng/ml) were prepared as 
described previously, extracted, and subjected to mass spectrometer for analysis. Linear 
regression analysis was carried out on known added concentrations of docetaxel (weighted 
1/x) against the peak area ratio of docetaxel to paclitaxel. Then, the regression coefficient 




5.2.2.6. Method Precision 
Quality control samples—limit of quantitation (LOQ), low quality control (LQC), 
middle quality control (MQC), and high quality control (HQC)—were prepared for the 
samples of docetaxel in methanol, PLGA nanoparticles, and PLGA-PEG nanoparticles as 
described and injected into the mass spectrometer (n=6). The coefficient of variations of the 
corresponding concentrations were determined in each case. 
 
5.2.2.7. Method Accuracy 
Quality control samples were prepared for samples of docetaxel in methanol, PLGA 
nanoparticles, and PLGA-PEG nanoparticles as described and subjected to mass spectrometer 
analysis (n=6). The method’s accuracy was determined as the difference between the 
measured concentration (based on the standard curve) and the nominal concentration divided 
by corresponding added (nominal) concentration multiplied by 100. 
 
5.2.3. Partial Analysis Validation Tests for Docetaxel in Mouse Tissue 
To determine the reliability and suitability of the method of analysis for docetaxel in 
mouse tissues, partial analysis validation tests were carried out as follows. 
 
5.2.3.1. Sample Preparation for Mouse Serum  
A stock solution of 100 µg/ml docetaxel was prepared by dissolving the drug in 
methanol and kept in -20 °C for further use. A working solution of 2000 ng/ml was prepared 
by addition of 20 µl stock to 980 µl of mouse serum. A stock solution of paclitaxel in 
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methanol was also prepared at 100 µg/ml to be used as internal standard. A working solution 
of 10000 ng/ml paclitaxel in methanol was prepared. 
 
5.2.3.2. Preparation of Standard and Control Samples 
A standard concentration set of 1000, 500, 250, 125, 62.5, 31.2, and 15.6 ng/ml and 
control concentrations of 100, 200, 400, and 800 ng/ml were prepared by further diluting the 
working solution with mouse serum.  
 
5.2.3.3. Technique for Extraction of Docetaxel from Mouse Serum 
Docetaxel and paclitaxel were extracted from the mouse serum as follows. The 
paclitaxel working solution was added to the tube. The solvent was evaporated and mouse 
serum containing docetaxel was added to the tube. Then, tert-butyl methyl ether (TBME) was 
added at the ratio of 1:10. The mixture was centrifuged and transferred to a -80 °C freezer. 
The supernatant was then evaporated and residue was reconstituted with mobile phase 
(methanol containing 0.1% formic acid) and injected into the mass spectrometer for analysis.  
 
5.2.3.4. Sample Preparation for Mouse Liver 
A stock solution of 100 µg/ml docetaxel was prepared by dissolving the drug in 
methanol and was kept at -20°C for further use. Working solutions of 5000, 2500, 1250, 625, 
312,156, and 78 ng/ml were prepared by further diluting the stock solution with methanol. A 
stock solution of paclitaxel in methanol was also prepared at 100 µg/ml to be used as the 





5.2.3.5. Preparation of Standard and Control Samples 
Standard and control samples were prepared in mouse liver homogenizate that was 
obtained as follows. Liver was weighed and enough normal saline was added to it to obtain a 
5% (w/v) mixture. The mixture was then homogenized on ice. A standard concentration set of 
500, 250, 125, 62.5, 31.2, and 15.6 ng/ml was prepared by further diluting the working 
solution with liver homogenizate. Control working solutions were prepared in methanol 
(1000, 2000, and 4000 ng/ml) and used to prepare 100, 200, and 400 ng/ml control 
concentrations of liver homogenizate following the same approach.  
 
5.2.3.6. Technique for Extraction of Docetaxel from Mouse Liver 
Docetaxel and paclitaxel were extracted from mouse liver as follows. Paclitaxel stock 
solution was added to a tube and the solvent was evaporated. Liver homogenizate containing 
docetaxel and TBME at 1:2 ratio were added to the tube. The sample was then centrifuged 
and transferred to a -80°C freezer. Samples were centrifuged again and the supernatant was 
separated and evaporated. Acetone was added to the residue, which was then transferred to a 
new tube and evaporated. The mobile phase (methanol containing 0.1% formic acid) was 
added to the residue. After centrifugation, the supernatant was injected into the mass 
spectrometer for analysis. 
 
5.2.3.7. Determination of Limits of Detection and Quantitation 
Docetaxel’s LOD and LOQ in mouse serum and liver were measured based on a 






Standard samples of docetaxel in mouse serum (15.6-1000 ng/ml) and liver (15.6-500 
ng/ml) were prepared as described previously, extracted, and injected into the mass 
spectrometer for analysis. Known concentrations of docetaxel were subjected to linear 
regression analysis (weighted 1/x) against the peak area ratio of docetaxel to paclitaxel. The 
R2, slope, intercept, and equation of the resulting calibration curves were then determined. 
 
5.2.3.9. Method Precision 
Quality control samples (LOQ, LQC, MQC, HQC) were prepared for samples of 
docetaxel in mouse serum and liver as described and injected into the mass spectrometer 
(n=6). The coefficients of variations of the corresponding concentrations were determined in 
each case. 
 
5.2.3.10. Method Accuracy 
Quality control samples were prepared for samples of docetaxel in mouse serum and 
liver as described and injected into the mass spectrometer for analysis (n=6). The method’s 
accuracy was determined as the difference between the measured concentration (based on the 
standard curve) and the nominal concentration divided by the corresponding added (nominal) 
concentration multiplied by 100. 
 
5.2.3.11.  Extraction of Docetaxel from Mouse Kidney, Heart, and Lung   
The drug extraction technique from mouse liver mentioned above was also used for other 
mouse kidney, heart, and lung tissues. The method’s extraction efficacy and linearity were 
evaluated in these tissues. Extraction efficiency was calculated as follows: 
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Extraction Efficiency (%) = (Peak area ratio of docetaxel to paclitaxel from extracted 






Experimental Section on Pharmacokinetics and Bio-distribution of Docetaxel 
 
6.1.Animals 
BALB/c mice were purchased from Charles River Laboratories (Saint Constant, QC, 
Canada).  The animals were housed in the mouse suite located in Lab Animal Services Unit 
(LASU) in the Health Sciences Building at the University of Saskatchewan under controlled 
temperature and humidity with a 12-hour light-dark cycle.  They were kept in the facility for 
a period of at least one week to acclimatize and had free access to water and standard 
laboratory mouse chow.  All animals were treated humanely and euthanized according to the 
protocols approved by the University of Saskatchewan Animal Ethics Board.  
 
6.2. Animal Experiments  
Animal experiments were conducted using 8-week-old female BALB/c mice after a 7-
day period acclimatization in the LASU. The 96 mice were randomly divided into three 
groups with free access to food and water. Each group received 5 mg/kg of docetaxel either 
in the form of the docetaxel-loaded PLGA nanoparticles, docetaxel-loaded PLGA-PEG 
nanoparticles or free-docetaxel solution. Docetaxel formulations were injected through the 
mouse tail vein (injection volume: 200µl, solvent: 0.9% sodium chloride). At various time-
points (0.5, 1, 2, 4, 6, 12, 18, and 24 hour) after dosing, mice were anesthetized and sacrificed 
by exsanguination. The blood was collected and the lungs, heart, liver, and kidneys were 
harvested; these were preserved in plastic bags in the -20°C freezer for later docetaxel 




6.3. Bio-distribution and Pharmacokinetic Analysis    
For bio-distribution studies, mouse organs were subjected to the extraction procedure 
(explained in chapter 5) and underwent mass spectrometric analysis to determine the 
concentration of docetaxel in each tissue. Then, the relationship between the docetaxel 
concentration and time was determined by plotting corresponding graphs. Pharmacokinetic 
analysis was performed using the collected mouse serum at different time-points as follows. 
Briefly, the obtained blood was centrifuged and the serum was separated from the rest of the 
blood components and subjected to the extraction procedure and further analysis by the mass 
spectrometer. Using Graphpad prism software (version 5.04), a plot of docetaxel 
concentration versus time was prepared. A non-compartmental pharmacokinetic analysis 
method was used to determine the pharmacokinetic-important parameters in mouse serum 
and other organs. Then, results from each study group were compared. Pharmacokinetic 
parameters were calculated as follows: 
1. Elimination half-life (T1/2): Graphical relationship between docetaxel concentration 
at y axis and time at x axis was established. Docetaxel concentration at y axis was 
then transformed to a natural logarithm (Ln) to convert the data into a straight-line 
relationship. Then, data-points from the terminal elimination phase was used in a non-
linear regression to plot a straight line (Y = -KeX + B). Half-life was calculated as: 
Equation 6-1:     T1/2 = 0.693/ Ke 
In which Ke is the slope of the plotted line from the non-linear regression analysis. 
2. Concentration at time zero (C0): Residuals were calculated between the plotted line 
(above) and the data-points at the distribution phase. Using residuals data-points and 




Equation 6-2:    C0 = A + B 
In which A and B are the intercepts from the residuals line and terminal elimination 
phase line, respectively. 
3. Area under the serum concentration versus time curve (AUC): AUC from time 
zero (C0) until 24 hours was calculated by software. AUC from t = 24 hours to infinity 
was calculated as: 
Equation 6-3:    AUC (24 to ∞) = C24/Ke 
Therefore, total AUC was calculated as: 
Equation 6-4:    AUC (0 to ∞) = AUC (0 to 24) + AUC (24 to ∞)  
4. Clearance (Cl) : Docetaxel clearance was calculated as : 
Equation 6-5:    Cl = Dose/ AUC (0 to ∞) 
In which dose is the amount of docetaxel injected intravenously and AUC (0 to ∞) is the 
area under the serum concentration versus time curve from time zero to infinity. 
5. Volume of Distribution (Vd) : Volume of distribution was calculated as: 
Equation 6-6:    Vd = (Dose)/ (AUC (0 to ∞)) × (Ke) 
6. Area Under the Moment Curve (AUMC): The product of concentration (including 
C0) multiplied by time at each time point was calculated (i.e., concentration × time). 
Then, the graphical relationship between (docetaxel concentration × time) at y axis 
and time at x axis was established. AUMC from time zero until t = 24 hours was 
calculated by software. AUMC from 24 hours to infinity was calculated as: 
Equation 6-7:    AUMC (24 to ∞) = [(C24 × t24)/(Ke)] + [(C24)/(Ke2)] 
Therefore, total AUMC was calculated as: 
Equation 6-8:    AUMC (0 to ∞) = AUMC (0 to24) + AUMC (24 to ∞) 
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7. Mean Residence Time (MRT) : The mean residence time of docetaxel was 
calculated as: 






Result and Discussion on Taguchi Design for Formulation and Optimization of 
Docetaxel-loaded PLGA Nanoparticles 
 
* Chapter 3 (Experimental Section on Taguchi Design for Formulation and Optimization of Docetaxel-loaded 
PLGA Nanoparticles) along with chapter 7 was submitted as an ‘Original Research Article’ to ‘Artificial Cells, 
Nanomedicine and Biotechnology: An International Journal’ for publication:  
 
Pedram Rafiei, Azita Haddadi. Taguchi Design for the Preparation and Optimization of Docetaxel-loaded PLGA 
Nanoparticles for Intravenous Drug Delivery Purpose. Artificial Cells, Nanomedicine and Biotechnology: An 




PLGA polymer has a variable nature. Depending on the number of monomers present 
in polymer chain, it can assume different molecular weights. The ratio of monomers (lactide 
and glycolide) in a PLGA chain can vary and provide polymers with different L:G ratios. In 
addition, PLGA polymer can assume ester or carboxylic acid terminal groups. Therefore, 
PLGA can possess different physicochemical properties based on its polymeric structure.  
PLGA nanoparticles are used to deliver different drugs in terms of physicochemical and 
pharmacological properties.  
Therefore, PLGA nanoparticles prepared for the delivery of various compounds can 
assume different properties depending on 
i) The type of PLGA polymer used for nanoparticle preparation, 
ii) The method used for nanoparticle preparation, and 
iii) The type of drug/compound associated with nanoparticles.   
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PLGA nanoparticle properties determine nanoparticles’ performance when used as 
drug delivery systems. Therefore, it is crucial to understand how PLGA polymer, the 
nanoparticle preparation method, and the associated drug contribute to nanoparticles’ 
properties. This knowledge is important because it provides control over nanoparticle 
properties and over PLGA nanoparticles’ performance as drug delivery systems. This 
knowledge of how PLGA polymer, the nanoparticle preparation method, and the associated 
drug contribute to nanoparticles’ properties is usually obtained by performing factorial 
experiments.  
Factorial experiments are used to understand the effect of independent variables 
(factors) on a dependent variable (response). The conventional approach to determine the 
effect of variables on a process, like the development of a drug formulation, has been to 
evaluate the effect of one variable while keeping the others constant to see if the variable 
significantly affects the process. Such approaches are usually strenuous and uneconomical, 
especially if the process is performed in replicates [276, 277]. Meanwhile, a much simpler 
screening of experimental parameters has been made possible through the application of 
experimental factorial designs with a reduced number of experiments (i.e., a fraction of the 
full factorial combinations) to draw out valuable conclusions and establish a relationship 
between the process variables and the outcome of interest [278]. The Taguchi method has 
been widely used to analyze many factors with few runs: equally weighted factors are 
analyzed independently of one another to offer a balanced design [279]. In addition, the 
estimation of one factor is not influenced by the effect from another factor.  
Here, the experimental design based on the Taguchi robust method was used to 
optimize PLGA nanoparticles loaded with docetaxel and an optimized method was identified. 
The optimized docetaxel-loaded PLGA nanoparticle formulation was further subjected to in 
vitro characterization and used for pharmacokinetic and biodistribution studies.  The L16 
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Taguchi design used here contributed to the identification of factors that could significantly 
influence nanoparticle-important characteristics including average size, PDI, zeta potential, 
and drug-loading efficiency. The design was helpful in ranking factors based on their level of 
effectiveness on various particle characteristics under study. Furthermore, analysis of the data 
from the experimental design helped build models that were statistically significant with good 
robustness. Generally, built models help predict particle characteristics from a combination of 
factors and various levels.  
 
7.1. L16(4**2 2**4) Experimental Design 
Table 7-1 demonstrates the combination of sixteen different factors and their 
corresponding levels based on the L16 Taguchi design. Runs were done in triplicate and the 
nanoparticles obtained from each run were characterized in terms of their size, PDI, zeta 
potential, and drug-loading efficiency. Then, statistical analysis was performed on each 
characteristic individually. Nanoparticles demonstrate average size between 93.5±6.9 nm and 
191.4±21.1 nm. The range of zetapotential exhibited by nanoparticles was between -17.8±1.2 
mV and -36.5±0.6 mV. Fabricated nanoparticles demonstrated a uni-distributed population 
having PDI values between 0.095±0.015 and 0.290±0.059. Nanoparticle preparation at 16 
different combinations of factors/levels resulted in a range of drug-loading efficiency 




Table 7-1. Combination of different factor/levels of the Taguchi design studied in the preparation of the docetaxel-loaded PLGA nanoparticles 





Org./Aq. Ratio (B) Polymer Mw 
(C) 






PDI Zeta Potential (mV) Entrapment (%)  
1 0.25 1:2 0.15 - 0.25 Acid 50:50 2.2% 151.1±19.3  0.175±0.080  -22.8±2.3  79.6±2.6 
2 0.25 1:3 0.15 - 0.25 Acid 50:50 9% 108.6±1.8  0.256±0.014  -29.8±4.5  41.5±3.6 
3 0.25 1:4 0.55-0.75 Ester 75:25 2.2% 159.8±11.4  0.113±0.019  -25.3±5.1  86.4±4.2 
4 0.25 1:5 0.55-0.75 Ester 75:25 9% 105.1±5.5  0.130±0.035  -17.8±1.2  43.2±3.3 
5 0.5 1:2 0.15 - 0.25 Ester 75:25 2.2% 191.4±21.1  0.219±0.070  -19.3±4.8  96.2±4.0 
6 0.5 1:3 0.15 - 0.25 Ester 75:25 9% 105.0±2.6  0.158±0.022  -18.9±1.0  60.0±3.1 
7 0.5 1:4 0.55-0.75 Acid 50:50 2.2% 135.1±1.6  0.122±0.004  -31.1±1.7  50.8±6.0 
8 0.5 1:5 0.55-0.75 Acid 50:50 9% 93.5±6.9  0.154±0.061  -28.7±3.7  35.1±3.4 
9 1 1:2 0.55-0.75 Acid 75:25 9% 117.2±8.6  0.148±0.019  -32.8±4.8  46.6±3.1 
10 1 1:3 0.55-0.75 Acid 75:25 2.2% 171.9±7.1  0.118±0.015  -32.5±0.3  49.7±0.8 
11 1 1:4 0.15 - 0.25 Ester 50:50 9% 100.2±1.5  0.177±0.015  -18.2±0.3  29.9±3.6 
12 1 1:5 0.15 - 0.25 Ester 50:50 2.2% 113.4±4.5  0.198±0.037  -26.0±2.7  42.9±1.6 
13 1.5 1:2 0.55-0.75 Ester 50:50 9% 119.8±2.0  0.095±0.015  -18.4±2.7  43.7±4.2 
14 1.5 1:3 0.55-0.75 Ester 50:50 2.2% 163.1±8.9  0.180±0.033  -21.1±3.6  41.4±4.1 
15 1.5 1:4 0.15 - 0.25 Acid 75:25 9% 104.0±8.1  0.290±0.059  -29.8±1.7  25.2±1.1 





7.1.1. Particle Size 
Figure 7-1 demonstrates the main effect plot for the means of particle size due to 
factors under study at different levels.  The difference between the maximum and minimum 
mean particle sizes is highest in the case of PVA concentration (43.8 nm) followed by 
organic:aqueous phase ratio (37.3 nm), lactide:glycolide ratio (11.0 nm), polymer Mw (9.2 
nm), polymer terminus (7.3 nm), and drug concentration (5.6 nm). The rankings of factors 
affecting the response (particle size) are exhibited in table 7-2 based on the mean particle size 
range variation. PVA concentration had the largest effect on particle size, followed by 
organic:aqueous phase ratio, lactide:glycolide ratio, polymer Mw, polymer terminus, and 
drug concentration. Figure 7-2 demonstrates the mean of signal/noise ratio (S/N) 
corresponding to each factor at various levels. S/N was calculated by the software using 
equation below: 
Equation 7-1:   S/N = −10*log(Σ(1/Y2)/n) 
Where Y is responses for the given factor level combination and n is number of 
responses in the factor level combination. 
  The magnitude of range between maximum and minimum S/N identifies the factor 
that leads to most reduced variability. The larger S/N range is preferred to have less variation 
in response. Accordingly, PVA has the largest S/N range (2.87) followed by organic:aqueous 
phase ratio (2.39), polymer Mw (0.66), lactide:glycolide ratio (0.64), polymer terminus 
(0.42), and drug concentration (0.37). Figure 7-3 represents the normal probability plots of 
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Figure 7-1. Main effect plot for particle size at different factor levels  
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Figure 7-3. Normal probability plot of residuals by the final model for particle size 
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Linear regression analysis, ANOVA, and F tests were performed on the data to fit a 
model that best defined the variations in particle size versus the six factors under study. R2 
was equal to 0.899 while the regression equation was calculated to be: 
 
Equation 7-2:  Particle Size = 189 - 2.01 (A) - 12.4 (B) + 9.18 (C) + 7.26 (D) + 11.0 
(E) - 43.8 (F) 
 
Tables 7-3 and 7-4 respectively exhibit the result of ANOVA and regression analysis 
for the fitted model of particle size distribution. The model fitted for particles size explained 
variations in particle size with statistical significance (p = 0.001). Regression analysis 
determined that PVA concentration and organic:aqueous phase ratio significantly contributed 
to particles size (p < 0.05).     
 
Table 7-3. ANOVA table for fitted model for particle size  














Table 7-4. Regression analysis of particle size versus nanoparticle preparation variables 
Predictor Coefficients SE Coefficients T P 
Constant 
Drug concentration (A) 
Organic/Aqueous phase ratio (B) 
Polymer Mw (C) 
Polymer Terminus (D) 
Lactide:Glycolide ratio (E) 






























To understand the relationship between the response of interest (i.e., particle size) and 
the factors that significantly affect that response (i.e., Organic/Aqueous phase ratio and PVA 
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concentration), response surface graphs were plotted and are presented in supplementary 
figure 1. The figure indicates that the maximum response (i.e., particle size) was obtained at 
low PVA concentration (level one) and 1:2 organic:aqueous phase ratio (level one) and vice 
versa.  
As exhibited in figure 7-1, increasing the ratio of aqueous phase decreased particle 
size. Here, the amount of aqueous phase in the suspension played an important role in 
determining the final size of the nanoparticles. In samples with a high volume of aqueous 
phase, nano-droplets were distributed throughout a large volume of liquid and therefore had 
less chance of adhesion. The rate of organic solvent diffusion from nano-droplets to the 
surrounding aqueous medium and the final evaporation from nano-suspension also decreased 
particle size. In a nano-suspension with a large volume of aqueous phase, the rate of organic 
solvent diffusion from nano-droplet to the aqueous medium was higher [280-282]. Therefore, 
nano-droplets solidified faster and had less chance of adhesion. Consequently, nanoparticles 
retained their sizes. Our results agree with those of Murugesan and colleagues [195] who 
demonstrated that the amount of aqueous phase during nanoparticle preparation has an 
inverse relationship with nanoparticle size. 
PVA concentration also had an inverse relationship with nanoparticle size. PVA, a 
non-ionic surfactant (spatial stabilizer), was stationed on the surface of nano-droplets during 
preparation, which prevented droplet adhesion and fusion. In case of high PVA 
concentrations, nano-droplets were surrounded with large numbers of PVA molecules, which 
stabilize the nano-droplets. This stability in turn resulted in fewer interactions between nano-
droplets, so the overall particle size remained unchanged. The study by Murugesan et al. 
[195] also demonstrated that increasing the concentration of stabilizing agent reduces 
nanoparticle size.    
101 
 
The ratio of monomers (L:G) also affected the size of nanoparticles. As mentioned in 
chapter one, lactic acid is chemically more hydrophobic than glycolic acid. Consequently, the 
50:50 (L:G) PLGA polymer was less hydrophobic than the 75:25 (L:G) PLGA polymer. 
Therefore, the organic phase prepared from 50:50 (L:G) PLGA had a lower hydrophobic 
integrity than the organic phase prepared from 75:25 (L:G) PLGA . During probe-sonication, 
organic phase droplets with lower hydrophobicity more easily broke into smaller droplets, 
which lowered nanoparticle average size. On the other hand, because of their lower 
hydrophobic integrity, the organic solvent escaped nano-droplets prepared from 50:50 (L:G) 
PLGA faster, which caused the nanoparticles to solidify more rapidly. This decreased the 
chance of droplet adhesion and fusion during the solvent evaporation period.   
Increasing the polymer molecular weight also increased average particle size. The 
PLGA polymer with low molecular weight resulted in an organic phase with low viscosity. 
During probe-sonication, organic phase droplets with low viscosity broke into small droplets 
more easily than droplets with higher viscosity. Therefore, low molecular weight PLGA 
provided nanoparticles with a lower average size compared to high molecular weight PLGA. 
Koopaei and colleagues [283] demonstrated that organic phase with higher viscosity leads to 
nanoparticles with a higher average size, which agrees with our result.           
 
7.1.2. Poly-dispersity Index (PDI) 
As exhibited in table 7-1, nanoparticle formulations demonstrated PDI values less 
than 0.3, which indicated a narrow distribution profile among the particle population. Figure 
7-4 demonstrates the main effect plot for the means of particle PDI. The figure demonstrates 
how the average PDI of nanoparticle populations changes at various factors/levels. The 
difference between maximum and minimum PDI for each factor was determined. Polymer 
molecular weight had the highest range (0.0819), followed by drug concentration (0.0419), 
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polymer terminus (0.297), organic:aqueous phase ratio (0.022), lactide:glycolide ratio 
(0.0076), and PVA concentration (0.0051). Table 7-5 ranks these factors based on the 
magnitude of effectiveness on particle PDI. Polymer molecular weight had the largest effect, 
drug concentration had second largest effect on PDI, and so on. Figure 7-5 demonstrates the 
S/N corresponding to each factor at various levels. S/N was calculated by the software using 
equation below: 
Equation 7-3:   S/N = −10*log(Σ(1/Y2)/n) 
Where Y is responses for the given factor level combination and n is number of 
responses in the factor level combination. 
 The range of the S/N of PDI between different levels were as follows: polymer Mw 
(4.08) > drug concentration (1.77) > organic:aqueous phase ratio (1.58) > polymer terminus 
(1.27) >  lactide:glycolide ratio (0.34) > PVA concentration (0.18). Accordingly, polymer 
molecular weight led to the most reduced variability. Figure 7-6 represents the normal 
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Figure 7-4. Main effect plot for particle PDI at different factor levels  
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Linear regression analysis, ANOVA, along with F tests, were performed on the data 
to fit a model that best defined the variations in particle PDI versus the six factors under 
study. R2 was equal to 0.717 while the regression equation was calculated to be: 
 
Equation 7-4:  Particle PDI = 0.282 + 0.00990 (A) + 0.00637 (B) - 0.0819 (C) - 
0.0297 (D) + 0.0076 (E) + 0.0051 (F) 
 
Tables 7-6 and 7-7 respectively exhibit the result of ANOVA and regression analysis 
for the fitted model of particle PDI. The p-value of the fitted model was 0.036 (p < 0.05), 
which indicates that the model is statistically significant to explain variations in PDI. Among 
the factors studied, polymer molecular weight contributed most significantly to variations in 
particle PDI (p = 0.002). 
   
Table 7-6. ANOVA table for fitted model for PDI  














Table 7-7. Regression analysis of PDI versus nanoparticle preparation variables 
   Predictor Coefficients SE Coefficients T P 
Constant 
Drug concentration (A) 
Organic/Aqueous phase ratio (B) 
Polymer Mw (C) 
Polymer Terminus (D) 
Lactide:Glycolide ratio (E) 






























To understand the relationship between the response of interest (i.e., PDI) and factors 
that significantly affected particle PDI (i.e., polymer molecular weight), response surface 
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graphs were plotted and are presented in supplementary figure 2. The maximum PDI was 
obtained when low molecular weight PLGA polymer (level 1) and high docetaxel 
concentration (level 4) were used for nanoparticle preparation and vice versa. The response 
surface graph of PDI versus polymer molecular weight and polymer terminus (i.e., factor 
with second-lowest p-value) demonstrates that maximum particle PDI was obtained at low 
molecular weight (level 1) and acid-terminated (level 1) polymer and vice versa. 
Analysis demonstrated that polymer molecular weight affected the particle PDI with 
statistical significance (p<0.05) (table 7-7). Viscosity of organic phase helped determine the 
average size of nanoparticles. PLGA polymers with higher molecular weight led to more 
viscose droplets (in the preparation emulsion) that broke into smaller droplets more 
difficultly. This difficulty kept the size of nano-droplet at a certain range, which decreased 
the diversity and variability in nanoparticles’ size and kept the PDI low. The response surface 
plot of PDI vs. polymer molecular weight (the significant factor) and factors with the lowest 
p-values following polymer molecular weight (i.e., drug concentration and polymer terminus) 
were plotted to determine the highest and lowest response (i.e., PDI) in each case 
(supplementary figure 2). When considering polymer molecular weight and drug 
concentration as variables, the maximum PDI was obtained at low polymer molecular weight 
and highest drug concentration, while the minimum PDI was acquired at the opposite 
condition (supplementary figure 2A). When low molecular weight polymer was used for 
nanoparticle preparation, organic phase had a lower viscosity than when high molecular 
weight polymer is used. During probe-sonication, organic-phase droplets with lower viscosity 
sequentially broke into smaller particles more easily. Consequently, low molecular weight 
polymer resulted in nanoparticles with smaller average size. The sequential breakdown of 
droplets resulted in a nano-suspension with nano-droplets possessing a wide range of sizes 
that increased the PDI. On the other hand, acid terminal functional group and low molecular 
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weight resulted in maximum PDI response while ester terminus and high molecular weight 
provided minimum PDI values. 
 
7.1.3. Particle Zeta Potential 
The zeta potential of nanoparticles was attributed to the role of the polymer terminus 
on the surface of nanoparticles and the further ionization of carboxylic acid (in the case of 
acid-terminated polymer) or hydrolysis of ester (in the case of ester-terminated polymer). 
Figure 7-7 demonstrates the main effect plot for the means of particle zeta potential. The 
figure exhibits the variation of zeta potential of nanoparticles according to nanoparticle 
preparation conditions at different factors/levels. The ranges between the minimum and 
maximum nanoparticle zeta potential were calculated between levels of each factors and were 
as follows (in decreasing order): polymer terminus (9.85 mV), organic:aqueous phase ratio 
(3.96 mV), drug concentration (3.43 mV), PVA concentration (2.54 mV), lactide:glycolide 
ratio (2.10 mV), and polymer Mw (0.81 mV). Table 7-8 exhibits the rankings of factors 
affecting the response. PLGA polymer terminus had the largest magnitude of effectiveness on 
particle zeta potential. Organic:aqueous phase ratio had the second largest effect on particles’ 
zeta potential, and so on. This result agrees with the fact that acid terminus can easily become 
ionized and expose more negative charges to the surface of nanoparticles. Figure 7-8 
demonstrates the S/N analysis of the linear model. S/N was calculated by the software using 
formula below: 
Equation 7-5:    S/N = −10*log(s2) 
Where s is standard deviation of the responses for all noise factors for the given factor 
level combination. 
 The range of S/N for each factor at different levels was calculated. The highest range 
between S/N was demonstrated by drug concentration (8.69) followed by organic:aqueous 
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phase ratio (7.77), polymer Mw (2.98), lactide:glycolide ratio (2.34), polymer terminus 
(0.70), and PVA concentration (0.58). Based on analysis of S/N calculations, drug 
concentration with largest range led to the most reduced variability in particle zeta potential. 
This, in part, might be because docetaxel and PLGA are hydrophobic molecules. 
Consequently, non-covalent interactions such as van der waals or hydrogen-bonds between 
these two molecules (particularly at different docetaxel concentration) can result in constant 
rearrangement of polymer terminus on the surface of nanoparticles and reduce potential 
variation in surface electric potential.  
Figure 7-9 represents the normal probability plot of residuals for particle zeta 
potential. It demonstrates the normality of variation observed in particles zeta potential. 
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Table 7-8. Ranking trend of factors affecting the particle zeta potential as the response of 
interest.   
 Factors 
Drug Conc.  Organic: 





L:G  PVA 
Conc.  


























Organic/Aqueous phase ratio Polymer Mw
Polymer Terminus Lactide:Glycolide ratio PVA concentration
 























Figure 7-9. Normal probability plot of residuals by the final model for particle zeta potential 
 
Linear regression analysis, ANOVA, along with F tests, were performed on the data 
to fit a model that best defined the variations in particle zeta potential versus the six factors 
under study. R2 was equal to 0.849 while the regression equation was calculated to be: 
 
Equation 7-6:   Particle Zeta potential = - 34.1 - 1.04 (A) - 1.24 (B) - 0.81 (C) + 9.85 
(D) - 2.10 (E) + 2.54 (F) 
 
Tables 7-9 and 7-10 respectively exhibit the result of ANOVA and regression analysis 
for the fitted model of particle zeta potential. The fitted model demonstrated a p-value equal 
to 0.003, meaning that the model could be used to define zeta potential of PLGA 
nanoparticles with statistical significance. Among other factors under study, the p-value 
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calculated for polymer terminus was less than 0.05, showing its statistically significant 
contribution to zeta potential characteristic of PLGA nanoparticles.   
 
Table 7-9. ANOVA table for fitted model for particle zeta potential  














Table 7-10. Regression analysis of particle zeta potential versus nanoparticle preparation 
variables 
Predictor Coefficients SE Coefficients T P 
Constant 
Drug concentration (A) 
Organic/Aqueous phase ratio (B) 
Polymer Mw (C) 
Polymer Terminus (D) 
Lactide:Glycolide ratio (E) 






























To understand the relationship between the response of interest (i.e., particle zeta 
potential) and the factor significantly affecting it (i.e., polymer terminus), response surface 
graphs were plotted and are presented in supplementary figure 3A and 3B. Supplementary 
figure 3A demonstrates that the maximum value of particle zeta potential was obtained when 
ester-terminated polymer (level 2) and a 1:2 ratio of organic:aqueous phase (level 1) were 
used during the nanoparticle fabrication procedure and that polymers with acid terminus at 
1:5 organic:aqueous phase ratio resulted in highest surface negativity. Also, supplementary 
figure 3B demonstrates that the minimum value of particle zeta potential was obtained when 
acid-terminated polymer (level 1) and a low PVA concentration (level 1) were used during 
nanoparticle fabrication and that using a high concentration of PVA and ester-terminated 
polymer resulted in nanoparticles with less surface negative zeta potential. This result can be 
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attributed the role of PVA as a spatial stabilizer and to the traces of PVA that remain on the 
surface of PLGA nanoparticles even after consecutive washing steps.   
 
7.1.4. Drug Loading Efficiency 
Figure 7-10 demonstrates the main effect plot for the means of drug-loading 
efficiency at different factors/levels. The range between the maximum and minimum drug-
loading efficiency was calculated for each factor and determined organic:aqueous phase ratio 
had the highest range (26.78%). The ranges for other factors were as follows: drug 
concentration (25.61%), PVA concentration (19.95%), lactide:glycolide ratio (10.04%), 
polymer terminus (9.67%), and polymer molecular weight (2.03%). Accordingly, table 7-11 
exhibits the rankings of factors affecting the response (drug-loading efficiency). 
Organic:aqueous phase ratio (rank 1) is considered to be the factor with highest magnitude of 
effect on drug loading efficiency. Drug concentration (rank 2) has the second largest effect on 
drug loading efficiency, and so on. Drug-loading efficiency is reduced parallel to the increase 
in drug concentration. This result is attributed to the fact that polymer matrix (forming the 
nanoparticles) gets saturated by drug molecules when a higher concentration of the drug is 
used. Another trend is the decrease in drug-loading efficiency parallel to the increment in the 
amount of aqueous solution. With the increase in aqueous solution, more drug molecules 
could escape from organic phase to aqueous phase, which reduced the overall drug-loading 
efficiency. Murugesan and colleagues [195] also evaluated the effect of initial docetaxel 
concentration and stabilizer concentration on drug-loading efficiency. They demonstrated that 
drug-loading efficiency inversely relates to the concentration of docetaxel during preparation. 
In other words, increasing the concentration of stabilizer or docetaxel reduces the loading 
efficiency of the PLGA nanoparticles’ preparation method. They also demonstrated that 
increasing the amount of aqueous phase during nanoparticle preparation reduces the drug 
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entrapment efficiency. Figure 7-11 demonstrates the S/N analysis of the linear model. S/N 
was calculated by the software using equation below: 
Equation 7-7:   S/N = −10*log(Σ(1/Y2)/n) 
Where Y is responses for the given factor level combination and n is number of 
responses in the factor level combination. 
 
 Based on the preferences, the larger S/N is better. Drug concentration demonstrates 
largest range (4.27) of S/N ratio.  The ranges for S/N ratio of other factors are as follows: 
organic:aqueous phase ratio (4.01) > PVA concentration (3.24) > polymer terminus (1.45) > 
lactide:glycolide ratio (1.40) > polymer Mw (0.17).  Figure 7-12 represents the normal 
probability plot of residuals for drug-loading efficiency. It demonstrates normality of drug 
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Table 7-11. Ranking trend of factors affecting the drug-loading efficiency as the response of 
interest.   
 Factors 
Drug Conc.  Organic: 





L:G  PVA 
Conc.  
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Figure 7-12. Normal probability plot of residuals by the final model for drug-loading 
efficiency 
Linear regression analysis, ANOVA, along with F test have been performed on the 
data to fit a model that best defines the variations in drug-loading efficiency versus the six 
factors under study. R2 was equal to 0.898 while the regression equation was calculated to be: 
 
Equation 7-8:   Drug Loading Efficiency = 97.9 - 9.51 (A) - 8.04 (B) - 2.03 (C) + 9.67 
(D) + 10.0 (E) - 19.9 (F) 
 
Tables 7-12 and 7-13 respectively exhibit the result of ANOVA and regression 
analysis for the fitted model of drug-loading efficiency, which demonstrated a p-value equal 
to 0.001. This means that the variations in drug-loading efficiency could be explained by the 
fitted model with statistical significance.  P-values related to the following five factors were 
lower than 0.05: drug concentration, organic:aqueous phase ratio, polymer terminus, 
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lactide:glycolide ratio, and PVA concentration. This finding provides valuable insight about 
nanoparticle preparation conditions when drug-loading is the intended characteristic.     
 
Table 7-12. ANOVA table for fitted model for drug-loading efficiency  














Table 7-13. Regression analysis of drug-loading efficiency versus nanoparticle preparation 
variables 
Predictor Coefficients SE Coefficients T P 
Constant 
Drug concentration (A) 
Organic/Aqueous phase ratio (B) 
Polymer Mw (C) 
Polymer Terminus (D) 
Lactide:Glycolide ratio (E) 






























To understand the relationship between drug-loading efficiency and the factors 
significantly affecting it (i.e., drug concentration, organic/aqueous phase ratio, polymer 
terminus, lactide:glycolide ratio, and PVA concentration), response surface graphs were 
plotted and are presented in supplementary figures 4 to 7. Supplementary figure 4 
demonstrates that minimum drug-loading efficiency was obtained when a 1:5 ratio of 
organic:aqueous phase (level 4) and the highest drug concentration (level 4) are used. Drug 
concentration level 4 (the highest concentration) combined with level 1 of polymer terminus 
(acid-terminated), level 2 PVA concentration (high), or 50:50 lactide:glycolide ratio also 
resulted in minimum drug loading. Supplementary figure 5 demonstrates that maximum drug-
loading efficiency was obtained when 1:2 of organic:aqueous phase ratio (level 1) and ester 
terminated polymer (level 2), low concentration of PVA (level 1), or 75:25 of 
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lactide:glycolide ratio (level 2) were used during nanoparticle preparation. Supplementary 
figure 6 demonstrates that maximum drug-loading efficiency was obtained when ester-
terminated polymer (level 2) and 75:25 of lactide:glycolide ratio polymer (level 2) or low 
concentration PVA (level 1) were used for nanoparticle fabrication. Supplementary figure7 
demonstrates that minimum drug-loading efficiency of nanoparticle preparation was obtained 
when 50:50 lactide:glycolide ratio polymer (level 1) and high PVA concentration (level 2) 
are used.   
 
 
7.2. Optimization of Nanoparticle Preparation 
Response optimization was applied to identify the combination of factors/levels 
during nanoparticle preparation that jointly optimize the nanoparticle characteristic of 
interest. Response optimization was performed for nanoparticle size, PDI, zeta potential, and 
drug-loading efficiency. Figure 7-13 demonstrates optimization plots of nanoparticle 
characteristics under study. Each plot exhibits how experimental nanoparticle preparation 












Figure 7-13. Response optimization plot showing the optimized factor/level setting for A) 




In each section, the middle row exhibits the composite (first column) and individual 
(other columns) desirability levels related to the factors under study. Individual desirability is 
presented schematically as black lines while composite desirability is presented as a number. 
They assess how the combination of factors satisfies the value defined for a nanoparticle 
characteristic (response). The desirability range is between 0 and 1. A desirability at 1 means 
that the ideal response is obtained. Conversely, a desirability of zero indicates that the 
response is out of the defined limits. The first row exhibits the factors and corresponding 
levels in the design from high to low levels (in black). The numbers in red represent the level 
of each factor at which the corresponding desirability is obtained. The third row, first column 
to the left, exhibits the response of interest and target value. Other columns to the right (third 
row) schematically demonstrate the target value (blue dashed line) and how moving from one 
level to another (in each factor) changes the response around target value (black lines in each 
column). Based on the obtained data from response optimization analysis, optimized PLGA 
nanoparticle fabrication conditions relating to individual nanoparticle characteristics (size, 
PDI, zeta potential, drug-loading efficiency) were determined to be as follows:     
 
Nanoparticle size: Composite desirability near 1 is obtained at level 3.8977 of drug 
concentration, 3.0965 of aqueous:organic phase ratio, 1.1200 of polymer molecular weight, 
1.0 of polymer terminus, 1.0263 of L:G ratio, and 1.0 of PVA concentration.     
 
PDI: Composite desirability near 1 is obtained at level 3.9556 of drug concentration, 2.0950 
of aqueous:organic phase ratio, 1.6775 of polymer molecular weight, 1.0 of polymer 




Zeta Potential: Composite desirability near 1 is obtained at level 3.9410 of drug 
concentration, 1.80 of aqueous:organic phase ratio, 1.0001 of polymer molecular weight, 1.60 
of polymer terminus, 1.0 of L:G ratio, and 1.0148 of PVA concentration.   
   
Drug Loading Efficiency: Composite desirability near 1 is obtained at level 3.6021 of drug 
concentration, 1.4470 of aqueous:organic phase ratio, 1.0492 of polymer molecular weight 
molecular weight, 1.0279 of polymer terminus, 1.0164 of L:G ratio, and 1.0 of PVA 
concentration.  
 
Taking the factor/levels at which suitable composite desirability level was obtained 
(regarding nanoparticle characteristics) collectively, optimized nanoparticle fabrication 
conditions were determined and used to prepare docetaxel-loaded PLGA nanoparticle 
formulations, which were then used throughout the research project: 
Docetaxel Concentration: Level 4 (1.5 mg/ml) 
Organic/Aqueous phase ratio: Level 2 (1:3) 
PLGA Molecular weight: Level 1 (0.15 - 0.25 dl/g) 
PLGA polymer Terminus: Level 1 (Acid terminated) 
Polymer lactide/glycolide ratio: Level 1 (50:50) 
PVA Concentration: Level 1 (2.2%) 





Result and Discussion on PLGA and PLGA-PEG Nanoparticle Formulation and 
Characterization 
* Chapter 4 (Experimental Section on Preparation and Characterization of Optimized PLGA and PLGA-PEG 
Nanoparticle Formulation) along with chapter 8 have been accepted for publication as an ‘Original Research 
Article’ in ‘Journal of Nanopharmaceutics and Drug Delivery ’:  
 
Pedram Rafiei, Azita Haddadi. Investigation of PLGA and PEG-PLGA nanoparticles loaded with docetaxel as 
an approach for sustained release intravenous application. Journal of Nanopharmaceutics and Drug Delivery, 
Accepted January 2017. 
 
Background 
Developing PLGA nanoparticle formulations for drug-delivery purposes requires the 
use of a proper fabrication method that provides nanoparticles with desired properties. After 
nanoparticle preparation, there is the need to perform rational characterization techniques on 
nanoparticles to understand their properties because nanoparticle properties contribute to 
nanoparticles’ drug-delivery performance and can help predict their fate after administration 
[284].  
Average diameter and zeta potential provide basic knowledge about nanoparticles. 
The amount of the drug associated with nanoparticles is also important to evaluate as it 
provides an assessment of the equivalent dose of the drug in the form of nanoparticles. Other 
than size, zeta potential, and drug loading, determining the rate and pattern of drug release 
from nanoparticles is required to understand the mode at which the drug becomes available to 
the location of interest. Whether the drug molecules’ association to nanoparticles affect the 
drug’s biological/pharmacological activity is also important to determine. Therefore, usually 
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after physicochemical characterization steps, biological activity of nanoparticles is also 
evaluated using cell culture models.  
Here, comparing different cryoprotecting agents led to choosing a proper 
cryoprotectant for freeze-drying of nanoparticles. The developed optimized nanoparticle 
fabrication technique was used to prepare docetaxel-loaded PLGA nanoparticles and surface-
modified (PEGylated) docetaxel-loaded PLGA nanoparticles. Taking into consideration the 
need for characterization steps before proceeding to animal experiments, prepared 
nanoparticle formulations were subjected to extensive characterization techniques. Thus, the 
average sizes, zeta potentials, drug-loading properties, and drug-release profiles of docetaxel-
loaded PLGA and PEGylated PLGA nanoparticle formulations were evaluated. The biologic 
effect of docetaxel loaded in PLGA and PLGA-PEG nanoparticles was evaluated in Hela 
cancer cell lines.        
 
8.1. Freeze-drying of Nanoparticles and Cryoprotection 
The changes in size, PDI, and zeta potential after freeze-drying nanoparticles with 
various cryoprotectants at different concentrations are exhibited in table 8-1. Nanoparticles’ 
average size before and after freeze-drying with different cryoprotectants is depicted in figure 
8-1.  
The average size of nanoparticles before freeze-drying was 143.5±12.8 nm. Particles 
demonstrated around a 500 nm increase ( ̴ 4.88–fold increase) in average size (701.3±352.0 
nm) after freeze-drying when no cryoprotectant was used. In addition, freeze-drying without 
cryoprotectant increased PDI and zeta potential from 0.279 to 0.762 and -20.5 to -10.5 mV, 
respectively. In contrast, a 119 to 241 nm, 129 to 239 nm, and 3 to 44 nm increase in size was 
observed in nanoparticles when 1-10 % (W/V) sucrose, 1-10 % (W/V) trehalose, and 0.25-
2% (W/V) PVA were used as cryoprotectants, respectively. For nanoparticles freeze-dried 
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with sucrose, PDI increased (from 0.279) to values between 0.337 and 0.444. Nanoparticles 
freeze-dried with trehalose demonstrated PDI values between 0.344 and 0.391. Using PVA 
for freeze-drying resulted in nanoparticles with PDI values between 0.243 and 0.292. Using 
sugars as cryoprotectants increased zeta potential to values between -11.9 and -8.6 mV for 
sucrose and -11.5 and -7.4 mV for trehalose. Zeta potential values of nanoparticles freeze-
dried with PVA were not measureable. 
 The ratio of nanoparticle size after and before freeze-drying (R = (Sf)/(Si)) with 
different cryoprotectants is exhibited in figure 8-2. The average size of nanoparticles 
increased 1.89- to 2.66-fold and 1.82- to 2.67-fold when trehalose and sucrose were used as 
cryoprotectants, respectively. PVA increased average particle size 1.01- to 1.30-fold. One and 
two percent (W/V) PVA demonstrated lowest R (̴ 1) while 10% (W/V) sucrose exhibited 
highest R (2.67). PVA appeared to be better preserving nanoparticle size compared to other 














Table 8-1. Characteristics of freeze-dried PLGA nanoparticles in the presence of 
cryoprotective agents at different concentrations. Data represents mean ± standard deviation 
(n=3). (PLGA = Poly (lactide-co-glycolide), FD=Freeze-drying, CRP = Cryoprotectant, 
PDI=polydispersity index, PVA= Poly (vinyl alcohol), nm=nanometers, mV=millivolts, Sf= 
average diameter after freeze-drying, Si= average diameter before freeze-drying).         
Formulation Average 
diameter (nm) 
PDI Zeta potential 
(mV) 
R = (Sf)/(Si) 
PLGA Nanoparticles 143.5±12.8 0.279±0.052 -20.5±2.2 - 
After FD without CRP 701.3±352.0 0.762±0.160 -10.5±3.0 4.88±2.24 
After FD with CRP: 
Sucrose 1% 262.0±7.2 0.350±0.013 -11.9±0.6 1.82±0.05 
Sucrose 3% 266.1±2.3 0.337±0.026 -10.2±0.6 1.85±0.01 
Sucrose 5% 289.7±11.5 0.343±0.016 -9.9±0.7 2.01±0.08 
Sucrose 10% 384.1±26.7 0.444±0.54 -8.6±1.0 2.67±0.18 
Trehalose 1% 272.1±3.2 0.344±0.021 -11.5±1.1 1.89±0.02 
Trehalose 3% 344.4±1.1 0.386±0.009 -10.1±2.1 2.39±0.01 
Trehalose 5% 358.0±28.6 0.387±0.029 -9.5±0.6 2.49±0.19 
Trehalose 10% 382.7±10.1 0.391±0.022 -7.4±0.5 2.66±0.07 
PVA 0.25% 187.1±1.3 0.271±0.041 - 1.30±0.01 
PVA 0.5% 162.6±5.7 0.243±0.015 - 1.13±0.04 
PVA 1% 146.1±4.6 0.292±0.031 - 1.01±0.03 





Figure 8-1. Average nanoparticle diameter before and after freeze-drying, and with and 
without cryoprotection (n=3). Various concentrations of cryoprotectants (nm=nanometers, 
FD=Freeze-drying, CRP = Cryoprotectant, PVA= Poly (vinyl alcohol)). 
 
Figure 8-2. Ratios of PLGA nanoparticles size after and before freeze-drying procedure in the 
presence of various cryoprotective agents at different concentrations (n=3). (nm=nanometers, 






















Freeze drying polymeric nanoparticles used for drug delivery helps improve their 
long-term stability [285, 286]. Accordingly, finding a suitable cryoprotective agent and using 
it at proper concentrations is greatly important. Trehalose demonstrates a similar performance 
to sucrose with respect to nanoparticles’ average size and PDI. Both sugars demonstrate an 
inverse relationship between the concentration and cryoprotective effectiveness. This could 
be attributed to more pronounced interactions (possibly hydrogen bonds) at higher 
concentrations between nanoparticles and cryoprotectant molecules that prevents the entire 
reconstitution of nanoparticles [287]. In other words, particle aggregation during freeze-
drying is increased by higher sugar concentration. The effectiveness of sucrose and trehalose 
in preserving PLGA nanoparticle properties has been demonstrated by various studies [288-
293]. Accordingly, the type of PLGA polymer, type of cryoprotectant, and cryoprotectant 
concentration are important factors in determining the performance of cryoprotection [287]. 
Here, cryoprotective performance of PVA was superior to that observed from sugars. In 
addition, PVA had a better cryoprotective performance when used at a higher concentration. 
This can be attributed to the pendant hydroxyl groups on the PVA structure that prevents 
particle aggregation. PVA is usually used as a stabilizer to produce stable nanoparticles with 
a small size and narrow size distribution [294]. Despite repeated washing steps, a fraction of 
PVA (used in nanoparticle preparation procedure) remains associated with the surface of 
nanoparticles [295, 296] and acts as a hydrophilic layer favouring the re-dispersion of the 
freeze-dried nanoparticles upon rehydration [290, 297]. The presence of PVA on the surface 
of nanoparticles at high concentrations masks the nanoparticles’ surface and makes it difficult 





8.2. Nanoparticles Formulation Characterization 
8.2.1. Determination of Size and Zeta Potential 
Table 8-2 demonstrates size, PDI, and zeta potential characteristics of plain and drug-
loaded PLGA nanoparticles. Docetaxel-loaded PLGA nanoparticles had an average size of 
around 120 nm, while plain PLGA nanoparticles showed an average particle size of around 
140 nm. Drug-loaded nanoparticles demonstrated PDI values between 0.216 and 0.289. 
Particle populations in both plain and drug-loaded samples demonstrated a homogenous 
distribution. PLGA nanoparticles exhibited zeta potential values between -20 and -32. 
 
Table 8-2. Size and zeta potential characteristics of four formulations of drug-loaded PLGA 
nanoparticles (n=3). 
Initial Preparation 
Concentration  Average Size (nm) PDI 
Zeta potential 
(mV) 
Plain  nanoparticles 140±9.0 0.299±0.054 -20.97±2.03 
0.25 mg/ml drug 122.2±5.1 0.216±0.040 -25.5±0.75 
0.5 mg/ml drug 122±1.4 0.229±0.010 -32.1±2.9 
1 mg/ml drug 128.6±9.0 0.289±0.051 -27.6±1.8 
1.5 mg/ml drug 123.6±9.5 0.245±0.041 -28.3±1.25 
 
Size, PDI, and zeta potential characteristics of plain and drug-loaded PLGA-PEG 
nanoparticles are exhibited in table 8-3. Plain PLGA-PEG nanoparticles demonstrated an 
average size range of around 180 nm. Docetaxel-loaded PLGA-PEG nanoparticles 
demonstrated an average size range between 184 and 188 nm. Plain and drug-loaded 
nanoparticles demonstrated uni-distributed populations as indicated by their PDI. PDI values 
of PLGA-PEG nanoparticles were around 0.100. Docetaxel-loaded nanoparticles 
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demonstrated zeta potentials between -24.7 and -27.0 mV, while plain PLGA-PEG 
nanoparticles had a zeta potential value of -26.7 mV. 
 
Table 8-3. Size and zeta potential characteristics of four formulations of drug-loaded PLGA-
PEG nanoparticles (n=3). 
Initial Preparation 
Concentration 
Average Size (nm) PDI Zeta potential 
Plain NPS 180.8±8.2 0.100±0.004 -26.7±4.9 
0.25 mg/ml  188.6±5.9 0.096±0.004 -24.7±2.4 
0.5 mg/ml  184.6±4.6 0.105±0.003 -27.0±5.6 
1 mg/ml  186±4.3 0.100±0.023 -25.6±4.6 
1.5 mg/ml 186.7±2.9 0.103±0.10 -25.9±3.5 
 
Docetaxel-loaded PLGA nanoparticles demonstrated lower particle size compared to 
plain nanoparticles. This is attributed to docetaxel and PLGA polymer molecular structures: 
they are both highly hydrophobic agents. During formulation processes, both PLGA and 
docetaxel were dissolved in an organic solvent where they can interact with one another and 
with solvent molecules through non-covalent interactions. When the organic solution forms 
nano-droplets in the aqueous phase, hydrophobic forces between the polymer and drug can 
result in droplets with more condensed structures, due to those non-covalent hydrophobic 
interactions, compared to when only polymer molecules are present. Consequently, drug-
loaded nanoparticles demonstrated a lower size distribution compared to plain nanoparticles 
[192]. 
However, it has been reported that loading the drug in nanoparticle formulations can 
result in an expansion of the polymeric matrix and increase in particle size [194], particularly 
when the drug concentration is high. To further evaluate this, three PLGA nanoparticle 
formulations were prepared at high docetaxel concentrations (3, 5, and 10 mg/ml). The 
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expected increase in size was evident when the preparation concentration was increased from 
0.25 to 10 mg/ml (supplementary Table 1).  
According to the PDIs of plain and drug-loaded nanoparticles, all formulations exhibit 
a uni-distribution pattern. Furthermore, a 5 to 12 unit increase in negativity of the zeta 
potential in drug-loaded nanoparticles is evident. However, it is reported that the association 
of the drug with the nanoparticles reduces the negativity of zeta potential by masking the 
effect of the adsorbed drug molecules on the nanoparticles’ surface [194]. Again, the increase 
in negativity of the zeta potential of our nanoparticles is attributed to docetaxel’s and PLGA 
polymer’s molecular structures. Non-covalent interactions between the polymer and 
docetaxel can potentially result in a pronounced arrangement of the polymer’s COO- 
terminals towards the particles’ outer surface [298]. Other reports on docetaxel-loaded PLGA 
nanoparticles demonstrated similar ranges of particle size and zeta potential to our 
nanoparticles (i.e., sizes between 100 and 200 nm and negative zeta potential) [176, 194, 196, 
299, 300]. 
Keum et al. [192] demonstrated that the size of the nanoparticles could be influenced 
by the mixing order of the drug and polymer and by sonicating the organic solvent prior to 
emulsification. They reported that sonication was likely to decrease the nanoparticle size 
owing to the increased energy released by emulsification, leading to a smaller particle 
diameter. 
We followed a similar procedure. The mixture of the drug and polymer in ethyl 
acetate was sonicated prior to emulsification with aqueous phase. Supplementary table 2 
summarizes the size, PDI, and zeta potential characteristics of particles obtained after this 
modification was made to the nanoparticle preparation procedure. Sonication decreased 
particle size and PDI, while not affecting zeta potential. This 30 to 40 nm reduction in size 
could be the result of better solvation of the drug and PLGA due to sonication of organic 
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solution and the reinforce hydrophobic interactions between the drug and polymer giving rise 
to nano-droplets with higher stability at lower sizes [192]. 
Plain and docetaxel-loaded PEGylated PLGA nanoparticles demonstrated a size range 
of around 180 nm. Drug-loaded PLGA-PEG nanoparticles showed a few nanometres of 
increase in particle size after association with docetaxel, which is attributed to the expansion 
of the polymer matrix due to the presence of the drug. Compared to docetaxel-loaded PLGA 
nanoparticles, PEGylated nanoparticles demonstrate larger particle sizes, which are attributed 
to the PEG moiety on the surface of PLGA-PEG nanoparticles. The PEG structure can 
protrude on the surface of particles and establish a core-shell structure with PLGA as the core 
and PEG as the shell [174]. Furthermore, it has been proposed that, in addition to the surface 
of nanoparticles, PEG structure of the di-block co-polymer can sometimes become entrapped 
inside nanoparticles matrix [185]. PLGA-PEG nanoparticles demonstrate zeta potentials 
similar to those of PLGA nanoparticles (around -25), while PEG is expected to mask the 
surface charge of particles and modify the zeta potential. Surface-modification efficiency of 
PEG generally dependents on the PEG layer thickness surrounding the nanoparticle, which is 
believed to be determined by the PEG polymer chain conformation, molecular weight, and 
surface density (coverage) [183, 186, 187]. Similar zeta potential of PLGA-PEG and PLGA 
nanoparticles is attributed to low surface coverage of PEG molecules (taking a ‘mushroom’ 
configuration) contributing to gaps in the protective layer [183] as a result of using PLGA 
with only 15% PEGylation (weight). 
Koopaei and colleagues [301] obtained docetaxel loaded PLGA-PEG nanoparticles 
with a size of 181±3.5 nm, which is in accordance with the size of nanoparticles obtained in 
our work. Other studies have reported similar ranges of particles size and zeta potential for 





8.2.2. Determination of Loading and Encapsulation Efficiency  
Table 8-4 demonstrates drug-loading (%), yield, and encapsulation efficiency (%) of 
the PLGA nanoparticle preparation method. Drug-loading (%) represents the amount of 
docetaxel (mg) loaded in 100 mg of nanoparticles. Encapsulation efficiency (%) represents 
the percentage of docetaxel loaded in nanoparticles with respect to the initial drug amount 
used for nanoparticle preparation.  At different formulations, between 1.20 and 5.58 µg 
docetaxel was loaded into one milligram of nanoparticles. Drug-loading percentages 
increased parallel to the initial concentrations of the docetaxel used during nanoparticle 
preparation process. Nanoparticle fabrication at four different initial docetaxel concentrations 
resulted in a drug encapsulation efficiency maximum of 47.76% and minimum of 37.25%. 
The nanoparticle preparation method demonstrated yields between 31.66% and 64.88%.  
 










0.25 mg/ml  0.12±0.004 39.76±4.56 47.76±1.68 
0.5 mg/ml  0.21±0.008 31.66±4.04 41.28±1.6 
1 mg/ml  0.45±0.044 56.33±11.15 45.26±4.4 
1.5 mg/ml 0.56±0.025 64.88±8.13 37.25±1.6 
 
Table 8-5 demonstrates various particle characteristics obtained from PLGA-PEG 
nanoparticles. Drug encapsulation efficiency of the PLGA-PEG nanoparticle preparation 
method was between 59% and 96%. The percentage of drug loading demonstrated an 
increasing trend parallel to the increment made in the initial docetaxel preparation 
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concentration (i.e., from 0.24% to 0.889%). The yield was between 56.2% and 85.7% and 
between 2.405 and 8.890 µg of docetaxel was loaded in each mg of nanoparticles.     
 










0.25 mg/ml  0.240±0.008 78.1±0.6 96.1±3.2 
0.5 mg/ml  0.3512±0.031 84.5±7.1 70.2±6.1 
1 mg/ml  0.623±0.008 56.2±12.3 62.3±0.8 
1.5 mg/ml 0.889±0.010 85.7±3.6 59.3±0.7 
 
The drug loading of PLGA nanoparticles demonstrated increases parallel to the 
increase in initial preparation concentrations of the drug. This finding was expected [176], 
because with increased drug concentration in the organic solution, more drug molecules can 
interact with PLGA [192]. However, from the lowest concentration of docetaxel (0.25 
mg/ml) to the highest (1.5 mg/ml), the percentage of encapsulation efficiency showed a 
descending trend from 47.76% to 37.25%. This is attributed to the fact that the PLGA matrix 
becomes saturated as the initial concentration of docetaxel increases [192]. Different studies 
have used different settings to fabricate docetaxel-loaded PLGA nanoparticles and thus have 
reported various drug loading and encapsulation efficiencies (ranging from 16% to 76%) 
[176, 194, 196, 299, 300]. 
PLGA-PEG nanoparticles demonstrated similar drug loading and encapsulation 
efficiency trend. Drug loading increased parallel to the increase in initial preparation 
concentrations, while the method’s encapsulation efficiency demonstrated a converse 
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relationship to the initial preparation concentration of the drug. In other words, encapsulation 
efficiency decreased from 96.1% to 59.3% when the initial drug payload increased from 0.25 
mg/ml to 1.5 mg/ml. The initial high encapsulation efficiency (e.g., at 0.25 mg/ml) might be 
due to high interactions of the drug with the polymer relative to the initial drug amount until 
polymer matrix becomes saturated with drug molecules, such as when a higher concentration 
is initially used in the preparation procedure [176]. 
 Compared to PLGA nanoparticles of same docetaxel preparation concentration, 
PLGA-PEG nanoparticles showed a higher drug loading. This could be attributed to the 
presence of PEG moiety in the infrastructure of PLGA-PEG nanoparticles. A hydrophilic 
PEG section of di-block copolymer that protrudes on the surface of nano-droplets can 
influence the hydrophobic interactions inside nano-droplets between the PLGA and drug 
molecules and ultimately provide more room to accommodate docetaxel molecules in the 
lipophilic matrix [302]. In addition to the surface of nanoparticles, PEG structure of the di-
block co-polymer can sometimes become entrapped inside nanoparticles matrix [185]. This, 
again, could potentially contribute to the accommodation of more docetaxel molecules in 
PLGA-PEG nanoparticles.   
 
8.2.3. Determination of Drug Release Profile from Nanoparticles  
The release profile of docetaxel from different PLGA nanoparticle formulations is 
exhibited in figure 8-3. As evident, all formulations exhibit a biphasic drug-release profile. 
Particles demonstrate a burst release during the first 24 hours, followed by a sustained drug 
release, resulting in cumulative liberation of between 16 and 36 % of the loaded drug.  The 
release profile of docetaxel from different PLGA-PEG nanoparticle formulations is exhibited 
in figure 8-4. As shown in the figure, docetaxel-loaded PLGA-PEG nanoparticles exhibited a 
biphasic drug release pattern. The release profile starts at a higher rate in the first 24 hours 
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followed by a lower pace. After 5 days, 50% to 60% of loaded drug was released from the 
PLGA-PEG nanoparticles. 
 
Figure 8-3. Release of docetaxel from four PLGA nanoparticle formulations (n=3). 
 
 



































































 Generally, this initial burst can be attributed to the drug molecules embedded at 
nanoparticle’s outermost layers and those adsorbed by the particles’ surface. The obtained 
profile after the initial burst shows a sustained release pattern, giving rise to drug-depletion 
from various formulations during the incubation period. Diffusion of the drug, erosion and 
swelling of the polymer matrix, and degradation of the polymer are considered to be the main 
mechanisms for drug release [192]. This sustained release behaviour can be attributed to the 
slow degradation rate of PLGA polymer [303]. Therefore, it is believed that the release of 
docetaxel from the nanoparticles depends mainly on drug diffusion and matrix erosion [304]. 
Accordingly, particle size, hardness, and porosity can potentially influence the drug release 
profile [122]. Despite the differences in the total percentages of the liberated drug from the 
nanoparticles, the biphasic release from PLGA nanoparticles has been reported by other 
studies [176, 194, 196, 301]. 
In a similar manner, docetaxel release behaviour observed from PLGA-PEG 
nanoparticles is also attributed to the liberation of surface-adsorbed/near-surface drug 
molecules (initial burst release) and further diffusion of the drug from the polymer matrix 
(sustained release). PLGA-PEG nanoparticles demonstrated a higher percentage of drug 
release (47% to 63%) compared to that observed from PLGA nanoparticles (16% to 36 %). 
This difference could be attributed to the role of PEG chain moieties on the surface of PLGA-
PEG nanoparticles. PEG molecules can attract water to the surface of nanoparticles and result 
in more pronounced wetting/hydration of PLGA-PEG nanoparticles [305] and ultimately 
bring about higher release percentages compared to naked PLGA nanoparticles. In addition, 
the PEG structure of the di-block co-polymer can sometimes become entrapped inside 
nanoparticles matrix [185]. This may affect the integrity of PLGA-PEG nanoparticle matrix 
by making it more hydrophilic, which would contribute to more pronounced hydration of the 
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nanoparticles. Various experiments reported a similar biphasic docetaxel release pattern from 
drug-loaded PLGA-PEG nanoparticles [176, 299, 301] to that observed in our formulations. 
According to Abouelmagd [306] and colleagues, release profile of poorly water-
soluble drugs such as paclitaxel could be different in various media. They studied the release 
profile of paclitaxel from PLGA nanoparticles in PBS and in PBS/fetal bovine serum (FBS). 
They observed that the extent of drug release was higher when FBS was present (98%) 
compared to PBS (34%). They attributed this difference to the role of serum proteins offering 
solubilizing effect to the drug. They concluded that measuring drug release in PBS could 
result in under-estimation of the extent of drug release.   
 
8.3. Determination of Biological Activity of Docetaxel Loaded in Nanoparticles  
Figure 8-5 exhibits the biological activity of docetaxel loaded in PLGA and PLGA-
PEG nanoparticles on Hela cancer cells compared to that of the free drug in a set of 
concentrations (25-400 ng/ml) at various incubation times. Hela cells were also treated and 
incubated with plain nanoparticles to determine cytotoxicity of empty PLGA and PLGA-
PEG. The results showed that plain nanoparticles did not influence cell viability. At six hours 
of incubation, the free docetaxel solution demonstrated cell viability of 81-94 % (at various 
concentrations). Cell viability for docetaxel-loaded PLGA and PLGA-PEG nanoparticles (at 
various concentrations) were 88-107% and 79-99%, respectively. At 12 hours of incubation, 
the free drug solution demonstrated 34-54% cell viability, while PLGA and PLGA-PEG 
nanoparticles respectively exhibited 29-62% and 32-74% cell viability. After 24 hours of 
incubation, the free docetaxel solution, docetaxel-loaded PLGA nanoparticles, and docetaxel-
loaded PLGA-PEG nanoparticles resulted in 5-31%, 3-32%, and 3-38% cell viability, 
respectively. Incubation of cells with the free docetaxel solution, docetaxel-loaded PLGA and 
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docetaxel-loaded PLGA-PEG nanoparticles for 48 hours resulted in 2-7%, 2-9% and 3-25% 











Figure 8-5. Effect of plain PLGA and PLGA PEG nanoparticles, free docetaxel, and 
docetaxel loaded in PLGA and PLGA-PEG nanoparticles on the viability of Hela cells 
(Human Cervix Carcinoma) after incubation for A) 6 hours, B) 12 hours, C) 24 hours, and D) 




As exhibited in figure 8-5, plain PLGA and PLGA-PEG nanoparticles did not affect 
viability of Hela cell lines even after 48 hours of incubation. Thus, the observed cytotoxicity 
from drug-loaded nanoparticles was due to the docetaxel loaded in nanoparticles and not 
plain nanoparticles [176]. It also demonstrates that biological/pharmacological activity of 
docetaxel is not affected by its association with the nanoparticles. The proliferation of Hela 
cancer cell lines was inhibited with even low drug concentration (25 ng/ml) formulas over the 
12, 24, and 48 hours of incubation. In contrast to the free drug solution, the cytotoxicity of 
docetaxel loaded in nanoparticles could be attributed to a series of mechanisms [300] as 
follows. Nanoparticles can potentially interact with cells and become located near the cell 
membrane. This could result in the up-holding of an elevated drug concentration adjacent to 
the cell membrane and result in a concentration gradient that promotes the drug’s influx into 
the cell [307]. It is believed that the efflux transport mechanisms of cancer cells (responsible 
for multi-drug resistance), such as P-glycoprotein (P-gp) pumps, could contribute to transport 
out a portion of free drug, which entered the cytoplasm by passive diffusion [308, 309]. 
Usually, this happens substantially with free drug administration [310]. Considering the 
possibility that nanoparticles could station near the cells and contribute to elevated drug 
concentration at the cell membrane, the efflux transport mechanism could become saturated  
and possibly result in pronounced drug uptake [311, 312]. Another possibility is that drug-
loaded nanoparticles could get up taken by cells  [313] and ultimately increase the uptake of 
the entrapped drug [314]. The possibility of cell-internalization could further bypass the 
effect of P-gp pumps. This potentially contributes to the drug accumulation near the drug’s 
site of action (i.e., cytoplasm) [315]. The release pattern of drug from nanoparticles could be 
mentioned as another possible contributing factor to the cytotoxicity of docetaxel 
encapsulated in nanoparticles, [168, 196, 316]. According to the release profile of docetaxel 
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from PLGA or PLGA-PEG nanoparticles (figures 8-3 and 8-4), only a portion of loaded drug 
is released and becomes available during the first 12, 24, or 48 hours of incubation. In the 
study by Abouelmagd [306] and colleagues, they observed that the extent of drug release was 
higher in the presence of serum proteins (98% in PBS/FBs versus 34% in PBS). They 
attributed this difference to the role of serum proteins offering solubilizing effect to the drug. 
They concluded that measuring drug release in PBS could result in under-estimation of the 
extent of drug release. Therefore, it is probable that nanoparticles release larger amount of 
docetaxel in culture media than in PBS alone (our release test).  In case of the free solution of 
drug, the whole amount of drug is available to cancer cells extracellularly during the 
incubation period. In contrast, only a portion of docetaxel is available to cells either 
extracellularly or intracellularly at a time, which contributes to the observed cytotoxicity. In 
their study, Sims and colleagues [317] evaluated the uptake and transport of PLGA 
nanoparticles in Hela cells. Accordingly, they demonstrated that, upon contact (incubation) 
with PLGA nanoparticles, Hela cells engage in both association and internalization acts. 
However, the association between the nanoparticles and cells was more pronounced 






Result and Discussion on Mass spectrometry Method for Quantification of 
Docetaxel 
* Chapter 5 (Experimental Section on Mass spectrometry Method for Quantification of Docetaxel) along with 
chapter 9 have been published as ‘Original Research Articles’ in ‘American Journal of Analytical Chemistry’ 
and ‘Current Pharmaceutical Analysis ’:  
 
Pedram Rafiei, Deborah Michel, Azita Haddadi. Application of a Rapid ESI-MS/MS Method for Quantitative 
Analysis of Docetaxel in Polymeric Matrices of PLGA and PLGA-PEG Nanoparticles through Direct Injection 
to Mass Spectrometer. American Journal of Analytical Chemistry. 2015, Volume 6, Number 2, pages 164-175 
 
Pedram Rafiei, Jane Alcorn, Azita Haddadi. Application of a rapid ESI-MS/MS method for quantitative analysis 
of docetaxel in mouse biological matrices through direct injection to mass spectrometer. Current 
Pharmaceutical Analysis. 2017, Volume 13. 
 
Background 
Various analytical methods have been developed to quantitatively evaluate docetaxel 
in polymeric matrices. The majority of studies have benefited from high performance liquid 
chromatography (HPLC) [176, 194, 196, 300, 318, 319], while a few have applied the UV 
method [299]. Likewise, several analytical methods have been developed to quantify 
docetaxel in biological matrices. Available reports have used only HPLC-UV [320, 321] or 
HPLC coupled to mass spectrometer [322-330]. Due to the inherent specificity and 
sensitivity, LC-MS/MS is the preferred analytical instrument for quantitative analysis of 
drugs in various matrices. However, long separation times are usually needed and many 
resources are required to establish a proper liquid chromatographic (LC) method, particularly 
if additional techniques (e.g., temperature-programmed or gradient elution) are used. 
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Therefore, using rapid and simple analysis methods for the fast screening of samples in 
biologic and non-biologic matrices seems more logical. LC as the limiting step of the 
quantitative analysis method can be omitted to further speed up the procedure. Many 
examples of analysis techniques applying mass spectroscopy without LC exist [331-334]. 
Direct injection into the mass spectrometer can be used as an alternative to LC and MS 
coupled methods [335, 336].  
Here, a method for rapid quantification of docetaxel in PLGA and PLGA-PEG 
polymer matrices, as well as mouse serum and liver, was developed and partially validated. 
Simple extraction techniques were used to extract docetaxel from various matrices followed 
by a positive electrospray ionization-tandem mass spectrometry detection approach. The 
procedure was performed without the application of a LC column.  
 
9.1. Determination of MS/MS Fragmentation Patterns 
Figures 9-1 and 9-2 demonstrate electrospray ionization (ESI)-MS/MS (positive ion 
mode) product-ion spectra of docetaxel (809.4 m/z) and paclitaxel (855.2 m/z). A large 
abundance of the precursor ion was observed in the MS/MS spectra of both materials as 
protonated entities ([M+H]+). The proposed fragmentation pattern of each compound is 
provided in upper-right section of the figures. In addition, the proposed molecular structures 
of the product ions resulting from the fragmentation of docetaxel and paclitaxel are presented 
in figure 9-3 and 9-4, respectively. As exhibited in figure 9-1, six product ions of docetaxel 
demonstrated high intensities: the product ions with an m/z of 226, 91, 105, 182, 528, and 
119. The most abundant product ion was used in subsequent MRM transitions. Among those, 
the product ion with m/z of 226 demonstrated the highest intensity. In the case of paclitaxel 
(figure 9-2), product ions with m/z of 105, 106, 122, 286, 287, and 570 produced high 
intensities, and the product ion with m/z of 105 provided the highest intensity.  
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Depending on the experimental conditions, docetaxel and paclitaxel tend to generate 
different adducts when ionized through an ESI source. Some studies have reported the alkali-
adducts (mainly sodium adduct [M+Na]+) are more intense (up to 5-fold) than the protonated 
form ([M+H]+) [327, 337, 338]. However, some reports have exploited the protonated adduct 
MRM transitions [339, 340] with good sensitivity. For instance, in the study by Du and 
colleagues [341] in which +ESI condition was used, docetaxel and paclitaxel formed the 
protonated adducts predominantly. Taking into consideration the conditions used in this 
analysis method (e.g., isocractic elution), we concluded that the protonated adduct could be 
the prominent ion. In addition, low concentration of formic acid in mobile phase has found to 
be effective in enhancing the ionization efficiency [342] and improve the signal response.  
Consequently, in our study, analysis was performed at the chosen MRM transitions in the 
presence of 0.1 % v/v formic acid in methanol to obtain the protonated adduct for the analyte 
and internal standard. Total run time of a sample was 2 minutes which was shorter than that 
used in previous studies [339, 340]. For example, in the study by Yamaguchi and colleagues 
[339] total analysis run-time was 5 minutes through which retention time of docetaxel and 
paclitaxel was 3.6 and 4.2 minutes. Du et al. [341]  used ultra-high performance liquid 
chromatography and docetaxel and paclitaxel had a run time of 2.5 minutes (retention time: 
1.35 minute). Figure 9-5 demonstrates the typical MRM graphs of docetaxel and paclitaxel in 
methanol. As shown, the peak response at the selected transitions had same retention times 
and varied in response.  MRM graphs of docetaxel and paclitaxel in extracts of non-
biological matrices (PLGA and PLGA-PEG nanoparticles) are demonstrated in 
supplementary figures 7. MRM graphs of docetaxel and paclitaxel in extracts of biological 





Figure 9-1. Electrospray ionization (ESI)-MS/MS (positive ion mode) product-ion spectrum of docetaxel (10 μg/mL in methanol containing 












 +MS2 (809.27) CE (53): 26 MCA scans from Sample 1 (TuneSampleName) of docetaxel_InitProduct_Pos.wiff (Turbo Spray) Max. 6.2e5 cps.






























327.0133.2 309.2 709.2 735.2239.2211.2195.2 791.4143.295.2 345.2
691.469.0 251.2 424.243.0 205.0 299.2 492.0387.2188.8 359.2











Figure 9-2. Electrospray ionization (ESI)-MS/MS (positive ion mode) product-ion spectrum of paclitaxel (10 μg/mL in methanol containing 




 +MS2 (855.33) CE (53): 26 MCA scans from Sample 1 (TuneSampleName) of paclitaxel_InitProduct_Pos.wiff (Turbo Spray) Max. 1.4e6 cps.
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Figure 9-3. Product-ion molecular structures from docetaxel after electrospray ionization 










Figure 9-4. Product-ion molecular structures from paclitaxel after electrospray ionization 











Figure 9-5. Typical MRM graph of A) docetaxel (m/z=226) and B) paclitaxel (internal 




9.2. Docetaxel in Non-biological Matrices 
9.2.1. Limits of Detection and Quantitation 
The LOD and quantitation LOQ of the method used to quantify docetaxel in methanol 
were found to be 1.95 ng/ml and 3.9 ng/ml, respectively. The LOD and LOQ of the used 
quantitation method of docetaxel in both nanoparticle types (PLGA and PLGA-PEG 
nanoparticles) were 62.5 ng/ml and 125 ng/ml, respectively. 
 
9.2.2. Linearity 
A linear regression analysis was carried out on known added concentrations of 
docetaxel against the peak area ratio of docetaxel to paclitaxel and weighted 1/x. The analysis 
produced linear responses throughout the wide range of docetaxel concentrations in methanol 
from 3.9 to 1000 ng/ml with R2, slope, and intercept values of 0.9966, 0.000789, and 
0.00269, respectively, providing the typical equation of y=0.000789x+0.00269 for a set of 
concentrations (n=3) as shown in supplementary figure 8.  
The analysis also produced linear responses throughout the wide range of docetaxel 
concentration of 125-16000 ng/ml, and 125-8000 ng/ml in PLGA nanoparticles and PLGA-
PEG nanoparticles, respectively. R2, slope, and intercept demonstrated values equal to 
0.9978, 0.00084, and 0.023 for PLGA nanoparticles and 0.9966, 0.000778, and 0.108, for 
PLGA-PEG nanoparticles, respectively. The typical equations of the lines for PLGA and 
PLGA-PEG nanoparticles were respectively y=0.00084x+0.023 and y = 0.000778x + 0.108 
for a set of concentrations (n=3). Supplementary figures 9 and 10 demonstrate typical daily 





9.2.3. Method Precision and Accuracy 
Within- and between-run variations (precision) and accuracy of the docetaxel 
quantitation method in methanol are shown in table 9-1. As evident, quality control samples 
demonstrated deviations of less than 15% (i.e., ±15%), showing that this method can 
quantitate docetaxel in methanol with acceptable precision and accuracy. The variation 
evident in LOQ concentration (3.9 ng/ml) was within an acceptable range (i.e., ±20%) (n=6). 
Within- and between-run variations (precision) and accuracy of the docetaxel 
quantitation method in PLGA and PLGA-PEG nanoparticles are shown in tables 9-2 and 9-3, 
respectively. The quality control samples demonstrated deviations of less than 15% (i.e., 
±15%), showing that the method can quantitate docetaxel in nanoparticle formulations with 
acceptable precision and accuracy. The variation evident in the LOQ concentration (125 
ng/ml) was within acceptable range (i.e., ±20%) (n=6). 
 
Table 9-1. Accuracy and precision of mass spectrometry analysis method for docetaxel 
quantitation in methanol. Data represents mean ± standard deviation (n=18). (CV% = 
Coefficient of Variation).   
Actual 
concentration 









100 ng/ml  99.8±8.7 8.7 99.7±8.8 100.6±5.9 5.9 100.6±5.9 
200 ng/ml 197.7±10.5 5.3 98.8±5.2 207.2±9.2 4.4 103.5±4.7 
400 ng/ml 371.2±16.7 4.5 92.8±4.2 370.3±45.5 12.3 96.8±4.4 





Table 9-2. Accuracy and precision of mass spectrometry analysis method for docetaxel 
quantitation in PLGA nanoparticles. Data represents mean ± standard deviation (n=18). 
(CV% = Coefficient of Variation).   
Actual 
concentration 









1250 ng/ml  1351.7±81.8 6.0 107.8 ±6.6 1285±135.8 10.5 102.8±11.0 
2500ng/ml 2613.3±117.6 4.5 104.6±4.6 2550±215.4 8.4 102.1±8.7 
5000 ng/ml 5375±258.1 4.8 107.6±5.2 5373.3±294.7 5.5 107.4±5.8 
10000 ng/ml 10323.3±803.5 7.8 103.2±8.0 9811.7±810.1 8.3 98.1±8.1 
 
Table 9-3. Accuracy and precision of mass spectrometry analysis method for docetaxel 
quantitation in PLGA-PEG nanoparticles. Data represents mean ± standard deviation (n=18). 













625 ng/ml  651.7±51.5 7.87 104.2±8.2 641.8±46.1 7.23 102.8±7.44 
1250ng/ml 1286.7±139.1 10.58 103.0±10.9 1375±85.2 6.16 110.1±6.78 
2500 ng/ml 2596.6±179.2 6.84 103.8±7.1 2588±195.7 7.54 103.4±7.8 
5000 ng/ml 5078.3±563.2 10.94 101.4±11.1 5230±562.9 10.75 104.5±11.24 
 
9.2.4. Overall Method Performance  
Overall, the applied method covered a linearity range of 3.9-1000 ng/ml, 125-16000 
ng/ml, and 125-8000 ng/ml of docetaxel concentration in methanol, PLGA nanoparticles and 
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PLGA-PEG nanoparticles, respectively. The method was sensitive enough to help evaluate 
the amount of the drug in the abovementioned matrices. In all cases, the obtained daily 
standard curves demonstrated R2s higher than 0.996. An analysis of docetaxel in methanol at 
LOQ concentration (n=6) demonstrated an accuracy and coefficient of variation (CV%) of 
less than 14.8% and 15.3% respectively. The evaluated within- and between-run variations of 
the docetaxel quantitation method in methanol (table 9-1) demonstrated CV%s of less than 
12.3% between concentration sets (i.e., good precision). An analysis of docetaxel in PLGA 
nanoparticles at LOQ concentration (n=6) exhibited an accuracy and CV% of less than 10.7 
% and 11.6%, respectively. Within- and between-run variation studies of the docetaxel 
quantitation method in PLGA nanoparticles (table 9-2) demonstrated CV%s of less than 
10.5% between various concentrations (i.e., good precision). The CV% for within- and 
between-run variation studies of docetaxel quantitation method in PLGA-PEG nanoparticles 
was less than 10.94% (table 9-3). Analysis of docetaxel in PLGA-PEG nanoparticles at LOQ 
concentration (n=6) demonstrated an accuracy and CV% of less than 13.42 % and 13.07%, 
respectively. In addition, to check accuracy, back calculation of docetaxel quality control 
concentrations in methanol, PLGA nanoparticles, and PLGA-PEG nanoparticles were 
conducted and exhibited values with an acceptable deviation from the actual concentrations 
(i.e., less than 15% deviation). These results suggested that the present method could 
accurately and reproducibly measure docetaxel in non-biological matrices including 
methanol, PLGA nanoparticles, and PLGA-PEG nanoparticles.  
 
9.3. Docetaxel in Biological Matrices 
9.3.1. Limits of Detection and Quantitation 
Supplementary figure 11 demonstrates a typical MRM graph of docetaxel and 
paclitaxel in mouse serum and liver. Both docetaxel and paclitaxel possess a retention time of 
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around 0.5 minute. The LOD and LOQ of the method used to quantify docetaxel in mouse 
serum and liver were 7.8 ng/ml and 15.6 ng/ml, respectively.  
 
9.3.2. Linearity 
The linear regression analysis carried out on known added concentrations of docetaxel 
against the peak area ratio of docetaxel to paclitaxel (weighted 1/x) produced linear responses 
throughout the wide range of docetaxel concentration in mouse serum from 15.6 to 1000 
ng/ml. R2, slope, and intercept demonstrated values equal to 0.9951, 0.00117, and 0.00125, 
respectively. The typical equation of the line was y=0.00117x+0.0125 for a set of 
concentrations (n=3). Supplementary figure 12 shows a typical daily calibration curve of the 
method.  
Known added concentrations of docetaxel against the peak area ratio of docetaxel to 
paclitaxel (weighted 1/x) in mouse liver were also subjected to linear regression analysis. 
Linear responses were obtained from the method throughout the wide range of docetaxel 
concentration (15.6 to 500 ng/ml). R2, slope, and intercept values were 0.9979, 0.00116, and 
0.0215, respectively, providing a typical equation of y=0.00116x+0.0215 for a set of 
concentrations (n=3). Supplementary figure 13 shows a typical daily calibration curve of the 
method. 
 
9.3.3. Method Precision and Accuracy 
Within- and between-run variations and accuracy of the docetaxel quantitation method 
in mouse serum are shown in table 9-4. The quality control samples demonstrated deviations 
of less than 15% (i.e., ±15%), showing the efficacy of the method to quantitate docetaxel in 
mouse serum with acceptable precision and accuracy. The variation evident in LOQ 
concentration (15.6 ng/ml) was within an acceptable range (i.e., ±20%) (n=6). 
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Within- and between-run variations and accuracy of the docetaxel quantitation method 
in mouse liver are shown in table 9-5. The quality control samples demonstrated deviations of 
less than 15% (i.e., ±15%), showing the efficacy of the method to quantitate docetaxel in 
mouse liver with acceptable precision and accuracy. The variation evident in LOQ 
concentration (15.6 ng/ml) was within an acceptable range (i.e., ±20%) (n=6). 
 
Table 9-4. Accuracy and precision of mass spectrometry method for docetaxel quantitation in 













100 ng/ml  98.0±3.1 3.2 98.0±3.1 92.4±7.9 8.5 92.4±7.9 
200 ng/ml 201.8±5.6 2.8 101.1±2.8 193.5±19.6 10.1 96.7±9.8 
400 ng/ml 393.2±25.7 6.6 98.4±6.5 370.7±22.9 6.0 92.7±5.6 










Table 9-5. Accuracy and precision of mass spectrometry method for docetaxel quantitation in 













100 ng/ml  90.7±4.0 4.4 90.7±4.0 90.9±7.1 7.8 90.9±7.1 
200 ng/ml 196.5±18.5 9.1 98.1±9.0 193.2±17.8 9.4 96.7±9.1 
400 ng/ml 397.8±25.1 6.4 99.5±6.4 377.0±32.9 8.7 94.2±8.2 
 
9.3.4. Overall Method Performance 
 Linear ranges from 15.6 to 1000 ng/ml and 15.6 to 500 ng/ml of docetaxel were 
covered by the method in mouse serum and mouse liver, respectively. R2 obtained daily from 
standard curves were higher than 0.995 for biological matrices under study. Analysis of 
docetaxel in mouse serum at LOQ concentration (n=6) exhibited an accuracy and CV% 
below 10.0 % and 9.7%, respectively. The docetaxel quantitation method in mouse serum 
exhibited CV%s below 10.1% (good precision), as obtained from within- and between-run 
variation studies (table 9-4). However, in the case of mouse liver, CV%s were lower than 
9.4% (table 9-5). In addition, docetaxel at LOQ concentration (n=6) in mouse liver 
demonstrated an accuracy and CV% of less than 11.9 % and 11.8%, respectively. Over all, 
acceptable deviations (<15%) from actual concentrations were obtained when docetaxel 
quality control concentrations in both matrices (i.e., mouse serum and mouse liver) under 
study were analysed and back calculated. Consequently, the analysis method developed and 
partially validated could measure docetaxel in the biological matrices with acceptable 




9.4. Docetaxel in Mouse Kidney, Heart, and Lung 
Supplementary figure 14 demonstrates typical MRM graphs of docetaxel and 
paclitaxel in mouse kidney, heart, and lung. A linear response was obtained throughout the 
wide range of docetaxel concentration (15.6 to 500 ng/ml) in mouse kidney, heart, and lung 
after linear regression analysis done on known added concentrations of docetaxel against the 
peak area ratio of docetaxel to paclitaxel (weighted 1/x). Regression parameters of the 
analysis (R2, slope, intercept, and corresponding typical equation of the line) for a set of 
concentrations (n=3) in each tissue is demonstrated in table 9-6. Typical daily calibration 
curves of the method in mouse kidney, heart, and lung are demonstrated in supplementary 
figures 15 to 17. 
Extraction efficiencies of docetaxel from mouse liver, kidney, heart, and lung are 
exhibited in table 9-7. The efficiency of the extraction was evaluated at three QC 
concentrations (100, 200, and 400 ng/ml) of docetaxel in homogenized tissues. The linearity 
response of the analysis method in mouse kidney, heart, and lung indicated the analysis 
method’s adaptability for the analysis of docetaxel in these organs. The method of extraction 
demonstrated an efficiency percentage of around 80% in mouse tissues except for mouse 
heart, which showed around 70% extraction efficiency. The reason might be docetaxel’s high 
affinity for microtubules and the fact that heart tissue is a microtubule-rich organ. 
 Typically, to overcome selectivity/sensitivity-related limitations and to 
minimize/eliminate the matrix effect usually seen with biological matrices, samples are pre-
treated to remove proteins and lipids to ensure proper analysis [343, 344]. Endogenous 
substances such as proteins, peptides, and phospholipids can potentially result in interference 
[345] by intervening the process of transfer of charged analyte to gas phase and consequently 
increase or decrease ionization efficiency [346]. Here, Liquid-Liquid phase extraction 
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without protein-precipitation has been applied as an effective approach using TBME which 
appears to provide a cleaner extract compared  to other organic solvents such as ethyl acetate, 
hexane, and diethyl ether [347-349]. 
  
Table 9-6. Typical daily standard curve regression parameters for a set of docetaxel 
concentrations (n=3) in mouse kidney, heart and lung tissues.   
                                                Parameter 
Tissue R2 Slope Intercept Line Equation 
Kidney 0.9977 0.00236 -0.00162 y=0.00236x-0.00162 
Heart 0.9973  0.00209 0.0107 y=0.00209x+0.0107 
Lung 0.9951 0.00174 0.0207 y=0.00174x+0.0207 
 
 
Table 9-7. Efficiency (%) of docetaxel extraction method from mouse tissues at different QC 
concentrations (n=3). 
 Individual extraction efficiency (%)  Overall 
Efficiency 
(%)  Tissue 100 (ng/ml) 200 (ng/ml) 400 (ng/ml) 
Liver 82.15±4.09 67.65±1.43 89.08±0.63 79.63±9.72 
Kidneys 86.97±0.94 76.97±0.67 74.57±4.05 79.66±6.09 
Heart 73.88±0.37 74.08±0.77 67.04±1.68 71.67±3.68 







Result and Discussion on Pharmacokinetics and Bio-distribution of Docetaxel 
 
* Chapter 6 (Experimental Section on Pharmacokinetics and Bio-distribution of Docetaxel) along with chapter 
10 have been published as an ‘Original Research Article’ in ‘International Journal of Nanomedicine’:  
 
Pedram Rafiei, Azita Haddadi. Docetaxel Loaded PLGA and PLGA-PEG Nanoparticles for Intravenous 
Application: Pharmacokinetics and Bio-distribution Profile. International Journal of Nanomedicine. 2017, 
Volume 12, pages 935-947. 
 
Background 
Once nanoparticle formulations are characterized in terms of physicochemical 
properties, they are tested in animal models for various purposes. These include tests to 
evaluate the toxicity, safety, and therapeutic efficacy of nanoparticles. In addition, the 
contribution of nanoparticles to the associated drug’s pharmacokinetics and biodistribution is 
evaluated. Nanoparticles may enhance a drug’s systemic circulation residence time or modify 
its tissue distribution. They may elevate the drug’s delivery to particular organs or decrease 
the drug’s distribution to other organs. Thus, the drug’s pharmacokinetics and biodistribution 
often changes when associated to nanoparticles. Modifications made to drugs’ 
pharmacokinetic and biodistribution by nanoparticles are greatly important because these 
modifications can reduce effects in one tissue and increase effects in another tissue. 
Therefore, monitoring the pharmacokinetics and biodistribution of the drug loaded into 
nanoparticles is important because it helps predict efficacy and side effects. The 
pharmacokinetics and biodistribution of nanoparticles depend on characteristics such as their 
average size, surface properties, and zeta potential. Accordingly, a relationship can be 
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established between nanoparticle characteristics and the mode of change made to the drug’s 
pharmacokinetics and biodistribution profile.   
Here, the pharmacokinetics and tissue distribution profiles for docetaxel loaded into 
PLGA nanoparticles, docetaxel loaded into surface-modified (PEGylated) PLGA 
nanoparticles, and free docetaxel were evaluated and compared after administration to animal 
model (mice). The nanoparticle formulations modified the pharmacokinetics and 
biodistribution of the drug. These modifications are reflected in docetaxel’s pharmacokinetic 
parameter estimates in mouse serum and monitored tissues and are attributed to 
nanoparticles’ sizes and surface characteristics.  
 
10.1.  Docetaxel in Mouse Serum 
Docetaxel serum concentration versus time curve for drug-loaded nanoparticles and 
for the free drug solution after IV injection to mice is shown in figure 10-1. The 
concentration of docetaxel in all formulations demonstrates a gradual declining trend. It is 
evident that the serum concentration of docetaxel provided by PLGA and PLGA-PEG 
nanoparticles is higher throughout the study compared to that provided by the free docetaxel 
solution. The observed difference between the treatment groups is statistically significant (p < 
0.05) at the time-points of 0.5, 1, 4, and 6 hours. The docetaxel concentration provided by 
nanoparticle formulations remains within a quantifiable range up to 24 hours, while the 
docetaxel concentration from the free drug solution is quantifiable only up to 12 hours. The 
docetaxel concentration from PLGA nanoparticles is higher than that of PLGA-PEG 
nanoparticles up to 4 hours. Conversely, after 4 hours, the docetaxel concentration from 
PLGA-PEG nanoparticles becomes dominant compared to PLGA nanoparticle.  
Table 10-1 demonstrates docetaxel’s important pharmacokinetic parameters in mouse 
serum. Compared to the free docetaxel solution, both types of nanoparticles decreased the 
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drug’s elimination rate constant (Ke) from serum (p <0.05), which is reflected in their 
corresponding half-lives. Interestingly, PLGA-PEG nanoparticles contributed to a 3.7-fold 
increase in T1/2, while PLGA nanoparticles increased it by only 1.4-fold. The level of serum 
exposure to docetaxel (AUC) increased most with PLGA-PEG nanoparticles (5.4-fold), 
followed by PLGA nanoparticles (3.9-fold), than with the free drug solution (p <0.05).  
Compared to the free drug solution, docetaxel systemic clearance significantly decreased 
when nanoparticle formulations were used (i.e., 3.5- and 4.9-fold for PLGA and PLGA-PEG 
nanoparticles, respectively) (p <0.05). Both nanoparticle formulations lowered docetaxel’s 
apparent volume of distribution (Vd) (p <0.05). Vd of docetaxel was decreased from 383.5 ml 
in the case of the free drug solution to 150.8 ml and 290.4 ml in the case of PLGA and 
PLGA-PEG nanoparticles, respectively. Furthermore, MRT of docetaxel demonstrates a 
statistically significant difference (p <0.05) between treatment groups. MRTs exhibited an 
approximately 4.8- and 2.4-fold increase in the case of PLGA-PEG (18.46 hour) and PLGA 
(9.29 hour) nanoparticles, respectively, compared to the free solution of docetaxel (3.81 









Figure 10-1. Docetaxel serum concentration versus time after IV injection of different drug 
formulations at a dose of 5 mg/kg (n=4) to Balb/C mice. A) Concentration Vs time, B) 
Natural logarithm (Ln) of concentration Vs time. * indicates statistically significant 




Table 10-1. Docetaxel pharmacokinetic parameters in mouse serum after IV injection of 
different drug formulations (n=4). (T1/2: half-life, Cls: Systemic Clearance, Vd: Apparent 
Volume of distribution, MRT: Mean Residence Time, AUC: Area Under the Curve). * 
indicates statistically significant difference between treatment groups. 
Docetaxel Formulation 
Tissue PK Parameter DTX Solution PLGA NPs PLGA-PEG NPs 
Serum T1/2 (h) * 4.30±0.17 6.05±0.78 15.87±1.66 
Cls (ml/h) * 61.79±15.61 17.23±7.16 12.54±4.53 
AUC (ng/ml × h) * 1,688±373 6,601±2,655 9,221±4,709 
Vd (ml) * 383.57±96.44 150.81±74.18 290.41±116.32 
MRT (h) * 3.81±0.23 9.29±0.45 18.46±2.82 
 
As exhibited in figure 10-1, drug concentration due to the docetaxel solution was 
significantly lower than that of the nanoparticle formulations throughout the study period. 
This is attributed to the large volume of distribution of docetaxel and also its binding affinity 
to various tissues [16, 17, 22]. In fact, although it is highly bound to plasma proteins such as 
albumin and acid glycoproteins [350], docetaxel can escape the blood and be distributed to 
various organs immediately after IV injection of the drug solution [31]. This could be the 
reason why docetaxel concentrations in serum dropped fairly rapidly compared to the 
nanoparticle formulations during the first few time-points followed by a rapid elimination 
phase. On the other hand, docetaxel nanoparticle formulations kept up the drug’s serum 
concentration for up to 24 hours post-injection. This could be attributed to the role of 
nanoparticles as long-circulating sustained-release drug-delivery vehicles. Obtained results 
agree with several studies that have demonstrated docetaxel-loaded nanoparticles’ ability to 
maintain docetaxel concentration levels in the blood better than the free solution of drug 
[167, 196, 197, 200, 201]. Up to four hours after injection, drug concentration due to PLGA 
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nanoparticles is higher than that due to PLGA-PEG nanoparticles. However, after 4 hours, 
drug concentration due to PLGA-PEG nanoparticles becomes dominant. This difference is 
likely due to the differences in size (i.e., larger average size of PLGA-PEG nanoparticles) and 
surface properties (i.e., hydrophilic surface of PEGylated nanoparticles) that ultimately 
contribute to different bio-distribution and entrapment levels in other organs. 
As exhibited in table 10-1, the half-life of docetaxel in serum increased when 
nanoparticle formulations were used. This is particularly evident in the case of PEGylated 
nanoparticles. This increase could be attributed to the presence of PEG moiety on the surface 
of PLGA nanoparticles and its role in conferring characteristics to nanoparticles to evade the 
clearance mechanisms of the body [200, 201, 351]. As a result, the level of serum exposure of 
docetaxel was also increased in the case of PLGA-PEG nanoparticles, followed by PLGA 
nanoparticles, compared to that obtained from free drug solution (p <0.05). This result agrees 
with those obtained by other studies evaluating the effect of docetaxel loading in PLGA 
nanoparticles on docetaxel pharmacokinetics [176, 201]. The nanoparticle formulations 
significantly reduced the levels of docetaxel systemic clearance from serum. Both 
nanoparticle formulations also lowered docetaxel’s apparent volume of distribution. Apparent 
volume of distribution due to PLGA-PEG nanoparticles is higher than PLGA nanoparticles. 
This could be attributed to the larger size of PLGA-PEG nanoparticles and higher possibility 
of entrapment in RES organs such as liver and spleen. MRT of docetaxel in serum increased 
when nanoparticle formulations were used, which means that PLGA nanoparticles, 
particularly PLGA-PEG nanoparticles, increased the average transit-time of docetaxel 
molecules through the body.  
Generally, the mode of modifications made to docetaxel’s pharmacokinetic 
parameters is in agreement with trends reported by other studies. Esmaeili et al. [196] 
reported that PLGA nanoparticles contributed to increment in the half-life of docetaxel with a 
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4.5- fold increase in AUC and 1.67-fold increase in MRT when compared to naked 
formulation of the drug. Yu et al. [167] also reported that AUC (1.5-fold), MRT (4.7-fold), 
and half-life (2.1-fold) of docetaxel were increased after loading in PLGA nanoparticles. 
Systemic clearance of docetaxel due to PLGA nanoparticles was decreased in parallel. Jain et 
al. [201] reported respectively 3.2-fold and 8.2-fold increase in AUC and half-life of 
docetaxel due to PLGA nanoparticles as compared to free solution of the drug. They also 
evaluated the effect of PLGA nanoparticle PEGylation. In contrast, PLGA-PEG nanoparticle 
formulation contributed to 7-fold and 13- fold increase in AUC and half-life of the drug, 
respectively (compared to free docetaxel). Accordingly, Senthilkumar and colleagues [176] 
demonstrated respectively 1.7-fold and 1.5-fold increase in docetaxel’s half-life and MRT 
while its systemic clearance was decreased 1.5-fold (when loaded in PLGA nanoparticles). 
Ratios were higher when PEGylated PLGA nanoparticles were used. Respectively, half-life 
and MRT were increased by 3.7- and 2.1-fold while systemic clearance was decreased by 2.7 
fold. 
 
10.2. Docetaxel in Mouse Liver 
Figure 10-2 exhibits the concentration versus time profile of docetaxel in mouse liver 
after IV administration of various drug formulations. Docetaxel from the free drug solution 
was present in liver only up to 12 hours. However, for the PLGA and PLGA-PEG 
nanoparticle samples, docetaxel is seen in the liver up to 18 and 24 hours, respectively. 
Comparing the two nanoparticle types, PLGA formulation contributed to higher docetaxel 
concentration up to four hours, but the trend is reversed after that. Throughout the study 




 Pharmacokinetic parameters of docetaxel in mouse liver are shown in table 10-2. T1/2 
of docetaxel in liver increased (p <0.05) from 6.15 hours from the free drug solution to 8.15 
and 19.03 hours from the PLGA and PLGA-PEG nanoparticles, respectively. Accordingly, 
the AUC of docetaxel concentration versus time for different formulations were as follows: 
PLGA-PEG nanoparticles>PLGA nanoparticles>free docetaxel solution (no statistically 
significant difference). On the other hand, the MRT of docetaxel increased (p <0.05) from 
7.31 hour (free drug solution) to 9.29 and 28.30 hour when PLGA and PLGA-PEG 
nanoparticles were used, respectively. 
 
Figure 10-2. Docetaxel concentration in mouse liver versus time after IV injection of 
different drug formulations at a dose of 5 mg/kg (n=4). * indicates statistically significant 






Table 10-2. Docetaxel pharmacokinetic parameters in mouse liver after IV injection of 
different drug formulations (n=4). (T1/2 :half-life, MRT: Mean Residence Time, AUC: Area 
Under the Curve). * indicates statistically significant difference between treatment groups. 
Docetaxel Formulation 
Tissue PK Parameter DTX Solution PLGA NPs PLGA-PEG NPs 
Liver T1/2 (h) * 6.15±0.77 8.15±0.47 19.03±6.42 
AUC (ng/ml × h) 16,459±4,610 24,551±5,373 38,981±29,630 
MRT (h) * 7.31±1.37 9.29±0.50 28.30±11.30 
 
As exhibited in figure 10-2, the gradual declining trend in docetaxel concentration 
over time is evident for all drug formulations. Accordingly, although docetaxel concentration 
due to PLGA-PEG nanoparticles was lower than that of the free drug solution and PLGA 
nanoparticles during the first four time-points (i.e., 0.5, 1, 2, and 4 hour), PLGA-PEG 
increased docetaxel’s concentration over the last four time-points (i.e., 6, 12, 18, and 24 
hours). The size distribution of PLGA-PEG nanoparticles contributed to this result. 
Compared to PLGA nanoparticles, PLGA-PEG nanoparticles possess a higher particle size 
range and therefore have better contact with the Kupffer cells of the hepatic lobules, as well 
as liver sinusoidal endothelial cells; thus, they become entrapped easier in liver sinusoids and 
ultimately remain in the liver for longer [352]. Park and colleagues [353] demonstrated the 
liver’s and hepatic cells’ ability to filter nanoparticles from systemic circulation. In their 
study, nanoparticles were highly localized in sinusoidal area while Kupffer cells largely 
retained the administered nanoparticles. Therefore, we can conclude that, over time, because 
of their lower particle size ranges, PLGA nanoparticles had less chance of entrapment in the 
liver [354, 355]. Consequently, PLGA-PEG nanoparticles remained in the liver for longer. 
Thus, the elimination half-life of docetaxel in liver due to PLGA-PEG nanoparticles was 
significantly higher than those due to the free docetaxel solution and PLGA nanoparticles. 
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The contribution of PLGA-PEG nanoparticles in increasing MRT of docetaxel in liver can 
potentially be used to target localized cancer tissues in liver [352]. Chu and colleagues [197]    
demonstrated higher liver exposure of docetaxel due to PLGA nanoparticles compared  to 
that of free docetaxel solution which is in agreement with our result.  
 
10.3. Docetaxel in Mouse Kidney 
Figure 10-3 demonstrates docetaxel concentration in mouse kidney at various time 
points after IV injection of three different drug formulations to mice. Here, the gradual 
declining trend in docetaxel concentration is evident in all formulations. The difference in 
docetaxel concentration between treatment groups was statistically significant (p <0.05) at all 
time-points except at four hours. PLGA nanoparticles demonstrated a significant contribution 
to docetaxel concentration in mouse kidney compared to other formulations (p <0.05). 
 Table 10-3 exhibits docetaxel’s pharmacokinetic parameters in kidney subsequent to 
IV administration of various drug formulations. Docetaxel’s T1/2 in kidney tended to decrease 
(p <0.05) when loaded into PLGA-PEG nanoparticles compared to the free solution of drug 
(i.e., from 7.54 hours to 4.91 hours). Loading docetaxel into PLGA nanoparticles contributed 
to a 1.5-fold increase (p <0.05) in docetaxel’s T1/2. The AUC is highest in the case of PLGA 
nanoparticles followed by the free docetaxel solution and PLGA-PEG nanoparticles (p 
<0.05). In addition, the MRT of docetaxel in kidney increased and decreased respectively in 
the case of PLGA (13.10 hours) and PLGA-PEG nanoparticles (5.72 hours) compared to free 
docetaxel solution (8.46 hours). The difference between the MRT of the treatment groups 




Figure 10-3. Docetaxel concentration in mouse kidney versus time after IV injection of 
different drug formulations at a dose of 5 mg/kg (n=4). * indicates statistically significant 
difference between treatment groups. 
 
Table 10-3. Docetaxel pharmacokinetic parameters in mouse kidney after IV injection of 
different drug formulations (n=4). (T1/2 :half-life, MRT: Mean Residence Time, AUC: Area 
Under the Curve). * indicates statistically significant difference between treatment groups. 
Docetaxel Formulation 
Tissue PK Parameter DTX Solution PLGA NPs PLGA-PEG NPs 
Kidney T1/2 (h) * 7.54±0.16 11.59±1.00 4.91±0.42 
AUC (ng/ml × h) * 47,622±7,473 97,937±27,834 40,280±8,811 
MRT (h) * 8.46±0.77 13.10±1.82 5.72±0.34 
 
As exhibited in figure 10-3, docetaxel concentration due to PLGA nanoparticles was 
higher than those obtained from PLGA-PEG nanoparticles or the free drug solution. The 
average size of PLGA nanoparticles is around 120 nm, while PLGA-PEG nanoparticles 
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possessed a larger average size range (i.e., 180 nm). Average size is an important determinant 
of the fate and bio-distribution of particles [356]. However, it is generally considered that 
particles with an average size of 10 nm and less are filtered in the kidneys [172, 204]. 
Therefore, the difference in nanoparticle size does not seem to be responsible for the different 
bio-distribution behaviour between PLGA and PLGA-PEG nanoparticles. Both types of 
nanoparticles can potentially get entrapped in kidney capillary bed [171, 207]. However, 
PLGA nanoparticles with un-modified surfaces were entrapped more. Due to the presence of 
PEG moiety on the surface of the PLGA-PEG nanoparticles, they tend to remain in the blood 
circulation longer [357]. Accordingly, compared to the free docetaxel solution, the PLGA 
nanoparticles increased docetaxel half-life in kidney while PLGA-PEG nanoparticles 
decreased it. This is again attributed to the difference in surface properties between 
nanoparticle formulations. PLGA-PEG nanoparticles had a lower AUC for kidney, which 
meant that PLGA-PEG nanoparticles demonstrated less kidney exposure compared to other 
formulations.     
 
10.4. Docetaxel in Mouse Heart 
Changes in docetaxel concentration in mouse heart versus time after IV administration 
of drug-loaded PLGA nanoparticles, PLGA-PEG nanoparticles, and solution of free drug is 
demonstrated in figure 10-4. Compared to PLGA-PEG nanoparticles, PLGA-nanoparticles 
and the free drug solution contribute to higher docetaxel levels in mouse heart, particularly 
during the first four time-points. The difference in docetaxel concentration between treatment 
groups is statistically significant (p <0.05) at the time-points of 0.5, 1, and 2 hours. Docetaxel 
concentration from PLGA-PEG nanoparticles demonstrates minimal variations during the 
distribution phase.  
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Loading of docetaxel in nanoparticles modified the pharmacokinetic parameters of the 
drug in mouse heart (table 10-4). The half-life of docetaxel in heart demonstrates a decrease 
from 21.74 hours (free drug solution) to 11.34 and 14.00 hours in the case of PLGA and 
PLGA-PEG nanoparticle formulations, respectively. The reduction evident in half-life is 
statistically significant (p <0.05). AUC of docetaxel obtained from different formulations 
demonstrate the following trend (p <0.05): free solution > PLGA nanoparticles > PLGA-PEG 
nanoparticles. MRT demonstrates decrement in the cases of both nanoparticle formulations 
(17.36 and 20.71 hours for PLGA and PLGA-PEG nanoparticles, respectively) compared to 
the free docetaxel solution (28.08 hours) (p <0.05).                 
 
Figure 10-4. Docetaxel concentration in mouse heart versus time after IV injection of 
different drug formulations at a dose of 5 mg/kg (n=4). * indicates statistically significant 





Table 10-4. Docetaxel pharmacokinetic parameters in mouse heart after IV injection of 
different drug formulations (n=4). (T1/2 :half-life, MRT: Mean Residence Time, AUC: Area 
Under the Curve). * indicates statistically significant difference between treatment groups. 
                                                                                     Docetaxel Formulation 
Tissue PK Parameter DTX Solution PLGA NPs PLGA-PEG NPs 
Heart T1/2 (h) * 21.74±3.88 11.34±2.25 14.00±4.76 
AUC (ng/ml × h) 100,652±39,953 90,445±37,835 56,297±27,440 
MRT (h) 28.08±8.10 17.36±2.28 20.71±8.73 
 
As exhibited in figure 10-4, docetaxel concentration due to PLGA nanoparticles and 
the free drug solution demonstrate a declining trend throughout the study time, in contrast to 
PLGA-PEG nanoparticles, which show a relatively constant level of docetaxel in heart during 
the first few time-points. In addition, the concentration of docetaxel provided by PLGA-PEG 
nanoparticles is significantly lower than that obtained from other drug formulations 
particularly during the first four time-points. Generally, after injection of drug formulations 
into the blood, the formulation are taken to the mouse heart [358]. A high portion of 
nanoparticles are believed to become trapped there, which results in high levels of docetaxel 
detected in the heart. In contrast to un-modified PLGA nanoparticles, due to the presence of 
PEG on the surface of PLGA-PEG nanoparticles, PLGA-PEG nanoparticles are believed to 
demonstrate less entrapment in the heart. Later, blood flow can wash away trapped 
nanoparticles from the heart. Microtubules are the major component of the cytoskeleton of 
myocytes that contribute to structural integrity of cardiac cells [359], and the heart is a 
microtubule-rich tissue [360]. Docetaxel has a high affinity for microtubules [361]. Docetaxel 
accumulates in the heart because the docetaxel formulation travels through the heart first and 
because of docetaxel’s affinity for microtubules. This might be the reason the free docetaxel 
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solution resulted in high concentrations in heart tissue compared to the nanoparticle 
formulations.             
As exhibited in table 10-4, the application of nanoparticle formulations contributed to 
a lower half-life for docetaxel in heart tissue compared to the free drug solution, likely due to 
the high levels of docetaxel tissue accumulation in heart after injection of free docetaxel 
solution. However, surface modification of PEGylated nanoparticles can potentially 
contribute to less entrapment and therefore less AUC of docetaxel concentration versus time 
for the PLGA-PEG nanoparticle formulation. On the other hand, PLGA nanoparticles with 
unmodified surface demonstrated higher entrapment and consequently a higher AUC. 
Nanoparticle formulations can be gradually washed away from the heart after their initial 
entrance to heart tissue post-injection, which could have influenced the T1/2 of docetaxel due 
to nanoparticles compared to the free solution of the drug. 
 
10.5. Docetaxel in Mouse Lung 
Figure 10-5 exhibits the concentration versus time profile of docetaxel in mouse lung 
after IV administration of various docetaxel formulations. Docetaxel levels in lung was high 
during the first time-points (i.e., up to 2 hours) particularly for PLGA nanoparticles and the 
free drug solution (p <0.05 at 0.5 and 2 hour). Afterwards, docetaxel levels significantly 
decreased from 2 to 24 hours. Docetaxel pharmacokinetic parameters in mouse lung after IV 
injection of different drug formulations are summarized in table 10-5. PLGA-PEG 
nanoparticles show the lowest half-life (4.12 hours) for docetaxel in mouse lung compared to 
other formulations (12.57 and 7.40 hours for the free drug solution and PLGA nanoparticles, 
respectively). The difference between the half-lives of docetaxel due to treatment groups was 
statistically significant (p <0.05). The free solution of docetaxel resulted in the highest AUC 
followed by PLGA and PLGA-PEG nanoparticles, respectively (p <0.05). Nanoparticle 
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formulations decreased MRT of docetaxel to 5.95 hours (2.88-fold) (PLGA nanoparticles) 
and to 5.37 hours (3.20-fold) (PLGA-PEG nanoparticles) compared to the free solution of the 
drug (17.19 hours) (p <0.05).  
     
 
Figure 10-5. Docetaxel concentration in mouse lung versus time after IV injection of different 
drug formulations at a dose of 5 mg/kg (n=4). * indicates statistically significant difference 
between treatment groups. 
 
Table 10-5. Docetaxel pharmacokinetic parameters in mouse lung after IV injection of 
different drug formulations (n=4). (T1/2 :half-life, MRT: Mean Residence Time, AUC: Area 
Under the Curve). * indicates statistically significant difference between treatment groups. 
                                                                                     Docetaxel Formulation 
Tissue PK Parameter DTX Solution PLGA NPs PLGA-PEG NPs 
Lung T1/2 (h) * 12.57±1.24 7.40±0.65 4.12±0.66 
AUC (ng/ml × h) * 190,205±19,402 98,826±38,035 59,603±40,803 




Generally, drug formulations are considered to enter mouse heart and lung 
immediately post-injection [358], which is accompanied with the significant influx of a large 
portion of injected material into the lung. Consequently, there is the chance that docetaxel 
from free drug solution accumulates in the lung. Afterwards, with further circulation of blood 
in the lungs, docetaxel concentration tends to decrease gradually. On the other hand, 
nanoparticles are believed to become trapped in the lung immediately after IV injection, as a 
result of the lungs’ capillary filtration effects [362, 363]. Nanoparticles can become 
physically entrapped in the lung or become recognized by the lung phagocytic macrophages 
[364, 365].  
PLGA nanoparticles appear to contribute to higher docetaxel concentrations in lung 
compared to PLGA-PEG nanoparticles (during the first few time-points). Considering their 
lower size-range (compared to PLGA-PEG nanoparticles), the unmodified surface of PLGA 
nanoparticles could be the main reason these nanoparticles are retained in the lung. The 
finding by Esmaeili and colleagues [196] agrees with our results. They reported a significant 
amount of nanoparticle entrapment in mice lung after IV injection of PLGA nanoparticles. 
Chu and colleagues [197] demonstrated higher lung exposure of docetaxel due to PLGA 
nanoparticles compared  to that of free docetaxel solution which is in agreement with our 
result.  
Based on docetaxel’s concentration-time profile, PLGA-PEG nanoparticles 
demonstrated less accumulation in lung. Pharmacokinetic analysis shows reductions in the 
lung half-life of docetaxel when nanoparticle formulations were used. This reduction was 
more pronounced in the case of PLGA-PEG nanoparticles. PLGA-PEG nanoparticles’ 
tendency to remain in the systemic circulation might be the reason for this. This is also 
evident by the reduction made in the MRT of docetaxel in lung when nanoparticle 
formulations were used. All these changes indicate that PLGA and PLGA-PEG nanoparticles 
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contribute to lower delivery, distribution, retention, and residence of docetaxel in lung. This 






Summary, Conclusions, and Perspectives 
 
11.1. Summary and Conclusions 
11.1.1.  Taguchi Experimental Factorial Design  
In the present work, an experimental design based on the Taguchi robust method was 
used to optimize PLGA nanoparticles loaded with docetaxel. As a fractional factorial design, 
16 runs of a combination of important factors/levels from a full factorial design were selected 
and used for nanoparticle fabrication. Docetaxel-loaded PLGA nanoparticles from the design 
demonstrated an overall uni-distributed population of nanoparticles with a range of size 
between 93 and 191 nm, zeta potential between -17 and -36 mV, and drug-loading efficiency 
between 25% and 96%. Among different factors under study, PVA concentration had the 
highest magnitude of effectiveness on particle size, while organic:aqueous phase ratio 
contributed most to size with statistical significance. In the case of zeta potential, the type of 
PLGA polymer terminus was the factor determining zeta potential with statistical 
significance. It was also the factor with the highest magnitude of effectiveness on zeta 
potential. Organic:aqueous phase ratio had the highest magnitude of effectiveness on drug-
loading efficiency. All factors under study, except PLGA molecular weight contributed to 
drug-loading efficiency with statistical significance.    
The L16 Taguchi design allowed for the fitting of statistically significant models with 
good robustness as suitable means to predict particle characteristics from the fraction of full 
combinations of factors/levels. Prediction of particle characteristics based on preparation 
conditions can help prepare nanoparticle formulations with intended properties. The design 
also allowed for the optimization of the nanoparticle fabrication method based on surface-
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response optimization techniques. This provided the knowledge to determine the fabrication 
conditions that create nanoparticles with desired characteristics of average size, PDI, zeta 
potential, and drug loading efficiency. Considering that the nanoparticle’s fate in the body is 
in part determined by its characteristics, having control over those characteristics grants the 
ability to control nanoparticles’ pharmacokinetics. 
   
11.1.2. Docetaxel-Loaded Nanoparticles     
The optimized method of nanoparticle fabrication, which was suggested by the 
experimental factorial design, was used to prepare docetaxel-loaded PLGA nanoparticles and 
PEGylated PLGA nanoparticles. The optimized fabrication method provided nanoparticles 
with characteristics suitable for an intravenous sustained-release drug-delivery system. 
Average particle sizes were approximately 120 nm for PLGA and 180 nm for PEGylated 
PLGA nanoparticles, which, being below 200 nm, were small enough to evade filtration in 
RES organs and large enough to evade filtration in the kidneys. Nanoparticles had negative 
surface zeta potential values between -24 and -32 mV, which allow for long circulating times 
for nanoparticles in the blood. Nanoparticles demonstrated a bi-phasic in vitro release profile, 
which is expected from drug delivery systems (PLGA and PLGA-PEG nanoparticle 
formulations) meant to provide systemic circulation with sustained drug release. Docetaxel 
loaded in nanoparticles demonstrated cytotoxicity against Hela cancer cells, which was 
comparable to that obtained from the free solution of the drug. It confirmed that docetaxel’s 







11.1.3.  Docetaxel Analysis Method       
A simple and rapid mass spectrometric method was developed and partially validated 
to quantify docetaxel in various biological and non-biological samples throughout the study. 
Method development was done over 125-16000 ng/ml docetaxel concentration for 
nanoparticles polymeric matrices and 3.9-1000 ng/ml docetaxel concentration for mouse 
biological matrices. The method was applied for quantitative analysis of docetaxel with 
acceptable levels of accuracy/precision.  
 
11.1.4. Pharmacokinetics and Biodistribution Profile of Docetaxel  
Docetaxel’s pharmacokinetic and biodistribution profiles were evaluated and 
compared in mice after IV administration of free docetaxel and docetaxel-loaded PLGA and 
surface-modified (PEGylated) PLGA nanoparticles, which were fabricated through the 
optimized preparation method. Based on the data obtained, the association of docetaxel with 
PLGA nanoparticles modified docetaxel’s pharmacokinetics and bio-distribution. Both 
nanoparticle formulations increased docetaxel’s half-life in serum and decreased its systemic 
clearance. Overall, they increased docetaxel’s MRT as well. Docetaxel’s distribution profile 
to various organs was also different when compared to the free drug solution. For example, 
PEGylated PLGA nanoparticles contributed to higher MRT in the liver, while surface-
unmodified PLGA nanoparticles resulted in higher MRT in the kidneys. Also, docetaxel’s 
exposure to heart tissue was reduced when nanoparticle formulations were used. Nanoparticle 
formulations were highly entrapped in the liver compared to other organs. Accordingly, the 
mode of changes made to docetaxel’s pharmacokinetics and bio-distribution was attributed to 
the size and surface properties of nanoparticles. Loading of docetaxel in nanoparticles 
contributed to increase in blood-residence time of docetaxel, fulfilling the nanoparticles’ role 
as a long-circulating sustained-release drug-delivery system. Surface-modification of 
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nanoparticles contributed to more pronounced blood concentrations of docetaxel, which 
confirms PEG’s role in helping nanoparticles evade the clearance mechanisms present in the 
systemic circulation and the body. The role of nanoparticle average size in modifying the bio-
distribution was also evident.  
 
11.2. Future Perspectives 
Improving Experimental Design: Valuable information related to PLGA 
nanoparticle fabrication is provided by the experimental design. The design deals with four of 
the preparation factors at two levels. Sixteen different combinations of factors/levels have 
already been completed. It is possible to add two more levels to PLGA Mw and PVA 
concentration. Consequently, such design would require preparation of nanoparticles at new 
factor/level combinations and ultimately results in new data points available for analysis. 
This would potentially increase the precision of analysis outcome. Therefore, as one of the 
future perspectives, it is recommended to add two more levels to the mentioned factors, and 
re-run the design. 
 
Directing Nanoparticles Towards an Organ:  The data from animal experiments 
demonstrate that the association of the drug to the nanoparticles could modify the 
pharmacokinetic and bio-distribution profile of docetaxel by a relationship to nanoparticles 
surface characteristics and average size. The observed trend can be used for directing 
nanoparticles towards a certain organ by further modifying nanoparticle size or surface 
properties.  
Example 1: PLGA-PEG nanoparticles with larger average sizes demonstrate more 
pronounced residence in liver. Therefore, it is possible to design nanoparticles with average 
sizes suitable for liver accumulation. This can be manipulated to direct nanoparticles to liver, 
182 
 
possibly for liver-related cancers. Therefore, as a future perspective, it is recommended to use 
the models built by the Taguchi design to prepare larger PLGA nanoparticles for hepatic 
drug-delivery purposes. 
Example 2: Surface-modification of nanoparticles with PEG increases the residence 
time of the drug in the blood. As a future perspective, it is recommended to use a di-block co-
polymer of PLGA-PEG with a higher percentage of PEG. The resulting PEGylated PLGA 
nanoparticles would have a thicker and denser PEG layer surrounding the nanoparticle. This 
could cause a more pronounced blood residence time for the nanoparticles. In case of 
sustained-release nanoparticle formulations, more pronounced blood residence time allows 
nanoparticles to release the drug in the blood. In case of targeted nanoparticle formulations, it 
allows nanoparticles to remain in blood until they reach their target tissue.    
 
Targeted Delivery of Docetaxel: PLGA nanoparticles offer the possibility of 
surface-modification with various agents. A well-known modification is to decorate PLGA 
nanoparticles with the ligands of receptors on cancer cell lines to facilitate specific drug 
delivery to cancer tissues (i.e., targeting anti-cancer agents). 
  Example: Epidermal growth factor receptor (EGFR) is an example of a receptor 
being overexpressed on breast cancer cells. Herceptin on the other hand is an EGFR antibody 
that works as a ligand to block the receptor and inhibit cancer cells’ ability to receive growth 
signals. Decorating docetaxel-loaded PLGA nanoparticles with herceptin could facilitate the 
delivery of docetaxel specifically to breast cancer cells. At the same time herceptin could 
block the EGFR. This offers a dual anticancer effect for both solid and metastasized cancer. 
 
Anti-tumour Efficiency of Docetaxel-loaded Nanoparticles in animal: This 
research evaluated the pharmacokinetic and bio-distribution profile of docetaxel loaded in 
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PLGA nanoparticles. However, it would be informative to evaluate the anti-tumour efficiency 
of docetaxel loaded in PLGA nanoparticles. Therefore, it is recommended to evaluate how 
the delivery of docetaxel by PLGA nanoparticles contributes to the anti-cancer effect of the 
drug in animal models.  
 
Application of Nanoparticles for in vivo Efficacy: Engineered nanoparticles with 
long-circulating sustained-release properties would keep systemic drug concentration within 
its therapeutic window. Also, engineered nanoparticles with targeting purposes would reduce 
the distribution of chemotherapeutic agent to non-cancer tissues. Either case could potentially 
reinforce the efficacy of the drug in cancer patients. Therefore, as a future perspective, 
application of docetaxel-loaded nanoparticle formulations in cancer patients and evaluation of 
therapeutic efficacy and toxicity is recommended.  
The ultimate consequence of nanoparticle application in patients would potentially be 
better efficacy, fewer side effects, tolerance to the chemotherapy, and having a better quality 
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Supplementary figure 1. Response surface plot of particle size Vs organic/aqueous phase 





























Supplementary figure 2.  Response surface plot of poly dispersity index (PDI) Vs polymer 





























Supplementary figure 3.  Response surface plot of particle zeta potential Vs polymer terminus 




























































Supplementary figure 4.  Response surface plot of drug-loading efficiency Vs drug 
concentration and A) organic/aqueous phase ratio, B) polymer terminus, C) lactide:glycolide 













































Supplementary figure 5.  Response surface plot of drug-loading efficiency Vs 
organic/aqueous phase ratio and A) polymer terminus, B) poly (vinyl alcohol) (PVA) 





























Supplementary figure 6.  Response surface plot of drug-loading efficiency Vs polymer 













Supplementary figure 7.  Response surface plot of drug-loading efficiency Vs 






Supplementary figure 7. Typical multiple reaction monitoring (MRM) graph of docetaxel 
(m/z=226) and internal standard (m/z= 105) (1000 ng/ml). A) docetaxel in methanol B) 
paclitaxel in methanol, C) docetaxel in PLGA nanoparticles extract D) paclitaxel in PLGA 
nanoparticles extract, E) docetaxel in PLGA-PEG nanoparticles extract F) paclitaxel in 

































Supplementary figure 8. Typical daily calibration curve of docetaxel in methanol (n=3). 
 
 
validation standard curve.rdb (809.265 / 226.000): "Linear" Regression ("1 / x" weighting): y = 0.000789 x + 0.00269 (r = 0.9966)
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Supplementary figure 9. Typical daily calibration curve of docetaxel in PLGA nanoparticles 
(n=3). 
standard curve for drug extraction from PLGA NPs.rdb (809.265 / 226.000): "Linear" Regression ("1 / x" weighting): y = 0.000839 x + 0.0234 (r = 0.9978)
1000.0 2000.0 3000.0 4000.0 5000.0 6000.0 7000.0 8000.0 9000.0 1.0e4 1.1e4 1.2e4 1.3e4 1.4e4 1.5e4 1.6e4




























Supplementary figure 10. Typical daily calibration curve of docetaxel in PLGA-PEG 
nanoparticles (n=3). 
 
PLGA-PEG NPs standard curve.rdb (809.265 / 226.000): "Linear" Regression ("1 / x" weighting): y = 0.000778 x + 0.108 (r = 0.9966)
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Supplementary figure 11. Typical multiple reaction monitoring (MRM) graph of docetaxel 
(m/z=528) and internal standard (m/z= 105). A) docetaxel in mouse serum (1000 ng/ml) B) 
paclitaxel in mouse serum (400 ng/ml), C) docetaxel in mouse liver extract (500ng/ml), and 






Supplementary figure 12. Typical daily calibration curve of docetaxel in mouse serum (n=3) 
 
standard curve of Dcoetaxel in mouse rerum.rdb (809.265 / 528.100): "Linear" Regression ("1 / x" weighting): y = 0.00117 x + 0.00125 (r = 0.9951)
50 100 150 200 250 300 350 400 450 500 550 600 650 700 750 800 850 900 950 1000



























Supplementary figure 13. Typical daily calibration curve of docetaxel in mouse liver (n=3) 
 
standard curve of Docetaxel in mouse liver.rdb (809.265 / 528.100): "Linear" Regression ("1 / x" weighting): y = 0.00116 x + 0.0215 (r = 0.9979)
20 40 60 80 100 120 140 160 180 200 220 240 260 280 300 320 340 360 380 400 420 440 460 480 500


























Supplementary figure 14. Typical multiple reaction monitoring (MRM) graph of docetaxel 
(m/z=528) and internal standard (m/z= 105). A) docetaxel in mouse kidney extract (500 
ng/ml) B) paclitaxel in mouse kidney extract (400 ng/ml), C) docetaxel in mouse heart extract 
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(500ng/ml) D) paclitaxel in heart extract (400ng/ml), E) docetaxel in mouse lung extract 




Supplementary figure 15. Typical daily calibration curve of docetaxel in mouse kidneys 
(n=3) 
standard curve of Docetaxel in mouse kidney.rdb (809.265 / 528.100): "Linear" Regression ("1 / x" weighting): y = 0.00236 x + -0.00162 (r = 0.9977)
20 40 60 80 100 120 140 160 180 200 220 240 260 280 300 320 340 360 380 400 420 440 460 480 500





































Supplementary figure 16. Typical daily calibration curve of docetaxel in mouse heart (n=3) 
 
 
Supplementary figure 17. Typical daily calibration curve of docetaxel in mouse lungs (n=3)  
standard curve of Docetaxel in mouse heart.rdb (809.265 / 528.100): "Linear" Regression ("1 / x" weighting): y = 0.00209 x + 0.0107 (r = 0.9973)
20 40 60 80 100 120 140 160 180 200 220 240 260 280 300 320 340 360 380 400 420 440 460 480 500


































standard curve of Docetaxel in mouse lungs.rdb (809.265 / 528.100): "Linear" Regression ("1 / x" weighting): y = 0.00174 x + 0.0207 (r = 0.9951)
20 40 60 80 100 120 140 160 180 200 220 240 260 280 300 320 340 360 380 400 420 440 460 480 500





























Supplementary table 1. Size, PDI, and zeta potential characteristics of PLGA nanoparticles 
formulations prepared at high docetaxel concentration. Data represents mean ± standard 
deviation (n=3). (PDI=polydispersity index). 
Docetaxel Preparation 
Conc. Average Size (nm) PDI Zeta potential (mV) 
3 mg/ml 132.4 ±6.8 0.214±0.025 -29.5±1.3 
5 mg/ml 129.5±8.0 0.215±0.046 -29.9±2.4 
10 mg/ml 143.9±9.5 0.241±0.048 -25.1±0.7 
 
 
Supplementary table 2. Size, PDI, and zeta potential characteristics of PLGA nanoparticles 
obtained by modified preparation technique (i.e., sonicated organic phase prior to 
emulsification with aqueous phase). Data represents mean ± standard deviation (n=3). 
(PDI=polydispersity index)   
Docetaxel Preparation 
Conc. Average Size (nm) PDI Zeta potential (mV) 
0.25 mg/ml  102.1±2.3 0.199±0.027 -25.8±13.4 
0.5 mg/ml  108.3±6.6 0.207±0.012 -30.4±0.2 
1 mg/ml  107.1±2.0 0.213±0.006 -20.0±0.5 
1.5 mg/ml 107.7±2.4 0.222±0.010 -25.1±1.0 
 
 
 
 
 
 
 
